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1. TYPE 1 DIABETES
Type 1 diabetes (T1D) is a chronic disease characterized by the immune-
mediated destruction of the pancreatic beta cells, resulting in insufficient 
insulin production and impaired glucose homeostasis. The symptoms include 
polyuria (frequent urination), polydipsia (increased thirst), polyphagia 
(increased hunger), and unexplained weight loss. Over 40 million people 
worldwide suffer from T1D and yearly 80,000 new diagnoses are made. Without 
medical intervention the consequences of T1D are fatal. More than a century 
ago, the Nobel Prize-winning discovery of Banting and Best paved the way for 
modern day insulin therapy. Once diagnosed, patients require lifelong insulin 
therapy to compensate for lost beta cell function. Yet, artificial regulation 
of blood glucose homeostasis is not accurate and the majority of patients 
have difficulties to keep their blood glucose levels within the recommended 
range. The fluctuations between hyperglycemia (high blood glucose) to 
hypoglycemia (low blood glucose) can result in acute life threating conditions 
such as diabetic ketoacidosis, nonketotic hyperosmolar syndrome, seizures, 
and coma1. T1D is also associated with diverse long-term complications such as 
diabetic retinopathy, nephropathy, neuropathy, and cardiovascular diseases2.
Currently there is no cure for T1D but methods of beta cell replacement are 
rapidly developing3. Pancreas transplantation offers improved endogenous 
glycemic control of T1D patients4. However, the invasiveness of the procedure 
and the need for continuous immunosuppressive drugs treatment to prevent 
graft versus host disease and the irreversible effect on kidney function toxicity 
does not outweigh the benefits5. In 2000, the Edmonton protocol for islet 
transplantation offered a new less-invasive strategy to restore endogenous 
beta cell function by islet cell transplantation. While follow-up studies showed 
promising results with improved life quality by improved glycemic control 
and less hypoglycemic episodes, the majority of transplanted patients did 
not preserve long-term insulin independence6-8. Though improvement 
in the islet isolation procedure, site of transplantation, reduction of toxic 
immunosuppression, and immune-protection devices may improve clinical 
outcome, replacement therapies (whole pancreas or purified islets) are facing 
shortage in organ donation. In order to overcome the lack of organ donors 
alternative sources of beta cells (i.e. embryonic stem cells or induced pluripotent 
cells) are examined9, 10. Also, reactivation and preservation of persistent beta 
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cells in T1D patients by specific or non-specific immune intervention therapy 
are currently under investigation11-13.
2. HUMAN PANCREATIC ISLET PHYSIOLOGY 
The human pancreas is a mixed gland that consists of an exocrine and 
endocrine compartment, exerting a function in the digestive system and 
endocrine system, respectively. The endocrine compartment, which makes up 
1-2% of the total organ weight, consists of clusters of endocrine cells scattered 
through the exocrine pancreas collectively called the islets of Langerhans. The 
islets of Langerhans are assembled of different endocrine cells: the glucagon-
producing alpha cells (circa 30%), the insulin-producing beta cells (circa 60%), 
the somatostatin-producing delta cells (circa 5%), the pancreatic polypeptide-
producing gamma cells (circa 3-5%), and the ghrelin-producing epsilon cells 
(<1%). Together, these endocrine cells orchestrate blood glucose homeostasis 
by tightly regulated hormone secretion, maintaining blood glucose levels 
in a narrow physiological range14. This is mainly acquired by the balanced 
secretion of insulin and glucagon. In fasting conditions, when blood glucose 
levels tend to decrease, glucagon is released from the alpha cells. Glucagon 
promotes hepatic glycogenolysis increasing endogenous blood glucose 
levels15. In contrast, elevated blood glucose levels after food intake stimulate 
insulin secretion from the beta cells. Insulin lowers blood glucose levels by 
stimulating glucose uptake from the blood and storage by cells in the form 
of glycogen16. Somatostatin, ghrelin and pancreatic polypeptide indirectly 
contribute by modulating insulin and glucagon secretion and promoting 
insulin sensitivity17-19. 
The unique islet cytoarchitecture, favoring heterotypic associations, likely 
contribute to cell-cell communication and fine-tuning of coordinated hormone 
secretion20-22. Although the endocrine cells within the islet of Langerhans each 
occupy different roles in nutrient metabolism, they all share a common origin 
in their development23. A complex network of transcription factors during 
early pancreas development drives lineage commitment and endocrine 
cell diversity24, 25. Elaborate examination of hormone expression in human 
pancreatic sections from normal cadavers ranging from pre-neonatal to elderly 
individuals indicates that the beta cell mass is established before the age of 5 




years, after which endocrine cell proliferation was rarely observed26. In matured 
endocrine cells the differentiated state is maintained by reinforcement of cell-
specific gene regulatory networks and repression of other transcriptional 
programs27-30. 
Within the islets of Langerhans, the beta cells are micro-factories that 
produce, store, and release insulin31. Insulin is synthesized as a 110-amino acid 
precursor molecule, preproinsulin, consisting of a signal peptide (SP), B-chain, 
C-peptide and A-chain. As soon as the N-terminal signal peptide emerges from 
the ribosome, it is bound by signal recognition particle (SRP) and directed to 
translocon Sec61. The signal peptide is removed and the remaining proinsulin 
molecule is cotranslationally translocated to the endoplasmic reticulum (ER)32. 
Here proinsulin is folded in the correct conformation and three disulfide 
bonds are formed33. Proinsulin is subsequently transported from the ER to 
the Golgi apparatus where it enters immature secretary vesicles and is finally 
processed to bioactive insulin and its by-product C-peptide by prohormone 
convertases34, 35. In order to adequately adapt to acute changes in extracellular 
glucose levels, beta cells are highly sensitive to fluctuations in glucose levels. 
Beta cells equalize to circulating blood glucose levels by the uptake of glucose 
via glucose transporter 1 (GLUT1)36. Internalized glucose is converted to 
pyruvate that results in the generation of ATP. The increasing ATP/ADP ratio 
results in the closure of ATP-sensitive K+-channels, membrane depolarization 
and opening of voltage-dependent Ca2+-channels. The influx of calcium into 
the cell triggers the exocytosis of stored secretory granules as well as promote 
insulin gene transcription to replenish insulin granules and maintain glucose-
stimulated insulin secretion (figure 1). Calpain-1, a Ca2+-activated protease, 
cleaves granule transmembrane protein islet cell autoantigen 512 (ICA512 
or IA-2). The cytosolic fragment of ICA512 is targeted to the nucleus where it 
upregulates transcription of secretory granule genes and insulin37-39. Insulin 
synthesis rates up to 1,000,000 molecules per minutes can be achieved which 
comprises about 50% of the total beta cell proteome40.
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Figure 1: Insulin synthesis, storage, and secretion from a pancreatic beta cell. Insulin biosynthesis, 
storage in secretory vesicles (left panel), and insulin secretion (right panel) are activated by the influx of 
Ca2+ after membrane depolarization caused by the influx and ATP-generating metabolism of glucose. 
Figure was produced using Servier Medical Art www.servier.com. 
3. IMMUNOPATHOLOGY OF TYPE 1 DIABETES
Genome-wide association studies have established a strong genetic risk to 
T1D and more than 60 candidate susceptibility loci have been identified41, 42. 
The highest risk is ascribed to immune-associated genes (50%), especially HLA 
class II alleles. The DR4/DQ8 or DR3/DQ2 haplotypes account for 80-90% of the 
patients43, 44. Albeit to a lesser extent, HLA class I was also shown to contribute 
to T1D risk45. In addition, many non-HLA genes have been found to associate 
with T1D although at lower odd ratios. These include: variation of a variable 
number of tandem repeats (VNTR) upstream of the insulin gene46, autoimmune 
regulator (AIRE)47, cytotoxic T-lymphocyte antigen (CTLA-4)48, 49, lymphoid-
specific protein tyrosine phosphatase 22 (PTPN22)50, and IL-2 receptor alpha 
(IL2RA or CD25)51. These risk factors might exert their effects by poor insulin 
representation in the thymus and defective peripheral immune regulation by 
inhibited T cell repression. Besides immune regulation, the associated loci might 




participate to T1D pathogenesis via different mechanisms, such as inadequate 
beta cell function, apoptosis signaling and interferon (IFN) signaling 52 .
The earliest indicators of the disease are accumulation of autoantibodies 
against beta cell antigens such as insulin (IAA), Glutamic acid decarboxylase 
(GAD), Islet antigen-2 (IA-2), and Zinc transporter 8 (ZnT8). Although the 
presence of multiple autoantibodies can be considered as biomarker for 
disease progression and largely increases the risk of developing T1D53-55, their 
contribution to the cascade of events leading to beta cell destruction and 
disease progression remains unclear56. 
The dynamics of the islet microenvironment and beta cell destruction is 
difficult to investigate in humans as non-invasive in vivo imaging techniques of 
pancreatic islets are challenging57 and the use of animal models to study T1D 
development remains controversial58, 59. The biobank Network for Pancreatic 
Organ Donors with diabetes (nPOD) provides a wide collection of human 
pancreatic donor material for research60. Analysis of pancreatic sections of T1D 
patients demonstrated the infiltration of a diverse collection of immune cells of 
both the innate and adaptive immune system in the islet micro-environment, 
including macrophages, natural killer cells, dendritic cells (DCs), B-cells, CD4+ T 
cells, regulatory T cells (Tregs), and primarily CD8
+ T cells (figure 2)61, 62. 
a. Role of central tolerance
The immune system is an assembly of delicate physiological mechanisms to 
protect the host from pathogens. T cells are able to distinguish healthy cells 
from infected cells by the recognition of peptides presented on the cellular 
surface by the human leukocyte antigen (HLA) complex. 
Peptide antigens are presented by two classes of HLA complexes, HLA 
class I and class II, and two specialized types of T cells respond63. HLA class II 
expression is limited to professional antigen-presenting cells (APC), DCs, B-cells 
and macrophages, and HLA molecules mainly present peptides derived from 
degraded extracellular material taken up via phagocytosis. Upon recognition 
by CD4+ T cells, the CD4+ T cells help the immune response by stimulating 
antibody secretion by B cells and support CD8+ T cell activation. HLA class I 
is assembled with peptides derived by the proteasomal degradation of 
intracellular protein. CD8+ T cells recognize peptides presented by HLA class I 
on the surface of all nucleated cells. Activation of CD8+ T cells upon recognition 
of their target results in destruction of the antigen-presenting cell.
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Figure 2: Antigen processing, presentation and immunology. Degraded intracellular proteins are 
processed and loaded in HLA class I molecule and presented at the cell surface. Antigens can also be 
taken up and processed by DCs via phagocytosis and presented in HLA class II. DCs regulate peripheral 
tolerance. If this fails recognition of epitope at the cell surface by CD8 can induce cell death. In case of 
T1D pathology, these epitopes are most likely from beta cell-specific proteins. The unfolded protein 
response activated by endoplasmic reticulum stress and the dissociation of BiP from PERK, IRE1 and 
ATF6 lead to inhibition of translation, increased folding, and degradation of proteins. UPR-induced 
inflammatory cytokine production can activate the immune system and affect peripheral tolerance 
mechanisms. Figure was produced using Servier Medical Art www.servier.com.
T cell recognition of foreign peptides is essential for immune defense against 
pathogens, however, recognition of self-peptides can cause autoimmunity. 
Lymphocyte receptors are highly variable as the result of gene rearrangements, 
allowing them to recognize an almost unlimited repertoire of antigens. In order 
to discriminate pathogenic peptides from self-peptides, lymphocytes are 
subjected to a delicate selection process to generate central tolerance64. This 
two-step selection process in the thymus consist of positive selection of T cells 
with a T cell receptor (TCR) that recognize HLA and, subsequently, negative 
selection of TCRs reactive to self-peptides. This ensures only self-tolerant naive 
lymphocytes enter the circulation.




b. The specific destruction of beta cells
The immune infiltrate in islets of T1D patients suggests substantial crosstalk 
between innate and adaptive immune cells, adding to the complexity of the 
disease65. However, the specific and selective destruction of the beta cells 
in the islet of Langerhans dictates a pivotal role for CD8+ T cells that target 
endogenous epitopes derived from beta cell-specific proteins presented by HLA 
class I molecules on the beta cells. In addition, CD8+ T cells are the predominant 
component of the immune infiltrate found in T1D patients and increasing 
numbers of cytotoxic T cells is associated with increased beta cell exhaustion61, 
62. Depletion of CD8+ T cells in mice was found to reduce diabetic penetrance 
and adoptive transfer of CD8+ T cells can induce diabetes66, 67. Knockout of 
MHC class I (HLA class I equivalent) prevents development of diabetes68. Also, 
studies in human pancreatic islets demonstrate the relevance of CD8+ T cells. 
Autoreactive beta cell specific CD8+ T cells are expanded in peripheral blood of 
patients and are capable of killing beta cells in vitro69.
Insulin is considered a key autoantigen in the development of T1D as 
proinsulin and insulin are common targets of autoantibodies, CD4+ and CD8+ 
T cells among (pre-)T1D patients70, 71. Characterization of CD8+ T cell epitopes 
indicate the leader sequence69, 72, the B-chain73, 74 as well as the C-peptide75 
are implicated in autoimmunity. Beside insulin, GAD65, islet-specific glucose-
6-phosphatase catalytic subunit (IGRP)76, 77, chromogranin A78, islet amyloid 
polypeptide (IAPP)77, ZnT879, 80 and tyrosine phosphatase-like insulinoma 
antigen 2 (IA-2)81 were identified as targets of autoreactive T cells.
Defects in T cell selection might result in the circulation of autoreactive T 
cells with as consequence the inappropriate T cell-mediated targeting and 
destruction of healthy peptide-presenting cells. Insulin expression levels 
in the thymus is important in the generation of self-tolerance. Expression of 
insulin in the thymus is controlled by the variable number of tandem repeats 
(VNTR) in the insulin promotor and autoimmune regulator (AIRE)82. Genetic 
polymorphisms in the VNTR are associated with disease susceptibility, in which 
short VNTR alleles (class I) predispose to T1D and longer VNTR alleles (class 
III) protect46, 83. Low thymic insulin levels resulted in more circulating insulin-
reactive T cells, likely caused by a failure of negative selection of insulin-specific 
T cells84. Another important factor in T cell education is peptide representation 
by HLA. An inverse correlation between binding affinity of beta cell peptides 
to HLA class I and corresponding CD8+ T cell responses has been reported85. 
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This indicates that low affinity peptides are less represented during thymic 
selection. These findings led to the identification of several PPI epitopes with 
very low HLA class I binding affinity86, 87.
c. Role of peripheral tolerance 
Even though the role of CD4+ and CD8+ T cells in T1D pathology is clearly 
demonstrated, the circulation of these autoreactive T cells is also found in 
peripheral blood of healthy individuals88-90. This indicates central tolerance is 
not absolute and likely peripheral tolerance mechanism are involved to prevent 
activation of these T cells. APCs (B-cells, DCs, and macrophages) and a specialized 
subset of regulatory T cells (Tregs) are considered important modulators of T cell 
activity. The interaction between APC and Tregs induces a tolerogenic environment 
inhibiting peripheral autoreactive CD4+ and CD8+ T cells. Multiple lines of 
evidence indicate that T1D patients are unable to maintain peripheral tolerance 
due to altered APC and Treg function
91, 92. This potentially contributes in loss of 
immunoregulatory function, stimulating a pro-inflammatory microenvironment 
and subsequent T cell-mediated beta cell destruction. 
4. ISLET MICROENVIRONMENT AND LOSS OF TOLERANCE
The incidence of T1D is increasing faster than can be explained by a shift in 
genetic susceptibility93, 94. Moreover, only a small proportion of HLA susceptible 
individuals actually develop T1D and the concordance of monozygotic twins 
with T1D is relatively low, suggesting environmental factors play an important 
role in disease onset95, 96. Several environmental factors have been associated 
with the development of T1D. Among them, the gut microbiome seems to be 
an important modulator of beta cell autoimmunity97. Enterovirus infection of 
human pancreatic islets in particular have been shown to induce secretion 
of cytokines and chemokines by endocrine cells and contribute to the 
inflammatory milue98. Post-transplant diabetes mellitus (PTDM) is a common 
complication after kidney transplantation, caused by the immunosuppressive 
drug tacrolimus that affects beta cell function99. These environmental factors 
are likely to increase endoplasmic reticulum (ER) stress which contributes to 
the induction of an inflammatory response as danger signal for the immune 
system100.




ER stress leads to accumulation of unfolded or misfolded proteins in the 
ER lumen, which leads to activation of the unfolded protein response (UPR)101. 
In homeostatic conditions, the three ER stress sensors protein kinase RNA-like 
endoplasmic reticulum kinase (PERK), activating transcription factor 6 (ATF6), 
and inositol-requiring enzyme 1α (IRE1α), are kept in an inactivated state by 
binding of ER chaperone BiP to the luminal domains of the sensors102. Upon 
accumulation of misfolded proteins, BiP dissociates from the receptors and 
binds to the exposed hydrophobic domains of the circulating misfolded 
proteins, thereby allowing self-activation of the receptors. ATF6 is translocated 
to the Golgi apparatus where protease digestion releases the cytosolic 
domain103. Once released, this domain moves into the nucleus where it acts 
as transcription factor. Both IRE1α and PERK are activated through auto-
transphosphorylation. Activated IRE1α induce the unconventional cytoplasmic 
splicing of X-box binding protein 1 (XBP1), thereby removing a 26-nucleotide 
intronic region and activating XBP1 as transcription factor, XBP1 spliced. 
These transcription factors induce the transcription of UPR target genes that 
include several chaperones and genes associated with ER-associated protein 
degradation (ERAD). Activated PERK leads to attenuated protein synthesis by 
phosphorylation of eukaryotic translation initiation factor 2α (eIF2α)104. The 
parallel signaling cascades ultimately lead to a reduction of the ER load and 
enhanced ER capacity by inhibiting of translation, increased degradation of 
misfolded proteins and increased protein folding.
When ER stress cannot be resolved, this will eventually lead to the activation 
of apoptotic programs105. However, even transient ER stress has significant 
consequences for the cell. ER stress can be an important indicator of pathogen 
invasion and cell dysfunction and therefore emits a danger signal to the immune 
system106, 107. Activation of the UPR is inevitably connected with the production 
of inflammatory cytokines and, in combination with hyperexpression of HLA 
class I108, optimizes immune surveillance. This is achieved by modulation of 
nuclear factor-κB (NF-κB) and activating protein 1 (AP-1) by the UPR signaling 
cascade and the subsequent transcription of proinflammatory cytokines 
IFN-β, IL-1β, TNF-α, and IL-6109-111. Beta cell autoimmunity will enhance this 
proinflammatory environment by secretion of IL-1β, TNFα, and IFNγ by immune 
cells112, 113.
As earlier discussed, the ER is of crucial importance in the biosynthesis, 
maturation and secretion of insulin. Glucose directly stimulates exocytosis 
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of stored insulin granules from the beta cell. In addition, to replenish the 
insulin storage and maintain glucose-responsive insulin secretion, insulin 
transcription and translation are induced. Perturbation of ER homeostasis can 
have detrimental consequences for the beta cells114. Secondary environmental 
triggers could be the final blow, tipping the scale and distort the natural ER 
balance. The implication of ER stress in disease pathogenesis is supported by 
the finding of increased ER stress markers in the islets of Langerhans of T1D 
patients115. Research indicated that ER stress precedes the onset of T1D and 
supposedly serves as a trigger for β-cell dysfunction and autoimmunity114, 
116. Moreover, insulitic islets showed overexpression of interferon-stimulated 
genes117. The inflammatory environment likely contributes to the induction 
and amplification of beta cell dysfunction and death118.
Inflammation and ER stress lead to profound changes in beta cells from 
the conversion of the genetic information into peptides loaded on HLA 
molecules119. Transcriptomic analyses performed on human islets maintained 
in presence or absence of proinflammatory cytokines have revealed a clearly 
different gene expression profile and a high proportion of RNA alternative 
splicing events (over 3000 genes undergo alternative splicing in stress 
condition)120. The increased cytosolic Ca2+ concentrations as consequence 
of ER stress, impact the activity of post-translational modification enzymes 
i.e. tissue transglutaminase 2 (Tgase2) and peptidylarginine deiminase 2 
(PAD2) that catalyzes deamidation or citrullination respectively121, 122. These 
modifications contribute to the formation of non-conventional polypeptides 
and immunopeptides. In case these modified proteins are not generated in 
adequate amounts during thymocyte maturation, T cells reactive towards this 
class of neo-self-epitopes are not eliminated during negative selection and 
are part of the matured circulating T cell repertoire123. Therefore tissue-specific 
neoepitopes provide a possible explanation for the loss of self-tolerance and 
rather support beta cell dysfunction as cause of disease pathogenesis, besides 
failure of mechanisms that induce self-tolerance. 
5. AIMS AND OUTLINE OF THIS THESIS
In this thesis the interplay between the islet microenvironment and the 
immunogenicity of human beta cells in type 1 diabetes pathology have been 




investigated. Chapter 2 demonstrates a direct link between ER stress, the 
increased visibility of beta cells to the immune system, and demonstrates the 
importance of the endoplasmic reticulum sensors in shaping antigenic peptide 
presentation to CTLs. Chapter 3 evaluates similarities between autoimmunity 
and an efficient anti-tumor response and proposes that beta cell autoimmunity 
is a well-intended immune response to dysfunctional beta cells. Furthermore 
the participation of the microenvironment on the generation of neoepitopes 
is discussed. The participation of an insulin-defective ribosomal product in T1D 
pathology is described in Chapter 4. Chapter 5 describes the characterization 
of a novel luciferase reporter to evaluate the ER stress status in human beta 
cells. Chapter 6 reveals the presence of a new insulin isoform in somatostatin-
producing cells. The significance of all these findings in T1D research is 
discussed in Chapter 7.
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The signal peptide of the preproinsulin is a major source for HLA class I 
autoantigen epitopes implicated in CTL-mediated beta cell destruction in 
Type 1 Diabetes (T1D). The combined action of signal peptide peptidase 
and endoplasmic reticulum aminopeptidase 1 (ERAP1) participates to the 
processing of the signal peptide and to the expression of this epitope at the beta 
cell surface. The regulatory mechanisms controlling signal peptide trimming 
and the contribution of the T1D inflammatory milieu on these mechanisms are 
unknown. We studied the role of inflammation and ER stress on ERAP1 gene 
expression. Inflammation and ER stress induction in human beta cells lead to 
increased expression of ERAP1 and to the decreased amounts of miR-17-5p. 
These results confirm the importance of ER stress in the increased visibility of 
beta cells to the immune system and position the IRE1α/miR-17 pathway as a 
central component in beta cell destruction processes. This pathway therefore 
forms a potential target for the treatment of autoimmune T1D in recent onset 
patients.
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Type 1 diabetes (T1D) results from selective and progressive destruction of 
insulin-producing cells by autoreactive CD8+ T cells1,2. Immunohistochemistry 
of insulitic pancreases obtained through the Network for Pancreatic Organ 
Donors with Diabetes program (nPOD)3 have shown a massive infiltration 
of immune cells and an increased expression of HLA class I and markers 
characteristic of a cellular stress response related to endoplasmic reticulum (ER) 
stress, referred to as the Unfolded Protein Response (UPR)4-6. Altogether these 
results suggest a correlation between ER stress and the increased visibility of 
beta cells to the immune system7. While several proteins have been identified 
as potential autoreactive T cell targets, evidence from studies in mice and men 
suggests that insulin itself could be a main autoantigen targeted by infiltrating 
CD8+ T cells in T1D8-10. The posttranslational processing pathway that generates 
insulin from its precursor molecule preproinsulin (PPI) is well established: 
the signal peptidase Sec11 cleaves off the signal peptide cotranslationally 
upon translocation of the protein into the ER via the translocon Sec6111. After 
proinsulin (PI) folding and the formation of three disulfide bonds, proinsulin 
is transported via the Golgi system into immature secretory vesicles where 
mature insulin is generated by the action of the prohormone convertases 
PC1/2. The central region of PI, the C-peptide, is cleaved out and the B- and 
A-chain located in amino- and carboxy-terminus, respectively remain together 
by the previously formed disulfide bonds yielding bioactive insulin11-14. 
Accumulating new data highlight the importance of the PPI signal peptide 
(SP), of 24 amino acids long, as source of insulin derived class I epitopes15. 
Peptide elution experiments performed on HLA-A2 surrogate beta cells led to 
the identification of prominent HLA class I binders located in the SP domain16 
and PPI(SP15-24)-directed CTLs were found to be highly prevalent in recent onset 
T1D patients17. Recently, using cell free translocation assays and CrispR/Cas 
technology elegantly demonstrated the importance of the combined action 
of the signal peptide peptidase and ER aminopeptidase 1 (ERAP1) in the 
trimming of the PPI SP and in the generation of the PPI(SP15-24) epitope
18. While 
the epitope length match with the structural characteristic of ERAP1 and the 
model described previously19,20, the link between T1D pathophysiology and 
the immunoreactivity against PPI(SP15-24) remains unclear. Here, we investigated 
the effect of inflammation and ER stress on ERAP1 gene expression in human 
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beta cells and show that proinflammatory cytokines as well as chemically 
induced ER stress modulate ERAP1 expression through induction of miR17-5p 
degradation. These data establish a direct link between ER stress, and beta cell 
immunogenicity and demonstrate the importance of the ER sensors in shaping 
antigenic peptide presentation to CTLs.
RESULTS
In T1D patients, surface presentation of autoantigens in HLA class I and their 
recognition by CD8+ T cells results in the induction of apoptotic cell-death 
in β-cells. To quantify CTL-induced cell death, we used a bioluminescent 
reporter (cFLuc-DEVD) in which luciferase activity is dependent on caspase-3 
cleavage21,22. To test this construct, we treated HeLa cells stably modified with 
the cFLuc-DEVD construct, with a potent apoptosis inducer and measured 
luciferase activity in cell lysates. As anticipated, staurosporin treatment resulted 
in a strong increase in light emission reflecting the increase caspase 3 activity 
(Fig. 1A). To determine whether this reporter could be used to monitor T cell-
induced cell death, we generated surrogate beta-cells by genetically modifying 
HEK 293T cFLuc-DEVD cells with a lentiviral vector containing the full-length PPI 
cDNA driven by a CMV early enhancer and promoter. Transduction of HEK 293T 
cells resulted in expression of the PPI expression cassette as was evident from 
qPCR analysis (Fig. 1B). Proinsulin synthesis was verified by western blot analysis 
(Fig. 1C). Overnight incubation of these surrogate beta cells, with increasing 
amount of PPI(SP15-24)-specific CTL led to increased light emission reflecting the 
CTL-induced apoptosis of the target cells. In contrast, luciferase activity was 
unaffected when unmodified HEK 293T cFLuc-DEVD cells were used as target 
(Fig. 1D). These data show that ectopic expression of PPI sensitizes HEK 239T 
cells to PPI(SP15-24)-specific CTL cytolysis and validate the specificity of our assay.
The localization of PPI signal peptide within the ER and the TAP independent 
routing of the PPI(SP15-24) point to alternative degradation mechanisms 
16. The 
presence of three alanine residues at the C-terminal part of the PPI signal 
peptide represents a high-affinity binding motif for the ERAP1 hydrophobic 
pocket and the two leucine residues in position 13-14 makes this region a 
suitable substrate for ERAP1 trimming19. To test whether ERAP1 plays a role in 
the generation of the PPI(SP15-24) peptide, we transduced surrogate beta reporter 
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2
cells with ERAP1-specifi c shRNA containing lentivirus (MOI=1). Expression of 
shERAP1 led to 90% reduction of ERAP1 mRNA compared to a non-specifi c short 
hairpin (Fig. 2A) without aff ecting ERAP2 gene expression (data not shown). 
Of note, the reduced ERAP1 expression in our assay had no impact on insulin 
gene expression or HLA-ABC surface expression (Fig. 2B, C). Downregulation 
of ERAP1 reduced PPI(SP15-24)-specifi c CTL-mediated target cell destruction, as a 
60% reduction of caspase-3 induced luciferase activity was observed at a 1:10 
Target:Eff ector ratio (Fig. 2D). Taken together, our data confi rm the implication 
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Figure 1: Characterization of caspase 3-inducible reporter and surrogate beta cells. (A) Transduced 
HeLa cells with cFLuc-DEVD reporter were exposed to 100nM staurosporine (ST) for 1 hr compared to 
non-treated controls (NT). Results are shown in relative light units (RLU). The results depict the average 
of 3 experiments. (B) Quantitation of PPI expression in HEK 293T/GFP cells and HEK 293T cells transduced 
with LV-CMV-PPI-bc-GFP by qPCR (MOI=1). Quantitative PCR analysis has been performed in triplicate 
and GAPDH corrected. (C) Western blot analysis of PPI expressing cells using an insulin-specifi c antibody 
and as control a human actin-specifi c antibody. (D) HEK293T/GFP cells expressing cFlucDEVD (open 
symbols) and HEK 293T cells expressing PPI and cFlucDEVD 293T cells (black symbols) were cocultured 
16h with increasing numbers of PPI(SP15-24)-directed CTL.
Proinfl ammatory cytokines play a central role in triggering autoimmunity 
by inducing ER stress in beta cells7,23-25. To evaluate the importance of 
infl ammation-induced ER stress on ERAP1 expression in human beta cells, we 
treated EndoC-βH1 cells with a mixture of the proinfl ammatory cytokines IFNγ 
and Il-1β. ERAP1 was upregulated in the presence of cytokines and this was 
associated by the upregulation of XBP1s, an important transcription factor 
induced upon ER stress (Fig. 3A). Similar results were obtained in primary 
human pancreatic islets (Fig. 3B). Increased ERAP1 gene expression was 
mirrored by ERAP1 protein levels (Fig. 3C). Activation of the endoribonuclease 
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IRE1α upon ER stress resulted in the processing of the XBP1 mRNA by and the 
removal of 26bp to generate an active XBP1s transcription factor. Inhibition of 
IRE1α by MKC3946, led to reduced XBP1 splicing 26. Accordingly, co-treatment 
with MKC3946 dampened cytokine-induced ERAP1 gene expression in EndoC-
βH1 cells (Fig. 3D) 
Figure 2: ERAP1 down-regulation by shRNA lentiviruses reduce CTL-mediated killing. A) PPI cFLuc-
DEVD HEK 293T cells transduced with lentiviruses containing a non-specific shRNA cassette (N.S.), or a 
shRNA cassette directed against ERAP1 (shERAP1). Four days post-transduction, cells were analyzed for 
ERAP1 expression by qPCR. (B) Expression of insulin gene in shERAP1 and non-specific shRNA (N.S.) cells 
assessed by qPCR. Quantitative PCR analysis has been performed in triplicate and GAPDH corrected. (C) 
HLA class I surface expression of non-specific shRNA (upper panel) and shERAP1 modified PPI cFLUC-
DEVD HEK 293T cells (lower panel). Non stained cells are used as control (dark grey). (D) Killing assay 
performed on non-specific shRNA (solid squares) and shERAP1 (open squares) expressing PPI cFLUC-
DEVD HEK 293T cells after 16 hr co-culture with increasing amounts of PPI(SP15-24) directed CTL. 
Luciferase activity in absence of CTLs was arbitrary set to 1. The results are shown as fold induction.
IRE1α has been shown to play a critical role in the control of beta cell 
dysfunction and death via degradation of miR-17-5p and the consequent 
activation of thioredoxin-interacting protein (TXNIP) 27. Target sequence 
analysis of miRNAs expressed in beta cells, revealed 6 potential miRNAs that 
regulate ERAP1 gene expression28 (Fig. 4A). All these miRNAs belonged to the 
miR-17 miRNA family, indicating a conserved miRNA regulatory mechanism 
(Table 1). In line with these predictions, stimulation of human beta cells with 
proinflammatory cytokines showed a correlation between increased ERAP1 
and XBP1s expression and decreased miR-17 expression as assessed by qPCR 
(Fig. 4B). Of note, endogenous insulin expression remained unchanged upon 
cytokine stimulation. To test whether miR-17 has a direct effect on ERAP1, we 
generated luciferase reporter constructs in which a fragment of the ERAP1 
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Figure 3: Eff ect of ER stress induction on ERAP1 expression. A) Relative ERAP1 (left panel) and XBP1s 
(right panel) expression in EndoC-βH1 cells after 24h treatment with IFNγ and IL-1β (CYT) compared to 
non-treated cells (NT) analyzed by qPCR. B) Relative ERAP1 expression in primary human pancreatic 
islets after exposure to proinfl ammatory cytokines for 24h (CYT) compared to non-treated islets (NT). C) 
Western blot analysis of EndoC-βH1 lysates for ERAP1 protein expression (upper panel). Actin was used 
as loading control (lower panel). Quantifi cation has been performed by ImageJ and corrected for actin. 
D) Relative ERAP1 gene expression in EndoC-βH1 cells after cytokines stimulation in presence or 
absence of MKC3946 (10uM). Quantitative PCR analysis has been performed in triplicate and GAPDH 
corrected.
3’UTR containing the potential miR-17 binding site was cloned between the 
stop codon and the poly-A of the luciferase coding sequence. A UTR mutant 
in which two mutations were introduced to prevent miR-17 binding was 
generated and used as control in our assay. Transient expression of miR-
17 in HEK 293T luciferase reporter reduced luciferase activity in presence of 
native UTR sequence, while luciferase activity cells transfected with a mutated 
reporter UTR sequence remained unchanged compared to control miR-1 (Fig. 
5A). These results confi rm that miR-17 can directly regulate ERAP1 expression. 
Supporting these fi ndings, the forced expression of miR17 in human beta cell 
blunted proinfl ammatory cytokine-induced upregulation of ERAP1 (Fig. 5B). 
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Altogether, our data demonstrate a link between proinfl ammatory cytokine-
induced ER stress and ERAP1 via IRE1α-mediated miR-17 suppression in the 
control of preproinsulin signal peptide trimming, autoantigenic epitope 
generation, and CTL-mediated target cell destruction.
Table 1: Prediction of ERAP1 targeting miRNAs expressed in human pancreatic beta cells. 








ERAP1-miRNA motif and the energy folding characteristic of the miR-17 family on the ERAP1 UTR 
region. Data presented are according to in silico predictions performed on https://cm.jeff erson.edu/
rna22/Interactive/RNA22Controller.
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Figure 4: Correlation between ER stress-induced miR-17 and ERAP1 gene expression. A) Venn 
diagram showing the overlap between miRNAs found in beta cells and predicted ERAP1 targeting 
miRNAs according to miRbase V21.0 and StarBase V2. B) Relative expression of ERAP1 (top left) XBP-1s 
(top right), MiR-17 (bottom left) and INS (bottom right) in EndoC-βH1 cells after cytokine stimulation 
(CYT) compared to non-treated cells (NT). Quantitative PCR analysis has been performed in triplicate. 
ERAP1, XBP1s, and insulin are GAPDH corrected. MiR-17 expression has been corrected for RNU6. 
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Figure 5: MiR-17 regulates ERAP1 gene expression. A) Schematic representation of the miR-17 targeting 
sequence in the 3-UTR of ERAP mRNA (wt UTR) and the mutated ERAP1 UTR (mut UTR) in the luciferase 
reporter constructs with the predicted folding energy (top). Relative luciferase activity after co-transfection 
of miR-1 (negative control) or miR-17 with ERAP1 wt UTR luciferase construct or ERAP1 mut UTR in 293T 
cells (bottom). Data are corrected for LacZ activity. B) Relative expression of miR-17 (left panel), ERAP1 
(middle panel) and INS (right panel) in EndoC-βH1 following miR-17 or control miR-1 transfection in the 
presence or absence of cytokine stimulation. Quantitative PCR analysis has been performed in triplicate. 
ERAP1 and insulin are GAPDH corrected, miR-17 expression has been corrected for RNU6.
DISCUSSION
Here, we demonstrate a new regulatory mechanism connecting ER stress 
induction and increased beta cell exposure to the immune system.The signal 
peptide of PPI represents a major source of antigenic peptides derived from 
insulin gene products 15,16. Increased ERAP1 expression in isolated human islets 
and human beta cells upon IFNγ/IL1β stimulation would lead to an increased 
signal peptide processing and beta cell destruction during inflammation in 
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T1D patients. While in vitro trimming assays have pointed out a peptide length 
limitation for ERAP1 cleavage (the upper length limit was defined at 16 residues19), 
our data corroborate previous results on the implication of ERAP1 in PPI(SP15-24) 
processing and presentation 18. The reduced apoptosis upon ERAP1 knockdown 
in surrogate beta cells after coculture with PPI(SP15-24)-specific CTLs is in line with the 
reduced expression of T cell activation marker (MIP-1β) observed by Kronenberg-
Versteeg et al. after targeting ERAP1 by siRNA in their assay 18. Intriguingly, based 
on the essential role of peptide trimming for proper presentation of many 
epitopes, a decrease expression of HLA class I would seem conceivable upon 
down-regulation of ERAP1. However, transduction of shRNA directed against 
ERAP1 had no effect on surface expression of HLA. The exact function of ERAP1 in 
controlling MHC class I expression remains unclear. While ERAP1 knockdown by 
siRNA in HeLa cells was shown to slightly reduced HLA class I expression, this has 
not been observed for H-2Kb surface expression in mice 29,30.
ERAP1 was initially described as IFNγ responsive gene31. Yet, cotreatment 
of proinflammatory cytokines with MKC3946 demonstrates that the IRE1α 
pathway participates to the regulation of ERAP1 gene expression and reveals 
a direct link between ER stress and ERAP1 gene expression. Several miRNAs 
have been implicated in the response to stress 32, among these miR-17 has 
been shown to be a master regulator of beta cell apoptosis by controlling 
the thioredoxin-interacting protein (TXNIP)27,33. Inhibition of TXNIP prevents 
diabetes development in mouse models fort T1D and T2D, however the role 
of TXNIP in beta cells is complex. TXNIP modulates the cellular redox state 
and participates to the induction of oxidative stress and consequently the 
induction of apoptosis by activation of caspase 2 and release of cytochrome C, 
as well as the amplification of insulitis by activating the NLRP3 inflammasome, 
activation of caspase 1, and maturation of Il1β 34-36. While TXNIP regulation 
was demonstrated to be independent of ATF6, PERK and IRE1α were shown 
to participate to TXNIP transcriptional and post-transcriptional control, 
respectively 37. Whether the other arms of the UPR are involved in ERAP1 
regulation and expression, as for TXNIP, needs to be determined. 
In this study, we confirmed the complexity of antigenic peptide generation 
originating from signal peptide domain of the human preproinsulin. The 
implication of the IRE1α/miR-17 pathway in regulating the resident ER protein 
trimming underscores the key role played by ER stress in the development 
of autoimmunity. The central role for IRE1α/miR-17 in beta cell dysfunction 
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and apoptosis via upregulation of TXNIP and autoantigen processing via 
upregulation of ERAP1 designate IRE1α as an interesting therapeutic target 
in diabetes. This intervention opportunity is supported by a recent finding of 
reversed autoimmune diabetes in NOD mice after IRE1α inhibition38.
MATERIALS AND METHODS
DNA Constructs 
pLV-CMV-cFLuc-DEVD was generated by insertion of a PmeI/PmeI fragment 
from the pcDNA3.1-cFLuc-DEVD21 into the backbone of pLV-CMV39 restricted 
with EcoRV. Preproinsulin cDNA was obtained from reverse transcriptase 
reaction of total human islets RNA extraction using the following primers: PPI-
Full(Fw): ATG GCC CTG TGG ATG CGC CTC CTG CCC; PPI-Full(Rv): GTT GCA GTA 
GTT CTC CAG CTG GTA GAG GGA GCA. LV-CMV-PPI was generated by insertion 
of the coding region of the preproinsulin cDNA into pLV-CMV-bcGFP. For miRNA 
reporter construct the following primers were annealed and cloned into pMIR-
REPORT (Thermofisher Scientific) open with PmeI. ERAP UTR Fw: 5’-gta att tga 
ata tag aca caa tgc act tta ttg cac ttt caa ttc tta taa agc; ERAP UTR Rv 5’-GCT TTA 
TAA GAA TTG AAA GTG CAA TAA AGT GCA TTG TGT CTA TAT TCA AAT TAC; ERAP 
UTR mut Fw 5’-gta att tga ata tag aca caa tgc act tta ttg tgc ttt caa ttc tta taa agc; 
ERAP UTR mut Rv 5’-GCT TTA TAA GAA TTG AAA GCA CAA TAA AGT GCA TTG 
TGT CTA TAT TCA AAT TAC. The constructs were verified by sequencing.
Cells and reagents
293T (HLA-A2 positive) were grown in high glucose DMEM supplemented 
with 10% (v/v) heat inactivated fetal bovine serum (Gibco BRL) and penicillin/
streptomycin at 37C, 5%CO2. PPI(SP15-24) directed CTLs were maintained in 
IMDM supplemented with 10% human serum, IL-2 and IL-15 and restimulated 
every 14 days with JY cells (pulsed with 10mg/ml PPI15-24 peptide) at 1:5 
ratio in presence of IL-2 and IL-15. PPI15-24 was synthesized using solid-
phase Fmoc chemistry, analyzed by reverse-phase high-performance liquid 
chromatography (RP-HPLC) and mass spectrometry for purity and identity. 
EndoC-βH1 cells, kindly provided by Dr. Raphael Scharfmann (Paris Descartes 
University, France), were maintained in low glucose DMEM supplemented with 
5.5 μg/ml human transferrin, 10 mM nicotinamide, 6.7 ng/ml sodium selenite, 
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50 μM β-mercaptoethanol, 2% bovine serum albumin fraction V, 100 units/ml 
Penicillin and 100 μg/ml Streptomycin. Cells were seeded in ECM, fibronectin 
pre-coated culture plates. 
Inflammatory stress was induced by a mixture of 1000 U/ml IFNγ and 2 ng/
ml IL1β for 24 h. Staurosporine was used at 100nM for 1h and Thapsigargin was 
used at 100nM for 24h. MKC3946 inhibitor was used at 10uM for 24h in our assay.
MiRNA transfection
Transient transfection of miRNA mimics were performed using Lipofectamine 
2000 (Invitrogen) according to manufacturer’s protocol. EndoC-βH Cells were 
transfected in a 24-well plate, using a final concentration of 50 nm miRNA 
precursor, Hsa-miR-17-5p precursor (PM12412, Ambion) or premiR Hsa-miR-1 
(Ambion), was used. Experiments were continued 24 h post transfection. For 
the validation of miRNA targeting sites, 125 ng pMiR-luc-ERAP1-wtUTR or 
pMIR-luc-ERAP1-mutUTR, 5 ng pLacZ and 50 nM miRNA precursor Hsa-miR-17-
5p precursor or premiR Hsa-miR-1 were used per well (96-well plate) to modify 
293T cells. Transfections were performed in triplicate and cells were analysed 
24 hours post transfection. 
Lentiviruses production and transduction
The vectors were produced as described previously39. Briefly, the lentiviral 
backbone containing the gene of interest and the three helper plasmids 
(encoding HIV-1 gag–pol, HIV-1 rev, and the VSV-G envelope protein) were 
co-transfected overnight using the calcium phosphate method into 293T 
cells. The medium was refreshed and viruses were harvested after 48 and 72 
h, passed through 0.45-um filters, and stored at -80°C. Virus was quantified by 
antigen capture ELISA measuring HIV p24 levels (ZeptoMetrix Corp., New York, 
NY, USA) as described40. Then, viral supernatants were added to fresh medium 
supplemented with 8 μg/ml Polybrene (Sigma), and the cells were incubated 
overnight. The next day, the medium was replaced with fresh medium. 
Transduction efficiency was analyzed 3 to 6 days post transduction.
ERAP1 downregulation
shRNA lentiviral constructs for ERAP1 knockdown were obtained from the 
Mission shRNA library (Sigma-Aldrich clones TRCN060539; TRCN060540; 
TRCN060541; TRCN060542). Based on preliminary assays to assess knock-down 
efficiency (data not shown), we selected the TRCN060542 clone for further use. 
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The shERAP1 encoding lentivirus was produced as described above.
FACS analysis
Cells were washed in PBS containing 0.1% BSA and subsequently incubated in 
100 μl of PBS/0.1% BSA with the appropriate amount of antibody for 60 min 
at 4°C in the dark. Cells stained with the proper isotype were used as negative 
control. HLA-A2 and HLA-ABC-FITC were purchased at BD Pharmingen Inc. (San 
Diego, CA, USA). For flowcytometry, 10,000 events were counted on a FACS 
LSRII (BD Pharmingen Inc., San Diego, CA). Data analyses were performed using 
FlowJo software.
RT-PCR / qPCR
Total RNA was extracted from cultured cells using Trizol reagent following 
manufacturer’s instructions. Isolated RNA was quantified using a Nanodrop 
1000 spectrophotometer. Approximately 500 ng RNA was reverse transcribed 
using Superscript RT II kit (Invitrogen, Karlsruhe, Germany). Expression of the 
genes interest was detected using the following primers: Insulin Fw GCA GCC 
TTT GTG AAC CAA CA, Insulin Rv CGG GTC TTG GGT GTG TAG AAG; ERAP1 
Fw GAA AAC CAT GAT GAA CAC TTG G, ERAP1 Rv CCA CCT CTT CTG GGA 
GGA TGA G; GAPDH Fw ACA GTC AGC CGC ATC TTC TT, GAPDH Rv AAT GAA 
GGG GTC ATT GAT GG, XBP1s Fw 5’-CTGAGTCCGCAGCAGGTG-3’, XBP1s Rv 
5’-GAGATGTTCTGGAGGGGTGA-3’; ATF3 Fw 5’-GTGCCGAAACAAGAAGAAGG-3’, 
ATF3 Rv 5’-TCTGAGCCTTCAGTTCAGCA-3’; CHOP Fw 5’- 
GACCTGCAAGAGGTCCTGTC-3’, CHOP Rv 5’- CTCCTCCTCAGTCAGCCAAG-3’; 
Polymerase chain reactions were performed on a PTC-200 (Biozym, Landgraaf, 
The Netherlands) using the following conditions: 94°C for 5 min; 35 cycles of 
30’’ at 94°C, 30’’ at 60°C, and 1.5 min at 72°C; 10 min at 72°C. Real-time PCR were 
performed in triplicate using the SybrGreen master mix kit (Applied Biosystems, 
Nieuwerkerk a.d. lJssel, The Netherlands) and an Applied Biosystems Step One 
Plus. Comparative ΔΔct values were performed using GAPDH gene as reference. 
Values are represented as mean ± standard error. 
For microRNA quantification, total RNA was reverse transcribed using 
Taqman microRNA Reverse transcription kit (Applied Biosystems) and detected 
using Hsa-miR17 Taqman microRNA assays (PN4427975, Applied Biosystems) 
and TaqMan 2x Universal PCR Master Mix, no UNG (applied Biosystems) 
according to manufacturer’s instructions. MicroRNA expression was normalized 
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to RNU6 using the following primers: RNU6 Fw 5’-CTCGCTTCGGCAGCACA-3’; 
RNU6 Rv 5’-AACGCTTCACGAATTTGCGT-3’.
Western blot analyses
Cells were lysed in RIPA lysis buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, SDS 
0.1%, 0.5% DOC, 1% NP40, with proteases inhibitors). For insulin staining, 
proteins extracts were loaded on 17% acrylamide/bis acrylamide SDS page 
gel, and after electrophoresis, transferred to Immobilon-P transfer membrane 
(PVDF); Millipore, Etten-Leur, The Netherlands and treated with anti-insulin 
(1:1,000; Santa Cruz SC-9168), and anti-actin (1:5,000, clone C4; ICN Biomedicals, 
Inc., Zoetermeer, The Netherlands) sera. For ERAP1 analyses, proteins extracts 
were loaded on 10% acrylamide/bis acrylamide SDS gel. After blotting, the 
membranes were stained with anti-ERAP1 (Santa Cruz B10; Sc-271823).
CTL killing assay & luciferase assay
2.104 to 5.104 modified HEK 293T cells were plated in 96 well plate and exposed 
for 16h to increasing amounts of PPI directed CTLs. After overnight coculture, 
media was removed and cells were lysed in luciferase lysis buffer [125 mM Tris/
HCl, pH 7.8, 10 mM CDTA, 10 mM DTT, 50% (v/v) glycerol, 5% (v/v) Triton X-100]. 
Light emission was determined using Lumat LB9501 luminometer (Berthold, 
Bad Wildbad, Germany). Luciferase activity from cells in absence of CTL was 
used as reference and arbitrary set to 1.
In silico analyses and statistical analysis
Data are presented as mean ± SEM. Calculations were performed using 
GraphPad Prism 7. 
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Type 1 diabetes (T1D) is characterized by the selective and progressive 
destruction of insulin-producing beta cells by the immune system. An 
incomplete thymic selection against self-reactive islet antigens partly 
explains how these T cells reach the periphery and become diabetogenic. 
Increasing evidence suggest that beta cells themselves also participate to 
their own demise by generating neoepitopes that could be recognized by 
the immune surveillance machinery. In this regard, these T cells eradicate 
self-tissue by mechanisms analogous to a classical antitumor response. 
Cancer immunotherapy has exploited mutations and transcriptional 
and translational errors to trigger a specific antitumor response. In this 
opinion article, we aim at merging insight in antitumor immunology and 
autoimmunity to reveal processes that had previously been ignored to create 
beta cell-specific neoantigens. 
Trend box
• The microenvironment during beta cell destruction in T1D resembles a 
prototype effective antitumor response, that is, clearance of abnormal, 
dysfunctional or potentially harmful cells.
• Modified proteins that escape thymic education and peripheral tolerance 
provide a new range of candidate neoantigens as targets in the pathogenesis 
of T1D, similar to mutated and tumor specific proteins in antitumor immunity. 
• Identification of modified epitope-specific T cells may serve as biomarkers in 
the early detection of dysfunctional beta cells, thereby guiding early immune 
intervention to avoid progressive beta cell immunogenicity and destruction.
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SIMILARITIES BETWEEN T1D AUTOIMMUNITY AND 
ANTITUMOR IMMUNITY
During thymic education, the majority of autoreactive T cells are eliminated by 
apoptosis while lower avidity T cells may escape negative selection in the thymus 
and reach the periphery [1]. Naïve islet autoreactive T cells are detectable in both 
T1D patients and non-diabetic subjects [2]. Activation of these T cells will require 
priming by the target tissue in dialogue with the immune system. Even after 
activation, peripheral islet autoreactive effector T cells will usually remain under 
control by various immune regulatory mechanisms including regulatory T cells 
(Tregs) [3,4]. There is increasing evidence that local inflammation combined with 
a genetic predisposition contributes to the break in immune tolerance, leading 
to insulitis and destruction of beta cells [5,6]. Yet, the circumstances under which 
these islet-autoreactive T cells become activated and specifically target beta cells 
in T1D patients still largely remains to be clarified.
Beyond imperfect thymic education of immune reactivity against native 
self-proteins, it is conceivable that dysfunctional beta cells either as cause or 
consequence of T1D etiology generate and accumulate aberrant, modified 
neo-autoantigens, which lack both central and peripheral immune tolerance. 
These neoantigens may prime, activate, maintain, exacerbate, and accelerate 
T1D, either directly by affecting target cell viability and integrity, or indirectly 
by the generation of neoepitopes priming diabetogenic T cells. 
Despite many differences, including time and magnitude of the immune 
response between anti-tumor immunity and beta cell autoimmunity, we 
contend that the inflammatory signals surrounding the islets of Langerhans 
during insulitis (Box 1) resemble the signals identified at the vicinity of tumor 
cells during successful anti-tumor immune surveillance. In T1D, environmental 
stress and other perturbations in and around pancreatic beta cells may 
also disturb the cellular equilibrium and affect high fidelity transcriptional, 
translational and post-translational processes generating neoantigens to 
which the immune system is trained to act upon[6]. Cancer immunity and 
immunotherapy have exploited these errors and modifications to trigger 
specific immune responses against tumor-associated self-antigens[7]. The 
participation of similar post-transcriptional and (post-) translational errors in 
the process of beta cell destruction still deserves investigation but point to a 
striking similarity in the immunopathogenesis of T1D and effective anti-tumor 
immunity (Figure 1).
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Here, we provide a comprehensive overview of post-transcriptional and 
(post- ) translational processes currently known to occur in autoimmune 
diseases and in tumor immunology. We describe the different pathways 
affected by an inflammatory environment leading to generation of tumor-
specific neoantigens to guide discovery of new, relevant islet epitopes that 
act as surrogates of diabetogenesis and insulitis. This may improve immune 
monitoring of disease progression and therapeutic intervention. 
Box 1. Why is beta cell destruction selective? Influence of islets microenvironment 
Islets of Langerhans are embedded in exocrine pancreatic tissue. In addition to 
their role in secreting digestive enzymes, autopsy studies suggest that the exocrine 
pancreas is involved in the development of autoimmunity by supporting trafficking 
of immune cells to the islet [89], even though the rate of exocrine inflammation was 
much less in pancreatic biopsy studies in living newly diagnosed T1D patients [90]. 
Strikingly, beta cells remain the primary target of destruction by the immune 
system. Several studies have shown that endocrine cells differ in their resilience to 
stress condition. Under pathophysiological mimicking T1D, beta cells were shown 
to be more sensitive than alpha cells to proinflammatory cytokines stimulation [91], 
and similar results were obtained after metabolic stress [92]. Endocrine cells seem 
differentially equipped to stand an environmental insult. The intrinsic properties 
of beta cells being insulin factories might explain this sensitivity to environmental 
changes [93]. The high oxidative stress with which beta cells have to deal with, 
combined with HLA class I hyperexpression observed in T1D that may even 
precede insulitis, may lead to T cell infiltration and beta-cell specific destruction by 
autoreactive T-cells [16]. Yet, other endocrine cells within the islet may participate 
in the dialogue with the immune system without apparently being targeted by the 
immune system. The role of alpha cells, for example, has been largely underestimated. 
The precise architecture of human islets interconnecting alpha and beta cells fosters 
a direct crosstalk. Pioneer studies from Unger and Orci in the 1970s demonstrated 
the importance of glucagon in T1D, suggesting T1D to be a ‘bihormonal’ disease 
characterized by reduced insulin and high glucagon levels [94]. Alpha cells could 
be a missing link in the communication chain between immune system and beta 
cells. The recent demonstration that alpha cells represent an intra-islet source of 
glucagon-like peptide-1 (GLP-1), known for preventing beta cell apoptosis and 
promoting beta cell function [95], combined with the recent demonstration that 
IL-6 enhances GLP-1 release by alpha cells, strengthens the concept of a direct and 
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intimate relation between the immune compartment, alpha cells and beta cells that 
may even be invigorated during inflammation [96].
FIGURE 1: Similarities in inflammatory microenvironment between immune-mediated destruction 
of tumor and beta cells. The proinflammatory milieu in effective antitumor immunity highly resembles 
pathogenic immune responses in type 1 diabetes (T1D). Colored components are effectively engaged 
in target cell destruction. The tumor microenvironment otherwise suppressing antitumor immunity by 
downregulation of human leukocyte antigen (HLA) class I on tumor surface and recruitment of myeloid-
derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs) and tumor-associated 
fibroblasts (TAFs) sustaining tumor survival, and promoting tumor cell growth and metastasis (left 
panel, grey tones) is outweighed by a proinflammatory immune infiltrate and adaptive immunity 
against the target cancer cells (colored).  Destruction of pancreatic beta cells in T1D follows similar 
proinflammatory processes (right panel, colored tones). We propose that lessons from a deleterious 
tumor microenvironment may guide studies investigating the roles of MDSCs, regulatory T cells (Tregs), 
and contribution of the beta cell microenvironment (other endocrine islet cells [alpha, delta, PP] and 
exocrine tissue) that may control pathogenic beta cell destruction (broken arrows). At the heart of 
target cell destruction, the adaptive immunity involves recognition of target cell antigens. Recent 
insight points to a role of modified tissue antigens, in addition to native autoantigens in both the 
pathogenesis of type 1 diabetes and effective antitumor immunity or immunotherapy. Abbreviations: 
DC, dendritic cell; KIR, killer cell immunoglobulin-like receptor; NK, natural killer cell; TNF, tumor necrosis 
factor. 
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BETA CELL MICROENVIRONMENT VERSUS TUMOR 
MICROENVIRONMENT
Environmental factors are implicated in both T1D etiology and effective anti-
tumor immunity. The resulting inflammation initiates progressive destruction 
of the target cells (beta cells and tumor respectively) by promoting the 
generation of immune responses against self-proteins via infiltrating dendritic 
cells.
In response to inflammatory environmental signals, both beta cells 
and tumor cells are in dialogue with the immune system by local release of 
proinflammatory cytokines (IL-1β)[8,9], chemokines (e.g., CCL2, CXCL10)[10-
12] and by the generation of neoantigens recognized by tumor specific or 
autoreactive T cells [13,14] (Figure 1). Increased Human Leukocyte Antigen 
(HLA) expression is one of the first features of islet distress, apparently preceding 
insulitis in case of T1D [15]. While tumors may develop ways to evade immune 
detection (e.g. down regulation of HLA class I, sialic acid expression, and direct 
inhibition of lymphocytes [16,17]), in beta cells the HLA class I hyper-expression 
in combination with production of chemo-attractants amplifies the visibility 
for immune surveillance and magnitude of the immune response [10,11]. This, 
together with signals generated by invading immune cells (e.g. CD8 and CD4 T 
cells), may contribute to the formation of a microenvironment comparable to 
an effective anti-tumor response. 
In case of progressive tumors, the microenvironment contains other cells 
that contribute to tumor growth, such as tumor-associated fibroblasts (TAFs) 
secreting TGFβ, FGF, IGF1 or other pro-angiogenic factors (VEGF, PDGF) [18,19], 
myeloid-derived suppressor cells (MDSCs) that prevent cytotoxic T cell activity, 
and recruitment of tumor-associated macrophages (TAMs) involved in escaping 
anti-tumor mechanisms by secreting immunosuppressive cytokines (e.g. IL10) 
[20,21]. Macrophages can be found in insulitic lesions [22] but while TAMs 
migrate to the inflammatory site, phenotype characterization of pancreatic 
macrophages in mouse suggest that M1 islet resident macrophages can be 
involved in beta cell destruction [23]. MDSCs have recently been reported 
to be increased in peripheral blood of T1D patients, whereas their frequency 
was decreased in the islet microenvironment in diabetic NOD mice, implying 
an underlying defect in immune suppression [24]. Natural thymus derived 
regulatory T cells (nTregs) (CD4+CD25high with demethylated FoxP3) impair 
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effective anti-tumor responses[25]. Immunotherapy targeting CD25 releases 
curative anti-tumor T cell immunity[26]. Studies in NOD mice suggested that 
progression to autoimmune diabetes was associated with a reduction of 
nTregs[27]. nTregs have not been detected in human insulitis yet, in marked 
contrast to mouse models this lack of ‘natural’ immune regulation would 
certainly aid to the immune imbalance favouring autoimmunity and T1D. In 
addition, while the frequency of circulating nTregs is similar in healthy and 
T1D subjects, their suppressive quality is reduced in T1D, whereas effector T 
cells seem resistant to suppression by nTregs from T1D donors [3,28,29]. Tissue 
specific Tregs reactive with islet autoantigens have also been reported to be 
less frequent in T1D than healthy subjects [3]. These islet specific Tregs may 
exert their suppressive activity in healthy and slow-progressive T1D subjects 
by unorthodox interaction of their T cell Receptor (TCR) with the islet peptide/
HLA class I molecule [30].
SOMATIC MUTATIONS IN DISEASE PROGRESSION
The vast majority of all cancers are linked to somatic mutations in association 
with environmental factors. Bacterial infections are often associated with gastric, 
bladder or colon cancer, infections with hepatitis viruses have been associated 
with increased hepatocellular carcinoma, EBV infection with Hodgkin’s 
lymphoma, while non-microbial environmental factors (environmental toxins, 
ultraviolet light or smoke) have also been shown to promote carcinogenesis 
(lung cancer, thyroid cancer, melanoma) [31,32]. These somatic mutations 
can accumulate during cell division but remain, usually without tumorigenic 
consequences. Yet, in rare cases, these mutations affect important cell regulator 
elements leading to anarchic cell division and apoptosis inhibition causing 
tumor development. Fortunately, the immune system is endorsed with highly 
efficient and sensitive immune surveillance specifically targeted to discover 
subtle differences in tissues distressed by infection or carcinogenesis. While 
some mutations contribute to tumorigenesis by activation of oncogenes[33], 
others play an important role in anti-tumor-immunity by generating specific 
tumor neoantigens that may trigger an immune response against cancer 
cells [34]. The low division rate of adult beta cells makes somatic mutations 
unlikely to happen during T1D development [35]. Similarly, somatic mutations 
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in TCR genes that could have led to a change in peptide affinity and specific 
recognition of beta cell self-peptide have not yet been reported. 
ENVIRONMENT AND RNA EDITING
Beta cells in insulitis and tumor cells under immune attack are immersed in a 
similar environment, receiving similar inflammatory signals that lead to the 
development of autoimmunity or anti-tumor immunity (as detailed in figure 
1). Next generation sequencing showed that most RNA, in healthy tissue, 
undergo alternative splicing by exon skipping or cryptic splicing sites leading 
to modification of the coding region [36]. Alternative splicing is an adaptive 
mechanism that participates to genome complexity. Proper introns removal from 
pre-mRNA is a complex mechanism involving the recognition of splicing sites 
by small nuclear ribonucleotide particles assembled as spliceosome complex. 
The still poorly understood regulation of these processes involves participation 
of cis-/trans-acting splicing proteins and is regulated by splicing enhancers/
inhibitors located in upstream exons or introns [37]. During tumor development, 
an inflammatory environment can lead to perturbation of splicing regulatory 
factors generating cancer-specific transcripts different from the classical pool 
of mRNA expressed in healthy tissue [38]. Several studies conducted in ovarian, 
breast and colon cancer showed that over 50% of the transcripts were affected 
during tumor development [39]. Since each of these alternative transcripts can 
possibly generate a pool of neo-polypeptides (functional or not), the peptidome 
of the tumor cell can be both complex and tumor specific [40]. First evidence of 
these alternative splice variant epitopes was provided by transcriptome analysis 
of melanomas and the discovery of the tumor antigen MAGE-1, able to stimulate 
human T cells [41]. Initially identified in melanoma, MAGE-1 belongs to a gene 
family (MAGE-A; MAGE-B, MAGE-C) characterized by a large terminal exon 
that is silent in normal tissue but expressed in tumor cells [42]. This differential 
expression between healthy tissue and cancer made MAGE gene products a 
target of choice for antitumor immunotherapy. 
In melanoma also incomplete splicing of the N-Acetyl glucosamyl 
transferase V with intron retention was observed in more than 50% of tumor 
cells whereas healthy tissue exclusively expressed fully spliced form. Again, this 
alternative splicing gave rise to the generation of unique epitopes encoded 
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by the intronic region recognized by CD8 T cells [43]. Although alternative 
transcripts are of interest as tumor progression biomarker, their relevance as 
target for immunotherapy remains questionable due to the heterogeneity of 
antigen expression in tumors; therefore tumor-specific vaccination might be 
inefficient with tumor cells lacking the antigen.
Recently, elevated alternative mRNA splicing events have been observed 
in inflamed human islet transcriptome studies providing evidence of beta 
cell neo-autoantigen generation during insulitis [44]. Although many splicing 
variants have been reported affecting cell function, the altered transcriptome 
in inflamed islets is a potential template for the generation of neoantigens and 
neoepitopes that subsequently can prime autoreactive T cells.[45]. 
Autoimmune disease reflects a combined loss of both central and peripheral 
tolerance leading to activation of autoreactive T cells. The differential protein 
expression between thymus and periphery of the proteolipid protein (PLP), 
is believed to contribute to multiple sclerosis (MS). While two transcript are 
expressed in the central nervous system, a full length PLP and a shorter variant 
lacking 35 amino acids encoded by a portion of exon 3 (DM20), only the short 
variant was detected in the thymus. Peripheral activation against sequence 
encoded by exon 3, leads to destruction of the myelin component in the central 
nervous system [46]. Similarly, differential expression of insulin, protein tyrosine 
phosphatase-like protein (IA-2) and Islet-specific glucose-6-P catalytic subunit-
related protein (IGRP) in the thymus and the pancreas may also contribute to 
lack of central tolerance, creating a fertile environment for the development of 
T1D. In the thymus, IA-2 is produced as a protein lacking the transmembrane 
and the juxta-membrane domain encoded by exon 13. The identification of a T 
cell response against an epitope located in this domain demonstrates the lack 
of tolerance to IA-2 [47]. Also, while the full IGRP transcript is expressed in the 
pancreas, the thymus expresses forms lacking exon 2, 3 or 4. This differential 
expression participates to the incomplete tolerance towards IGRP in T1D and 
makes these regions, as well as the junction with other exons particularly 
immunoreactive [48,49]. Additionally, three extra splice variants, consequence 
of cryptic splicing sites in exon 5, have been identified specifically in the 
pancreas [48], leading to protein truncation, frameshifts and neoepitopes 
prone to immunogenicity. Strikingly, the relatively high frequency of cytotoxic 
CD8 T cells reactive with these neoantigens was similar in T1D and healthy 
controls, underscoring the lack of thymic education and central tolerance and 
53804 marjolein Kracht.indd   57 08-05-19   18:02
Chapter 3.1
58
indicate that such T cells are part of the classical T cell repertoire [48]. Yet, their 
activity and rate of proliferation is increased in T1D subjects [50].
ENVIRONMENT AND TRANSLATION FIDELITY
Under stress, the cellular equilibrium may become disturbed, affecting high 
fidelity translational processes. So-called Defective Ribosomal Products (DRiPs) 
arising from translation of untranslated regions (UTR), ribosomal frame-shifting 
and alternative translation initiation, have been reported in tumor immunology 
to generate a unique class of tumor-associated antigens selectively expressed 
by malignant cells[51]. Interestingly, these translational products represent 
a pool of short lived polypeptides rapidly identified and degraded by the 
cellular quality control machinery that could represent a major source of HLA 
class I epitopes[51,52]. Among these, different reading frames of melanoma-
overexpressed antigen (MELOE1), New York oesophageal squamous cell 
carcinoma 1 (NY-ESO-1), and L-antigen familiy 1 (LAGE-1) are common tumor-
antigens, expressed in a variety of malignancies, and are highly immunogenic 
as tumor infiltrating lymphocytes (TILs) have been detected against multiple 
class I and class II epitopes in the circulation of cancer patients[53-55]. Currently, 
these tumor antigens serve as biomarkers and are explored as therapeutic 
targets in order to promote the natural immune response against these cells. 
Phase I/II trials with engineered human-derived T cells in patients with multiple 
myeloma demonstrated long-term engraftment, T cell infiltration in tumors, 
and retained T cell cytotoxicity [56].
Translation initiation and efficiency are highly sensitive to environmental 
conditions. Increased phosphorylation of eukaryotic initiation factor-2 (EIF2), 
due to upregulated kinase activity in response to stress, prevents the exchange 
of GDP for GTP, increasing the time required for scanning ribosomes to initiate 
translation [57]. In general, this leads to repressed protein synthesis, but for 
a subset of mRNAs involved in the regulation of the cellular stress response 
(ATF4, ATF5, GADD34 and CHOP), this enhances expression by increasing 
translation initiation at alternative AUGs. Proof for a role of endoplasmic 
reticulum (ER) stress in human insulitis was provided by immunostainings of 
pancreatic sections showing that islets from T1D donors display ER stress by 
increased levels of CHOP and BIP, compared to non-diabetic control tissues 
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[58]. Yet, little is known how ER stress affects the translation fidelity of beta cell 
specific proteins.
So far, the contribution of DRiPs as new source of neo-autoantigens has 
not been explored in T1D. In another autoimmune disease, a single report 
demonstrated the presence of autoreactive T cells directed against a frame-
shift epitope from endogenous IL-10 in synovial fluid of a patient with Reiter’s 
syndrome, where an autoimmune reaction triggered a response to a primary 
infection resulting in inflammatory arthritis [59]. 
ENVIRONMENT AND POST-TRANSLATIONAL 
MODIFICATIONS
Protein modification is tightly linked to extracellular events. For instance, tissue 
transglutaminase 2 (tTG2), whose activity is regulated by inflammatory signals, 
was shown to promote the epithelial-to-mesenchymal transition preceding 
tumor formation by switching E-to N-cadherin expression [60]. Also, tTG2 
expression correlates with renal cell carcinoma progression and contributes to 
the development of chemoresistance in malignant melanoma [61].
Post Translational Modifications (PTM) may arise from enzymatic 
modifications (e.g. citrullination, glycosylation, deamidation) as well as non-
enzymatic (spontaneous) modifications (e.g. methylation, carbamylation, 
oxidation, nitration) [62-65] and can result in a change in antigenic properties 
by single amino acid substitution, increasing HLA binding affinity thereby 
exposing cells to immune surveillance [65]. Deamidation of asparagine as 
the result of enzymatic cleavage of asparagine linked glycans by peptide-N-
glycanase (PNGase) is a well-known source of tumor neoepitope formation in 
melanoma [66]. PTM of tyrosinase by deamidation presented the first proof of 
principle [67]. This modification did not alter binding to HLA but allowed for 
recognition by melanoma specific CD8 T cells. Formation of stable succinimide 
intermediates during deamidation, as well as non-enzymatic degradation of 
asparagine through UVA exposure, has also been shown to produce MHC class 
I binding neoepitopes [68,69].
Phosphorylation of cellular proteins is a key step in almost all intracellular 
signalling pathways. Nevertheless, dysregulation of phosphorylation, a 
hallmark of tumorigenesis, can create tumor specific phospho-peptides [70]. 
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A recent study showed that over 60% of the identified phospho-peptides were 
tumor specific and can be presented on both HLA class I and class II molecules, 
creating opportunities for both CD4 and CD8 T cell involvement in cancer 
immunotherapy [71,72]. The amount of peptide potentially generated by 
tumors cells can also be amplified by post degradation processes (Box 2).
A variety of PTMs of islet autoantigens in T1D have also been reported in 
recent years and shown to be clinically relevant, as they were associated with T cell 
responses [65,73]. One of the first implications of PTMs in T1D was a disulphide-
bond formed between two adjacent cysteine residues at position A6 and A7 of 
the insulin-A chain, which was recognized by autoreactive T cells isolated from 
T1D subjects [74]. Further research to PTMs of islet autoantigens revealed an 
increase tTG2 activity in isolated islets when maintained in pathophysiological 
conditions, while deamidation by tTG of potential islet epitopes increased the 
peptide binding affinity to high-risk HLA-DQ molecules [73,75]. CD4+ T cells were 
found to a single and double deamidated form of the insulin B30-C13 epitope in 
new-onset T1D patients [73], which correlated with increased pro-inflammatory 
T cell responses. Beside modified insulin, multiple post-translationally modified 
GAD65-derived epitopes have been described [76]. A transglutamidated and a 
citrullinated GAD65 epitope were found and recognized by autoreactive CD4+ T 
cells. In addition, these T cells were detected in significantly higher frequencies 
in peripheral blood of T1D patients than in healthy controls, while the quality of 
the immune response against this PTM was pro-inflammatory in T1D patients 
versus anti-inflammatory in non-diabetic subjects [76]. 
Box 2. Proteome diversity: The case of transpeptidation in T1D
Besides protein degradation, the proteasome is able to fuse peptides by a process 
called transpeptidation. Degradation of proteins by the proteasome results in the 
formation of an acyl-enzyme intermediate complex in which the C terminus remains 
attached to the catalytic core through an ester link. Upon hydrolysis, the hydroxyl 
group of the peptide is restored and the peptide released from the proteasome and 
loaded on MHC molecules without further modification [97]. However, depending 
on the stability of this intermediate, the fragment can undergo a nucleophilic attack 
by the N terminus of another newly cleaved peptide fragment, thereby joining two 
otherwise distant sections of a protein. In tumor immunology, CD8 T cells recognizing 
a peptide resulting from the junction of noncontiguous peptide fragments of 
melanocytic glycoprotein gp100 (PMEL17) were found infiltrating melanoma cells 
[97]. Similarly, hybrid peptides generated from reverse splicing [98], in which the 
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peptide fragments are fused in reverse order, and hybrid peptides generated from 
trans-splicing were identified, in which the origin of the joined splicing fragments are 
derived from different proteins [99]. The case of transpeptidation in T1D has recently 
been underpinned by the discovery of hybrid peptides of proinsulin fragments 
fused with chromogranin A or IAPP that became targets of islet infiltrating T cells in 
mice and men, reinforcing the potency of neoepitopes created by peptide fusion in 
the pathogenesis of T1D and providing another plausible explanation to the break 
in tolerance observed [100]. 
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
The hypothesis that diabetes could result from a ‘normal’ defence mechanism 
against beta cells that have accumulated changes and aberrations narrow 
the differences between tumor and autoimmune disease (see Outstanding 
questions). Both effective anti-tumor immunity and T1D would follow 
similar rules leading to recognition of self-modified peptides. Although 
the participation of mutations in T1D is unlikely, the fact remains that many 
gene variants can predispose to T1D. Polymorphisms of islet autoantigens 
have been reported to be immunogenic [77,78]. Intriguingly, T1D patients 
preferentially developed islet autoantibodies against the autologous variant of 
zinc transporter-8 [78,79].
Clinical cases reinforce the interdependence between tumor and diabetes. 
T1D patients tend to have lower risk of cancer, at least before insulin therapy. 
In two patients with repeated hypoglycaemia, surgical removal of their 
insulinoma revealed clinical signs of T1D with increased level of islet specific 
autoantibodies (Insulin, IA-2, GAD65 and ZnT8). Interestingly, the presence 
of insulitic lesions in the resected pancreas suggests priming anti-islet 
autoimmunity [80]. We speculate that this was the result of collateral damage 
of a well-intended response against the insulinoma. Similarly in case of 
myasthenic syndromes, where successful immunity against thymoma or small 
cell lung carcinoma can result respectively in myasthenia gravis and Lambert-
Eaton myasthenic syndrome, autoimmunity has been confirmed against native 
self-proteins in the neuromuscular synapse [81,82]. Autoreactivity against PTM 
has hitherto not been assessed in these cases. Though, the link between islet 
autoimmunity and successful tumor immunotherapy became overwhelmingly 
clear recently, in studies using a check point blockade (inhibition of the 
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regulatory co-stimulatory molecule PD-1, e.g. by monoclonal antibody 
therapy with pembrolizumab or involumab) [83]. Removing the hand-break 
of the immune system released effective anti-tumor immunity in particular 
against mutated epitopes [84,85]. Vaccination studies using tumor antigens 
as immunotherapeutic strategy also may benefit from using mutated proteins 
rather than native tumor antigens, be it that the mutations may be patient 
or even metastasis specific[86]. These findings from effective cancer therapy 
may bear relevance to understanding natural immune regulation, as well as 
breaking immune tolerance to islet proteins in T1D. Perhaps modified islet 
autoantigens rather than native self-proteins act as primary targets leading to 
islet autoimmunity and beta cell destruction. Intriguingly, acute development 
of T1D ranks amongst the primary side effects of successful immunotherapy of 
cancer patients with anti-PD1 antibodies [87]. This last lesson from cancer also 
underscores the important role of PD-1 ligation in immune regulation in both 
progressive tumors and protection from T1D that may guide the way to novel 
immunotherapeutic intervention strategies [88].
Outstanding questions
• How do environmental factors and conditions affect antigen modification in 
T1D? Are these modified antigens a cause, consequence or epiphenomenon 
in the pathogenesis of T1D? 
• Does intra-islet communication contribute to beta cell functionality in health 
and disease? Pancreatic islet have an architecture favoring beta-alpha cell 
interactions; the inter-endocrine dialog may provide insight in molecular 
mechanisms in homeostasis versus T1D pathology. 
• Are mutations involved in T1D similar to effective antitumor immunity? 
Changes in either targeted autoantigens, T cell receptors, or autoreactive T 
cells may affect immunogenicity, immune regulation and microenvironment.
• Why is destructive autoimmunity in T1D limited to insulin-producing beta 
cells? Insulitis is driven by the presence of beta-cells.
• Why does the disease present in focal lesions in the pancreas? Does this 
point to beta cell or islet heterogeneity?
• Is T1D the cost of a well-intended response to stressed and dysfunctional 
tissue? The immune system is trained to detect and remove tissue featuring 
changes as induced by infection or carcinogenesis.
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Type 1 diabetes (T1D) is an autoimmune disease characterized by the selective 
destruction of the insulin-producing beta cells. Beta cell dysfunction caused 
by an inflammatory microenvironment is believed to trigger the peripheral 
activation of CD4 and CD8 autoreactive T cells. This review will compile post-
transcriptional and post-translational modifications (PTM) involved in the 
generation of beta cell neoantigens and proposes a reconstruction of the 
sequence of events connecting environmental changes and autoimmunity.
Highlights
• Beta cells communicate with other endocrine cells and immune cells during 
the course of T1D.
• Beta cells contribute to their own demise by generating neoantigens 
targeted in T1D pathogenesis. 
• Inflammation affects splicing, degradation and modification of proteins and 
peptides. 
• PTM should be investigated as candidate targets of autoantibodies and CD8 
T cells.
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Insulin producing beta cells are targeted by islet-infiltrating immune cells 
that recognize beta cell autoantigens in type 1 diabetes (T1D). Activated islet-
autoreactive T cells occur in both circulation and insulitic lesions [1-3], but it 
remains poorly understood how these cells avoid thymic education, central 
and peripheral tolerance and immune regulation, and how they are primed. 
Improper presentation of self-antigens by antigen-presenting cells due to low-
affinity native antigens may trigger these T cells to escape thymic deletion [4-
6]. Besides failures in central tolerance, it is conceivable that beta cells are key-
players in their own destruction by generating neoantigens avoiding central 
tolerance [7]. 
Accumulating evidence supports that local inflammation surrounding the 
islet of Langerhans alters the beta cell transcriptome and proteome, affecting 
the beta cell autoantigen repertoire [8]. In addition, beta cells are not just passive 
victims but actively participate in a dialogue with the immune compartment by 
locally releasing cytokines and chemokines upon insulitis [9-11]; the human islet 
architecture favors a direct cross talk between alpha and beta cells, suggesting 
a participation of intra-islet communication in balancing the islet micro-
environment [12,13]. Here, we will make the case for discordances between the 
peripheral and thymic antigen repertoire to contribute to the lack of, or break 
in, peripheral tolerance by neoantigen-mediated beta cell destruction in T1D. 
We will also attempt to position genetic predisposition to disease, and link islet 
and macro-environment to the generation of neoantigens and loss or lack of 
immune tolerance. Finally, a connection between gut resident pathogens and 
the course of T1D in relation to neoantigens will be proposed [14]. 
GENE POLYMORPHISMS AND POST-TRANSCRIPTIONAL 
MODIFICATIONS IN AUTOIMMUNE DISEASE
Haplotypes at the human leukocyte antigen (HLA) loci are strongly associated 
with genetic risk for T1D development (in particular HLA-A2 and HLA-DQ). HLA 
molecules dictate the repertoire of peptides to be presented to the immune 
system and shape the adaptive immune system in the thymus. Genome wide 
association studies identified an additional 40 common polymorphisms 
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associated with T1D susceptibility [15]. Moreover, genetic variations or single 
nucleotide polymorphisms (SNPs) may affect regulatory elements or dictate 
RNA splicing. In T1D, allelic variation in the variable number of tandem 
repeats (VNTR) of the insulin gene were found to correlate with thymic insulin 
expression dictating the peripheral tolerance to insulin [4,16,17]. Also, SNPs in 
cytotoxic T lymphocyte-associated protein 4 (CTLA4) [18], expressed on the 
surface of activated CTLs and crucial for regulating peripheral T cell responses, 
are associated with a loss of self-tolerance. A SNP within the CTLA4 3’UTR led to 
an alteration in the ratio of CTLA4 mRNA splice isoforms of the CTLA4 gene. This 
shifted splicing efficiency correlated with increased disease susceptibility. We 
recently discovered that the same SNP was associated with islet autoimmunity 
by affecting CTLA4 mRNA stability [19]. Similarly, rare deleterious variants in 
PTPN22 in T1D patients with multiple-affected siblings were found to result 
in CD4 T cells hyporesponsive to antigen stimulation [20]. Rare SNPs in non-
coding regions can alter regulatory elements such as promoter sequences or 3′ 
untranslated regions (UTRs). This influences gene expression levels by interfering 
with miRNA regulation [21], a mechanism of post-transcriptional modification. 
In support of this, variation of functional miRNA-binding elements within the 
3′-UTRs of T1D-associated genes (CTLA4 and IL10) can have consequences 
for regulation of T1D risk genes [22].In addition to genetic variations, post-
transcriptional modifications may contribute to autoimmune diseases by 
the generation of antigens escaping tolerance induction. The differential 
expression of IGRP variants between beta cells versus thymus was shown to 
result in the generation of islet neoantigens and the high immunogenicity 
against these splice products detected in both non-diabetic and type 1 
diabetic subjects points to a lack of central tolerance [23]. Alternative splicing 
of IA-2 led to differential IA-2 expression in the pancreas versus the thymus 
which may underlie a permissive mechanism for the potential development of 
autoimmunity against IA-2 [24]. 
POST-TRANSLATIONAL MODIFICATIONS OF ISLET 
ANTIGENS IN TYPE 1 DIABETES
Post-translational modifications (PTM) increase the proteome and affect 
epitope binding properties to HLA class I and class II molecules, predisposing 
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to autoimmune diseases by changing the intrinsic structural and electrical 
properties of proteins or epitopes [25,26]. Polymorphic HLA-DQ molecules 
predisposing to risk for autoimmune diseases such as T1D favor certain peptide 
repertoires to be presented to the immune system and modifi cations of 
proteins and fragments may introduce peptide affi  nity, locking such antigenic 
peptides into the HLA groove [27] (Figure 1).
Figure 1: The key fi tting the lock: deamidation of islet peptides promotes their binding to disease-
predisposing HLA class II molecules. Peptide binding to HLA-DQ molecules involves anchor pockets 1, 
4, 6, 7 and 9 of the peptide. Amino acids at position 1 and 9 of a binding peptide are crucial in defi ning 
peptide binding affi  nity to HLA-DQ8, whereas amino acids on positions 2, 3, 5 and 8 of the peptide 
epitope are engaged in recognition by T cell receptors (TCRs) (Top). Active tissue transglutaminase (tTG) 
can modify glutamines (Q) on positions p1 and p9 of a binding peptide by into glutamic acid (E), 
introducing a more favorable charge to the anchor pockets 1 and 9 (bottom), thereby strongly 
enhancing the binding affi  nity of this peptide to HLA-DQ8. 
Animal models of autoimmune diabetes showed that PTMs create new 
autoantigens recognized by diabetogenic T cells [28]. The fi rst evidence of PTM 
in T1D in humans involved chemical modifi cation in the form of a disulfi de bond 
between adjacent cysteine residues on the A chain of human insulin as a target 
of T cells [29]. Enzymes can create another range of modifi ed antigenic peptides. 
Tissue transglutaminase (tTG) is an enzyme responsible for modifying gluten 
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and gliadin into allergens in coeliac disease by deamidation of glutamine into 
glutamate. This enzyme is also present in relative high levels in pancreatic islets 
[www.proteinatlas.org], but becomes active in the context of inflammation [30]. 
Indeed, deamidated proinsulin was recently demonstrated in inflamed human 
islets of Langerhans [30]. We recently showed that active tTG deamidates 
proinsulin, thereby promoting binding affinity to high-risk HLA-DQ molecules 
[34]. T cell responses directed against deamidated proinsulin were observed in 
the majority of the newly diagnosed T1D patients, compared to less than half of 
the patients responding to native proinsulin. Perhaps surprising, deamidated 
islet epitopes could also be isolated from high-risk HLA class II of dendritic cells 
pulsed with native islet antigens, implying that dendritic cells, too, are able to 
post-translationally modify, process and present deamidated neoepitopes and 
turn these into potent autoantigens in T1D [33]. The increased tTG activity in islet 
cells and dendritic cells suggests that tTG is responsible for this inflammation-
induced modification. The conversion of (protein-bound) arginine into the 
non-standard amino acid citrulline by peptidylarginine deiminases (PADs) is 
interesting in the context of autoimmunity since PADs have not been detected 
in the thymus [31], possibly excluding T cell education toward citrullinated 
peptides. Citrullination of GAD65 peptides enhances the binding to HLA-DR4; 
these peptide-HLA complexes were recognized by autoreactive CD4 T cells 
isolated from T1D patients [25]. Also citrullinated glucose-regulated protein 
78 was identified as a modified autoantigen in murine beta cells and was a 
target for autoreactive T cells in mice, indicating that PTM of islets autoantigens 
is directly involved in beta cell destruction [32]. Recently, a new class of 
modification wherein fusion peptides from non-contiguous peptide fragments 
generate novel epitopes has been reported to be involved in T1D [2]. In this 
study diabetogenic CD4 T cell clones isolated from non-obese diabetic mice 
recognized epitopes consisting of proinsulin peptides covalently crosslinked 
to other peptides present in insulin secretory granules. This peptide fusion, 
thought to be formed through a transpeptidation reaction, led to the creation 
of hybrid insulin peptides that were detectable in beta cells. CD4 T cell lines 
from the residual pancreatic islets of two type 1 diabetic pancreas donors also 
recognize such hybrid peptides [2]. These types of neoantigen generation may 
explain how immune tolerance is broken in T1D (Figure 2).
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FIGURE 2. A roadmap to protein modifications in the development of T1D. Environmental changes 
due to infections by pathogens or change in diet may affect the immune system. Cytokines and 
chemokines secreted by both innate immune cells and adaptive immune cells may interfere with the 
communication between beta cells and other pancreatic cells and disturb post transcriptional and post 
translational fidelity in beta cells. Such processes may contribute to the generation of modified 
autoantigens. Of note, environmental changes would also contribute to the generation of autoantigens 
by modification of native proteins or peptides taken up and modified by dendritic cells.
An important function of PTM is regulation of protein localization. Upon 
inflammation-induced ER stress, the palmitoylation cycle of GAD65 is disrupted 
[33]. This results in an aberrant endomembrane distribution and accumulation 
of palmitoylated GAD65 in Golgi membranes which accordingly triggers 
autoimmunity, presumably by increased uptake and processing by APCs. 
Although a role of autoantibodies in T1D pathology is still unproven, insulin 
autoantibodies (IAA) remain the earliest marker of beta cell autoimmunity. 
Interestingly, among the rare patients being IAA- negative, more than 30% 
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were tested positive for autoantibodies against modified insulin [34]. The 
same group showed the presence of autoantibodies against modified collagen 
[35], suggesting that autoantibodies against modified islet antigens can 
add significant value for (early) diagnosis of T1D. Yet, humoral autoimmune 
responses to neoantigens have largely been ignored. It is not inconceivable that 
autoantibodies to native self-proteins only represent the tip of the iceberg. This 
assumption is corroborated by the situation in other inflammatory diseases, 
such as coeliac disease and rheumatoid arthritis.
THE ROLE OF INFLAMMATORY CYTOKINES IN THE 
GENERATION OF ISLET NEOANTIGENS
During acute insulitis, the combined effect of proinflammatory cytokines 
and chemoattractants on beta cells leads to hyperexpression of HLA class I, 
triggering beta cell exposure to immune cells and the selective infiltration of 
autoreactive CD8+ T cells [1]. More than just recruiting immune cells to the 
inflammation site, inflammatory signals interfere with cellular processes during 
conversion of genetic information into proteins. At the RNA level, IFN-γ, IL1β 
combined treatment led to profound changes in beta cell gene expression, 
including genes involved in the splicing machinery [36,37]. As a consequence, 
transcriptome analysis of purified human islets maintained in proinflammatory 
cytokines has shown that over 30% of the genes expressed in human islets 
undergo alternative splicing, providing evidence for the generation of beta cell 
neo-autoantigen generation during insulitis [8]. 
Inflammatory cytokines perturb the intracellular calcium level, affecting 
the ER homeostatic balance and activating Ca2+ dependent enzymes involved 
in post-translational modification (e.g., tTG and PAD [38,39]). Recently, we 
have shown that supernatant of an activated GAD65-specific CD4 T cell 
clone induced post-translational modifications of human islet antigens and 
in particular, deamidated peptides derived from PPI were [30] a prototype 
target for autoreactive T cells in T1D patients [40,41]. Although the Unfolded 
Protein Response triggered by ER stress is highly involved in PTM modification 
in T1D [42], a prolonged exposure to metabolic or inflammatory stress may 
also promote additional coping mechanisms, including initiation of recycling 
programs by vesicle formation [43]. In synoviocytes and monocytes isolated 
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from RA patients, m-TOR activation by Rapamycin was shown to activate PAD 
activity in autophagosomes and was proposed as mechanism for citrullination 
[43]. 
The local inflammation is an important component of beta cell destruction 
and in the generation of PTM modified epitopes. However, the identity of pro-
inflammatory cytokines in the vicinity of the inflamed beta cells appears to 
determine the type and the intensity of beta cell stress [44,45]. Unfortunately, 
studying the interplay between the immune compartment and the islet 
compartment is challenging and our knowledge from the role of cytokines in 
T1D, largely derived from studies in rodent or cell lines with excessive un(patho)
physiological cytokine concentrations, lacks consistency. For example, the 
mediators themselves (e.g., IFN-g or TNF alpha) seem to both promote and 
prevent beta cell destruction [46]. But more importantly, in humans the 
situation might not be necessarily the same! Our view of the role of cytokines 
in human T1D is limited and “in situ” investigations, where biopsies from living 
subjects are analysed, are rare but suggest that the amount of cytokines 
secreted by infiltrating immune cells within T1D islets might have been largely 
overestimated [47]. 
Inflammation also alters processing of the HLA class I binding peptide 
repertoire. The subunits b1, b2, b5 from the 20S proteasome catalytic domain 
are replaced under inflammation by their inflammatory counterparts. Hence, 
the immunoproteasome formed may reshape the peptide repertoire and the 
potential CTL response [48] by different proteolytic activity, affecting processes 
like transpeptidation [49,50] that could contribute to ligandome diversity. 
Of note, CD8 T cell autoimmunity to modified proteins has not yet been 
investigated in any detail in humans, which is remarkable, given the large body 
of recent evidence of CD4 T cell autoimmunity against PTM products.
THE INFLUENCE OF THE ENVIRONMENT 
Other pancreatic endocrine or exocrine cells have been largely ignored in the 
selective beta cell destruction process. Studies are supporting a guardian-type 
role of alpha cells in particular, under stress stimulation by GLP-1 secretion 
[51,52], but consequences of GLP-1 stimulation or other incretins on the beta 
cell proteome still remain to be investigated. Undoubtedly, the islet micro-
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environment is relevant [53]. We recently discussed the inverse relationship 
between the tumour microenvironment and islets during insulitis [54]. 
The macro-environment also contributes to development of T1D, and its effect 
on autoantigenesis should be considered. The notion that approximately 
50% of identical twins are discordant for T1D demonstrates that T1D is not 
an inherited genetic disease and is largely influenced by environmental 
factors, possibly acting in concert with genetic risk factors [55]. The gut and 
the pancreas are linked through a system in which gut-derived immune and 
metabolic signals have the potential to induce effects in the pancreas. The gut 
microbiome influences host metabolism and immunity and might play a role 
in T1D pathogenesis. Although profound changes in host gene expression and 
proteome were observed following enterovirus infection, the link between 
virus infection and generation of beta cell neoantigens remains unestablished. 
Similarly, recent microbiome analysis pointed to a correlation between bacteria 
in Finnish and Estonian infants and autoimmune diseases [56], indicating the 
possible implication of a “gut storm” in T1D pathology [57]. Although a direct 
link with the generation of modified antigens in T1D was not tested, studies in 
coeliac disease and rheumatoid arthritis revealed a direct effect of microbial 
tTG from Streptoverticillium and PAD from Porphyromonas gingivalis enzymes 
on PTM modification of host substrates [58,59]. It is conceivable that such 
processes may also occur in T1D. 
The importance of the gut in the pathology of T1D is also illustrated by the 
role of diet changes in autoimmune development. Gluten free diet decreases 
intestinal inflammation and prevents CD development [60,61]. Similarly, 
such nutritional intervention may impact the gut microbiome and delay 
incidence of T1D as demonstrated in rodents [62]. In patients with both CD 
and T1D, a gluten-free diet improves glycaemic control in some studies, but 
not consistently [63]. Children with anti-islet cell autoimmunity presented an 
Akkermansia-dominated gut microbiome resulting in higher levels of butyrate 
production with subsequent protective effects on development of T1D [64]. A 
relation with PTM is yet to be investigated. 
The question remains whether PTM provokes or results from islet autoimmunity? 
Does the surrounding islet micro-environment or macro-environment generate 
PTM of islet antigens priming naïve T cells? Intriguingly, be it inconclusive, T 
cell lines were generated against modified, but not native proinsulin [65]. 
Once activated, these T cells cross-reacted with native proinsulin. This could 
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imply that PTM epitopes act as initial targets, leading to the loss of tolerance in 
autoreactive T cells in T1D patients.
CONCLUDING REMARKS
Modified islet epitopes are newly appreciated actors in T1D pathogenesis. A 
better understanding of the processes and micro- and macro-environmental 
factors contributing to the generation of protein modifications to which 
immune tolerance is lacking or lost may prove essential for prevention or 
intervention of type 1 diabetes. Appreciating the role of beta cells in their 
own fate, in dialogue with other islets cells, the immune system and the gut 
microbiome, has brought new dimensions to deciphering changes in immune 
homeostasis in the pancreas during insulitis. This is critical to define the terms 
of loss of islet autoimmunity and the restoration of immune tolerance.
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Identification of epitopes that are recognized by diabetogenic T cells and cause 
selective beta cell destruction in type 1 diabetes (T1D) has focused on peptides 
originating from native beta cell proteins. Translational errors represent a major 
potential source of antigenic peptides to which central immune tolerance is 
lacking1, 2. Here, we describe an alternative open reading frame within human 
insulin mRNA encoding a highly immunogenic polypeptide that is targeted 
by T cells in T1D patients. We show that cytotoxic T cells directed against 
the N-terminal peptide of this nonconventional product are present in the 
circulation of individuals diagnosed with T1D, and provide direct evidence that 
such CD8+ T cells are capable of killing human beta cells and thereby may be 
diabetogenic. This study reveals a new source of nonconventional polypeptides 
that act as self-epitopes in clinical autoimmune disease. 
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Islet-reactive CD8+ T cells selectively and progressively destroy the insulin-
producing beta cells in type 1 diabetes (T1D)3-6. Metabolic or inflammatory 
stress in the vicinity of the beta cells may contribute to the generation of 
neoantigens to which central immune tolerance is absent, thereby triggering 
autoimmunity 7, 8. For example, larger numbers of splicing events are detected 
in human beta cells maintained in vitro in the presence of proinflammatory 
cytokines, mimicking the pathophysiological conditions of T1D9, 10. In 
addition, CD4+ T cells that recognize deamidated autoantigens11-13 or fusion 
epitopes14 have been detected in individuals with T1D. Inflammatory stress 
may perturb the cellular equilibrium and affect high-fidelity transcriptional 
and translational processes during conversion of the genetic information into 
proteins15, 16. In tumors, uncontrolled cell proliferation correlates with enhanced 
translation and accumulation of aberrant translation products. Such so-called 
defective ribosomal products (DRiPs)17-19, arising from translation of normally 
untranslated regions (UTR), ribosomal frame-shifting or alternativeinitiation 
of translation, generate a unique class of tumor-associated antigens that are 
selectively expressed by malignant cells20, 21. 
Human pancreatic beta cells are insulin factories dedicated to the 
maintenance of glucose homeostasis; insulin, stored in secretory granules, 
represents 10-15% of the protein content of these cells22, 23. Upon glucose 
challenge, insulin molecules are released into the circulation by exocytosis and 
insulin mRNA is rapidly translated by polysomes to increase insulin biosynthesis. 
Studies of samples from humans with T1D and mouse models of the disease 
indicate that native insulin and its precursors act as primary autoantigens24-26, 
and fragments of signal peptide of the preproinsulin (PPI) were identified as 
main targets of cytotoxic islet-autoreactive CD8+ T cells in human T1D27. In a 
process similar to the emergence of DRiPs during tumor development, the high 
demand for insulin may lead to the generation of aberrant insulin polypeptides 
by impaired translation fidelity, rendering beta cells immunogenic. These 
errors may yield antigens that trigger or accelerate islet autoimmunity in T1D, 
particularly as a result of stresses that, for example, may be evoked by viral 
infection28, reduced pancreas size29 or inflammation30. Here, we investigated 
whether beta cells produce aberrant translation products that can lead to the 
generation of diabetogenic epitopes. 
Leaky ribosome scanning for translation initiation at a downstream AUG 
can generate out-of-frame translation products31. Within the human insulin 
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mRNA, two putative downstream translation initiation sites with strong Kozak 
consensus sequences are located at positions 72 and 341. Although translation 
initiation on the AUG at position 72 (which is in frame with the canonical AUG of 
PPI) would produce a truncated isoform of PPI, initiation on the AUG at position 
341 would generate an alternative polypeptide in a +2 reading frame that does 
not share any sequence identity with the canonical translation product of the 
insulin gene (Fig. 1a,b). The absence of a stop codon in this frame would lead 
to translation into the poly(A) tail. To validate that translation initiation can 
occur at this particular AUG, green fluorescent protein (GFP) fusion constructs 
were generated, in which the GFP coding sequence was fused in frame with 
the bona-fide PPI AUG60 (insulin(INS)-GFP) or with the alternative AUG at 
position 341 (INS-DRiP-GFP). As a control, a third construct was generated, 
in which the alternative reading frame was cloned immediately after the 
CMV promoter (DRiP-GFP) (Fig. 2a). Following transfection in HEK 293T cells, 
in order to achieve high protein expression, both INS-GFP and INS-DRiP-GFP 
constructs led to expression of GFP fusion proteins migrating at 40 kDa and 
33 kDa, respectively. The control construct, DRiP-GFP, confirmed the molecular 
weight of the unconventional product (Fig. 2b). As expected, cells transfected 
with INS-DRiP-GFP also coexpress proinsulin as assessed by western blot (Fig. 
2c) and immunohistochemistry (Fig. 2d). 
To determine the effect of endoplasmic reticulum stress (ER stress) on 
translation initiation, cells transfected with INS-DRiP-GFP were stimulated 
with the ER stress-inducers thapsigargin (TG) or tunicamycin (TM). The 
expression of DRiP polypeptide was increased by TG but not TM treatment as 
quantified both by western blot (Fig. 2e, upper) and flow cytometry analysis 
(Fig. 2e, lower). Altogether, these data indicate that the production of the 
INS-DRiP polypeptide may result from calcium depletion in the ER and the 
subsequent increase in levels of cytoplasmc calcium, rather than the classical 
ER stress caused by assumulation of misfolded proteins as induced N-linked 
glycosylation inhibition (TM)32.
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Figure 1: Schematic representation of open reading frames (ORFs) found in the human insulin 
mRNA. (a) Full-length insulin mRNA with the bona fide PPI ORF (black uppercase letters), 5’ and 3’ UTRs 
(grey uppercase letters) and the poly(A) signal sequence (bold grey letters) are shown. The PPI amino 
acid sequence is shown in blue font, the amino acid sequence of the +2 reading frame is shown in small, 
light grey font and the amino acid sequence of the alternative open reading frame (altORF) INS-DRiP is 
depicted below the mRNA sequence in bold red. . All AUG codons within the mRNA are framed with a 
black box, and those used as translation initiation site are indicated with colors corresponding to the 
resulting amino acid sequence. The * indicates the stop codon in the given amino acid sequence. The 
putative nonAUG (CUG) start site upstream of the DRiP sequence is framed with red dashed line. The 
3’-UTR SNPs are annotated and both polymorphisms are depicted, as are the potentially affected amino 
acids in the nonconventional polypeptide. (b) Left, schematic representation of full-length human 
insulin mRNA. The 5’- and 3’-UTR are depicted in black and the insulin-encoding ORF starting at AUG60 
in blue. Alternative translation initiation sites are shown in italic and the poly(A) tail is indicated in bold. 
The altORF encoding the INS-DRiP polypeptide is shown in red, and the first amino acid (1) and the last 
amino acid preceding the poly(A) tail (43) are depicted. Right, translation initiation scores of every AUG 
within the insulin mRNA sequence as predicted by NetStart 1.0 prediction server. Prediction scores 
greater than 0.5 are considered probable translation start codons.
On the basis of the insulin sequence, translation of this neopolypeptide 
continues beyond the original PPI stop codon and leads to translation of two 
single nucleotide polymorphisms (SNPs) (rs3842752 and rs3842753) that are in 
strong linkage disequilibrium and are associated with development of T1D33. 
Although these SNPs have been judged to be functionally irrelevant because 
of their location within the INS 3’UTR34, in this scenario, the SNPs rs3842752 
and rs3842753 may generate four different polypeptide variants of the INS-
DRiP polypeptide containing, respectively, cysteine-to-arginine (C-to-R) and 
histidine-to-proline (H-to-P) substitutions that may act as neoantigens in T1D 
(Fig. 3a). To test the immunogenicity of the INS-DRiP variants, T cell proliferation 
assays were performed on freshly isolated peripheral blood mononuclear cells 
(PBMCs) of juveniles with T1D patients for detection of islet autoimmunity 
(Supplementary Table 1 and Fig. 3b). Proliferative responses were detected 
in the majority of T1D cases that strongly correlated in reactivity between 





































































































































Figure 2: The human insulin mRNA harbors an alternative open reading frame. (a) Schematic 
representation of the GFP fusion constructs INS-GFP, INS-DRiP-GFP, DRiP-GFP and the normal GFP 
construct. The canonical PPI AUG is shown in bold and AUG341 is shown in italic. The expected size of the 
GFP protein and the fusion variants are depicted on the right. The sequences encoding preproinsulin 
and the INS-DRiP are depicted in blue and red, respectively. The sequence encoding GFP is shown in 
green. The 5'-UTR is shown in black. (b) Western blot analysis of 293T cell lysates transfected with GFP, 
INS-GFP and DRiP-GFP constructs (left panel) and 293T cell lysates either nontransfected (NT) or 
transfected with the INS-DRiP-GFP construct (right panel). Western blot analysis was performed 48 h 
post transfection and analyzed with an anti-GFP antibody (top panels) or anti-actin antibody used as 
loading control (lower panels). (c) Western blot analysis using anti-insulin antibody (top panels) or anti-
actin antibody (lower panels) of the previously described transfected cells. * indicates an INS-GFP 
degradation product visible by anti-GFP and anti-insulin-staining. (d) Confocal images of 293T cells that 
were transiently transfected with DRiP-GFP and INS-DRiP-GFP constructs. The left panels show the GFP 
fl uorescence of the GFP fusion variants, the middle panels show the expression of proinsulin in the 
transfected cells and the right panels show the overlay with DNA staining as seen by Hoechst staining. 
(e) Analysis of the eff ect of ER stress on translation initiation. INS-DRiP-GFP transfected cells were 
stimulated 24 h post transfection with Thapsigargin (TG 2 µM) or Tunicamycin (TM 2µg/ml) for 6 h. DRiP 
and proinsulin expression were evaluated after western blot analysis using anti-GFP and anti-insulin 
antibodies, respectively. Actin expression was used as loading control (left panel). Quantitative analyses 
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of the effect of stress inducers on protein translation was determined (i) by densitometry analyses of the 
GFP (black bars) and insulin bands (grey bars) and shown as induction ratio ± s.d. where the intensity of 
the nontreated cells was used as reference (right panel) and (ii) by comparing GFP fluorescence upon 
stress induction by FACS. Nontransfected cells were used as control (dashed lines in both histograms). 
GFP expression of the INS-DRiP-GFP transfected cells in nontreated and treated conditions are depicted 
with white-filled and grey-filled histograms, respectively. Statistical analysis of the GFP-positive 
population in e was performed using an unpaired two-tailed Student’s t-test (n=3 from 2 independent 
transfection experiments). 
the ‘susceptible’ (R-P) and ‘protective’ (C-H) INS-DRiP variant, suggesting that 
the SNP region itself did not contribute to immunogenicity and underscoring 
the lack of presentation of the SNP by HLA-DQ (Fig. 3b, left). Intriguingly, the 
few individuals carrying genetic risk variants associated with protection from 
T1D (HLA-DQ6.2 or INS SNP C-H) did not respond to INS-DRiP polypeptides, 
supporting the hypothesis that DQ6.2 and INS SNP C-H contribute to central 
immune tolerance in thymic education (Fig. 3b right). Strong T cell responses 
to INS-DRiP were detected in individuals with increased genetic risk for T1D 
(those heterozygous for HLA-DQ2 and HLA-DQ8 (HLA-DQ2/8); i.e., HLA-
DQ8trans (formed by the α-chain of HLA DQ2 (DQA1*05:01) and the β-chain of 
HLA-DQ2 (DQB1*03:02))or HLA-DQ2trans(formed by the α-chain of HLA-DQ8 
(DQA1*03:01) and the β-chain of HLA-DQ2 (DQB1*02:01)) (Fig. 3c). Of note, the 
T cell response to INS-DRIP was similar in amplitude in comparison to the other 
known antigen targets in T1D (Supplementary Fig. 1a-c).
Next, we interrogated whether dendritic cells (DC), which are uniquely 
capable of priming the immune system, were able to process and present 
peptides from the INS-DRiP polypeptide. Monocyte-derived, immature DC 
generated from DQ2- or DQ8-homozygous, or DQ2/8-heterozygous donors 
were pulsed with the INS-DRiP variants. After 24 h of culture, the DC HLA-DQ 
ligandome was determined by mass spectrometry, revealing a short peptide 
fragment of 9 amino acids from the N-terminus of the INS-DRiP polypeptide as 
a single candidate epitope. A full overlap of the experimental fragmentation 
profile of the identified peptide and its synthetic counterpart confirmed proper 
MS identification (Fig. 3d). Cell-free HLA-DQ binding studies confirmed a 
strong binding affinity of the 9-mer peptide to HLA-DQ8cis and HLA-DQ8trans 
molecules but not to HLA-DQ2cis or HLA-DQ2trans molecules (Fig. 3e). These 
data show that the INS-DRiP peptide fragment is naturally processed by DCs 
and is preferentially presented by T1D highest-risk HLA-DQ8trans, which is 
expressed in DQ2/8 heterozygous individuals. Also, monitoring the immune 
response to INS-DRiP1-9 by interferon (IFN)-y and GrzB Elispot indicates that the 
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peptide-stimulated production of granzyme B occurs exclusively in individuals 
with T1D (Supplementary table 1 and Supplementary Materials). Together, 
these results indicate that the N-terminus of the INS-DRiP polypeptide is 
particularly immunogenic and suggests that a cytotoxic T lymphocyte (CTL) 
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Figure 3: Immunogenicity of insulin-derived, nonconventional polypeptide. (a) Frequencies of allele, 
genotype, haplotype and phenotype of the T1D patient panel used in this study. Individual genotypes 
and phenotypes are depicted in supplementary table 1. The allele A or G in SNP rs3842752, result in a 
transcript with U or C leading toward expression of cysteine (C)- or arginine (R)-containing INS-DRiP, 
respectively; the allele T or G in SNP rs3842753 , result in a transcript with A or C leading toward 
expression of histidine (H)- or proline (P)-containing INS-DRiP, respectively. (b) Lymphocyte proliferation 
against the recombinant INS-DRiP variants (C-H and R-P) in PBMCs from fresh blood of individuals with 
T1D who are homozygous for the susceptible INS-SNP phenotype R-P/R-P (left) or heterozygous with 
the protective phenotype HLA-DQ6.2 or INS-SNP C-H (right). A significant correlation between immune 
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responses to the INS-DRiP R-P and C-H was determined by two-tailed Pearson correlation test (P<0.0001). 
(c) Proliferative responses against the recombinant INS-DRiP R-P polypeptide of PBMCs isolated from 
individuals carrying the high risk HLA-DQ2/8 genotype (DQ2/DQ8) in comparison to individuals 
carrying DQ2/x or DQ8/x and individuals negative for both DQ variants (DQx/DQx), where x represents 
any DQ molecule other than DQ2 or DQ8. The P value has been calculated by a Mann-Whitney t-test. (d) 
Mass spectrometry analysis of the MLYQHLLPL peptide eluted from HLA-DQ2/8 expressed on DCs 
pulsed with recombinant INS-DRIP polypeptide (tandem mass spectrum, upper panel) and the spectrum 
of the synthetic INS-DRiP1-9 peptide (lower panel). (e) Binding validation of INS-DRiP1-9 peptide to the 
T1D high-risk DQ2cis, DQ2trans, DQ8cis and DQ8trans molecules as shown by the experimentally 
determined IC50 values. Data represent mean ± s.e.m. (n=3 independent binding experiments).
The INS-DRiP polypeptide was screened for potential human leukocyte 
antigen (HLA)-class-I-binding epitopes. The INS-DRiP sequence was analyzed 
by three major histocompatibility complex (MHC) class I epitope prediction 
algorithms: NetMHC 3.4, SYFPEITHI and BIMAS. One strong HLA-A2-binding 
peptide was identified that was identical to INS-DRiP1-9 eluted from HLA-
DQ8trans  (Supplementary Table 2a). The INS-DRiP1-9 epitope MLYQHLLPL was 
confirmed to bind with high affinity to HLA-A2, which is the most prevalent 
HLA variant within the T1D population (Supplementary Table 2b and 
Supplementary Materials)35, 36. 
We next assessed the clinical relevance of the INS-DRiP1-9 epitope by 
exploring the presence of specific CD8+ T cells in peripheral blood samples of 
T1D HLA-A2+ individuals with T1D and in HLA- and age-matched healthy donors 
(detailed in Supplementary Table 3)37. Significantly higher levels of INS-DRiP1-
9-specific CD8
+ T cells were detected in individuals with T1D as compared to 
healthy donors, whereas antiviral CD8+ T cell frequencies were similar between 
the two groups (Fig. 4a). Phenotypical analysis of INS-DRiP1-9-Tm
+ CD8+ T cells 
showed more cells with the effector phenotype (CCR7-/CD45RA-) in donors 
with T1D than in healthy donors (Supplementary Fig. 2). 
To further characterize these T cells, INS-DRiP1-9-specific T cell clones were 
generated from PBMCs of individuals with T1D patients by dual HLA tetramer 
staining, and their cytotoxic properties were determined on peptide loaded 
HLA-A2+ JY cells (Fig. 4b,c and supplementary Fig. 3). Of note, these DRiP-specific 
CTL clones were generated from an individual with long-term diabetes (clone 
#1) as well as an individual with new-onset diabetes (clone #2); this indicates 
that such T cells are participating at different stages of disease progression. 
Complete lysis of peptide-pulsed target cells was detected, whereas target 
cells loaded with an irrelevant peptide remained unaffected (Fig. 4c). Peptide-
specific T cell activation resulted in a significant increase in the secretion of 
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IFNγ and tumor necrosis factor (TNF)-α and, to a lesser extent, macrophage 
inflammatory protein (MIP)-1β when compared to unstimulated T cells (Fig. 
4d). We next examined the cytotoxic potential of the INS-DRiP1-9-specific CTL 
on human islet cells expressing HLA-A2. In order to specifically investigate beta 
cell death, dispersed primary human islets were transduced by a lentivirus 
containing the beta cell-specific viability reporter (i.e., a short-half-life luciferase 
reporter gene under the control of the human insulin promoter, HIP-LUC2CP) 
as previously described38. Following LV-HIP-LUC2CP transduction, human 
pancreatic islet cells were incubated with CTLs specific for INS-DRiP1-9, CMVpp65 
or PPI15-24, and cytolysis was determined by measuring reduction of luciferase 
activity. PPI15-24-specific and INS-DRiP1-9-specific CTLs significantly reduced 
beta cell survival (Fig. 4e, left), whereas beta cell survival was unaffected by 
CMV-specific CTLs38. Together, beta cell destruction by the INS-DRiP1-9-directed 
CTLs confirmed that the DRiP1-9 epitope is naturally generated, processed and 
presented on the cellular surface on human beta cells. The partial destruction 
of beta cell by INS-DRiP1-9 specific CTL is in tune with the error hypothesis and 
points to beta cell heterogeneity and immunogenicity; this is perhaps due to 
differential sensitivity to stress factors. To test whether inflammation increases 
beta cell susceptibility to cytolysis by INS-DRiP1-9-specific T cells, beta cells 
were preconditioned with medium containing high glucose combined with 
proinflammatory cytokines IL-1β and IFNγ to mimic T1D pathology (Fig. 4e, 
right). As anticipated from our results regarding the effect of ER stress on DRiP 
translation (Fig. 2f ), these inflammatory conditions further increased beta cell 
death in the presence of INS-DRiP1-9-specific CTLs (Fig. 4f ). INS-DRiP1-9 specific 
CTL cocultured with human islets consistently secreted the effector cytokines 
MIP-1b, IFNg and TNF when recognizing the INS-DRiP epitope presented by 
HLA-A2, corroborating specific stimulation and activation of the CD8+ T cells 
by islets cells (Fig. 4g). 
We present the first evidence of naturally processed and presented 
epitope derived from nonconventional islet proteins leading to the destruction 
of human beta cells by cytotoxic CD8+ T cells. We identified an immunogenic 
polypeptide translated from the insulin mRNA that is capable of triggering 
T cell proliferation in PBMCs from individuals with the highest odds ratio for 
T1D. In addition, we demonstrate that the epitope, presented by HLA-A2 as 
well as the highest-T1D-risk HLA-DQ8trans molecules expressed on DQ2/8 
heterozygous DCs, is implicated in T1D pathogenesis as patient-derived 
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-specific CTLs kill human beta cells in vitro. (a) Frequency of INS-DRiP1-9-specific 
CTLs (left panel) and virus-specific CTLs (EBV/LMP2, measles/H250 and CMV/pp65) (right panel) 
detected in the circulation of individuals with T1D (red, filled circles), individuals with new-onset T1D 
(red, open circles) and matched healthy control subjects (green, filled circles). Statistical analyses of the 
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two groups were performed using GraphPad; an unpaired t-test with Welch correction was applied. (b) 
Generation of INS-DRiP1-9-specific CD8
+ T cell clone from the PBMCs of HLA-A2+ individuals with long-
term T1D. INS-DRiP1-9 specific T cells were detected by dual HLA-A2
INS-DRiP
1-9 tetramer staining after 
periodic peptide-specific stimulation (upper panel). The frequency of INS-DRiP1-9-specific T cells prior 
to sorting is indicated in the dot plot. Specificity of tetramer-sorted CD8+ T cells was validated upon 
expansion (lower panel). (c) Chromium release assay performed on JY cells loaded with either INS-
DRiP1-9 (black squares) or a non-relevant peptide (SP-PPi15-24) (open circles) in presence of INS-DRiP1-9 
CTLs. Each E:T ratio was measured in triplicate. (d) Cytokine secretion by INS-DRiP1-9-directed CTLs after 
co-culture with INS-DRiP1-9 loaded JY cells. Data are shown as the mean ± s.d. (n=2 biological replicates). 
(e) Beta cell specific killing assay performed on dispersed human islet cells maintained in normal 
medium (homeostatic conditions; 5 mM glucose) (left panel) or inflammatory conditions (20 mM 
glucose, 1,000 U/ml IFN-γ and 2 ng/ml IL-1β) (right panel). Results are shown as % of beta cell death (% 
of decreased luciferase) after 48 h coculture with PPI-directed CTL (open triangles), pp65CMV-directed 
CTL (open circles) or INS-DRiP1-9-directed CTL (black squares). Data are shown as the mean ± s.d. 
(Representative results of n=4 from each pancreas donor, n=4). Statistical analysis was performed using 
a two-way ANOVA with Holm-Sidak’s multiple comparison test relative to the pp65 CMV-directed CTLs. 
(f ) Percentage of beta cell death observed in two different pancreas preparation after incubation with 
INS-DRIP1-9-specific CTLs in homeostatic or inflammatory condition (E:I ratio 1:5). (g) Cytokine secretion 
(IFN-γ, TNF-α, and MIP-1β) by INS-DRiP1-9-specific CTLs after coculture with HLA-A2
+ human islet cells in 
low-glucose culture conditions. Data are shown as the mean ± s.d. (representative results from n=3 from 
each pancreas donor). 
CTLs specific for this epitope are able to kill human beta cells in vitro. The 
presence of phenotypically naïve DRiP1-9-specific CTLs in healthy individuals 
and memory T cells in individuals with T1D indicates that neoantigen-specific 
CTLs are part of the normal T cell repertoire, and that the higher frequency and 
activated phenotype of these CTLs detected in PBMCs of individuals with T1D 
patients points to peripheral activation linking DRiP1-9-specific CTLs with the 
immunopathogenesis of T1D. 
Our study proposes a new pathway of beta cell destruction by the immune 
system in which the generation of the neoepitope, such as INS-DRiP1-9, plays 
a central role. The mechanisms regulating the synthesis of the INS-DRiP 
polypeptide are still unknown, but two scenarios can be envisaged. In the first 
model, exon 2 of the insulin gene would be spliced from the pre-mRNA, thus 
positioning the AUG341 as the first AUG encountered by the ribosome during 
scanning. Alternatively, the ribosome scan-through of the canonical AUG 
may result in translation initiation at a downstream AUG in the mature insulin 
mRNA. Since we could not detect such splicing variants in mRNA analysis 
of human pancreatic islets under either normal or pathogenic conditions 
(supplementary figure 4), we favour the alternative translation initiation as the 
most plausible mechanism. Although the results obtained on 293T cells should 
be interpreted with some caution, environmental modifications leading to ER 
stress appear to be an important component that can control expression of 
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alternative reading frame as described for other stress-induced proteins (i.e., 
ATF4 and ATF5) 39, 40. The fact that human beta cells are exceptionally sensitive 
to stress ER reinforces this finding 41. In addition to an effect on translation 
initiation processes, environmental stress may also have an impact on the 
degradation of insulin byproducts. The absence of an in-frame stop codon 
in the INS-DRiP potein is peculiar and may imply the participation of distinct 
elimination mechanisms that are engaged in clearing nonstop proteins42, 43. Yet, 
we cannot exclude the possibility that the increased beta cell death observed 
in pathophysiological condition results also from an increase in  HLA-peptide 
complexes at the beta-cell surface, similar to those seen in insulitic lesions 
found in the pancreases of individuals with  type 1 diabetes30. Nevertheless, 
the implication of translational mistakes in autoimmunity begs for revision of 
transcriptome-based approaches for epitope discovery and offers alternatives 
for tissue- and antigen-specific therapeutic approaches aiming at the induction 
of immune tolerance. Our findings further support the emerging concept 
that beta cells are destroyed in T1D by a mechanism comparable to classical 
antitumor responses whereby the immune system has been trained to survey 
dysfunctional cells in which errors have accumulated1.
MATERIALS AND METHODS
Prediction of alternative translation and HLA binding. 
Candidate alternative translation initiation sites were identified using NetStart 
1.0 software44. Potential HLA-A2 binding peptides were predicted by prediction 
algorithms NetMHC 3.4 45.
Proteins and Peptides.
Human recombinant proteins GAD65, IA-2 and PPI were synthesized as 
previously described46. Recombinant INS-DRiP R-P and INS-DRiP C-H were 
obtained from human islet cDNA by PCR, consisting of the 43 amino acids 
encoded within the insulin mRNA excluding the poly(A) tail. These sequences 
were subsequently cloned into a bacterial expression vector Gateway cloning 
technology (Invitrogen, Carlsbad, CA, USA) creating an N-terminal histidine 
tag, used for protein purification on nickel column (GE Healthcare, #17531801). 
Peptides were synthesized by solid-phase Fmoc chemistry and validated by 
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ultra-performance liquid chromatography and mass spectrometry. Peptides 
(purity > 85%) were dissolved in 5% DMSO/PBS to a 1mM stock solution.
Peptide binding assays.
HLA class II binding affinity of peptides was measured in a cell-free competitive 
peptide binding assay47, 48. Binding competition between an increasing amount 
peptide of interest (0-300 μM) and a fixed amount of biotinylated reporter 
peptide (0.6 μM) in HLA-DQ2 and HLA-DQ8 molecules isolated from transduced 
293T cells was determined. After overnight incubation at 4°C, plates were 
washed, and europium-streptavidin in assay buffer was added to each well 
followed by incubation while shaking. After washing, wells were incubated 
with enhancement buffer. Plates were read using a time-resolved fluorometer 
(1234, Wallac). IC50 values were calculated using Graphpad software employing 
a Sigmoidal dose-response (variable slope) equation based upon the observed 
binding of the tested peptides against the fixed concentration indicator 
peptide. The concentration of test peptide required for half-maximal inhibition 
of binding of the reporter peptide indicates the IC50 value. IC50 < 1 μmol/L is 
considered strong binding, between 1-10 μmol/L, between 10-100 μmol/L 
and above 100 μmol/L are considered intermediate, weak and no binding, 
respectively.
Generation and pulsing of human DCs.
Monocytes were isolated from buffy coats of homozygous HLA-DQ2, 
homozygous HLA-DQ8 or heterozygous HLA-DQ2/8 donors using CD14+ 
Macs sorting (Miltenyi Biotec, #130050201) and monocyte-derived DCs were 
generated as described previously49. Briefly, peripheral blood mononuclear 
cells (PBMCs) were isolated by Ficoll gradient and subsequently CD14+ 
monocytes were isolated and cultivated with GM-CSF (800 U/ml) and IL-4 
(500 U/ml) (invitrogen, Breda, the Netherlands) for 6 d to obtain immature 
DCs (iDCs). These iDCs (0.5 x 106/well) were pulsed with recombinant INS-DRiP 
polypeptide (10 mg/mL) in the presence of lipopolysaccharide (100 ng/ml) and 
IFN-γ (1000 U/ml) to induce DC maturation. After 30 h, the pulsed and matured 
DCs were harvested, washed with PBS and lysed in 1ml lysis buffer (50 mM 
Tris, 150mM NaCl, 5 mM EDTA, 0.5% Zwitterion, 10 mM iodoacetamide and a 
complete protease inhibitor mix (Roche Applied Science). To remove nuclei 
and insoluble material the lysates were centrifuged for 60 min at 10,000 x g.
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Peptide elution of HLA class II and mass spectrometry analysis.
The HLA-DQ molecules were extracted from the DC lysates by affinity 
purification50, 51. Lysates were precleared with Sepharose beads and mixed 
with Sepharose beads coupled with a pan-DQ antibody (purified from SPV-L3 
hybridoma). After 60 min of incubation the beads were washed with 5 bed 
volumes lysis buffer subsequently followed by 4 bed volumes of low salt buffer 
(120 mm NaCl, 20 mm Tris-HCl, pH 8.0), 8 bed volumes of high salt buffer (1 m NaCl, 
20 mm Tris-HCl, pH 8.0), 4 bed volumes of no salt buffer (20 mm Tris-HCl, pH 8.0), 
and 4 bed volumes of low Tris buffer (10 mm Tris-HCl, pH 8.0). The HLA-peptide 
complexes were eluted with 5 bed volumes of 10% acetic acid. The eluate 
was applied on a small homemade C18 column and eluted in two fractions 
with 20 and 30% acetonitrile. Subsequently, the HLA peptides were analyzed 
via on-line C18-nanoHPLC-MS with a system consisting of an Easy nLC 1000 
gradient HPLC system (Thermo Scientific), and a Q Exactive mass spectrometer 
(Thermo Scientific). Fractions were injected onto a homemade precolumn (100 
µm x 15 mm; ReproSil-Pur C18-AQ, 3 µm, Dr. Maisch, Ammerbuch, Germany) 
and eluted via a homemade analytical nano-HPLC column (15 cm x 50 µm; 
ReproSil-Pur C18-AQ, 3 µm). The gradient was run from 0 to 30% solvent B 
(10:90:0.1 water/acetonitrile/formic acid [v/v/v]) in 120 min. The nano-HPLC 
column was drawn to a tip of ~5 µm and acted as the electrospray needle of 
the MS source. The Q Exactive mass spectrometer was operated in top10 mode. 
Parameters were resolution 70,000 at an automatic gain control target value 
of 3 million maximum fill time of 100 ms (full scan), and resolution of 35,000 
at an automatic gain control target value of 1 million/maximum fill time of 
128 ms for MS/MS at an intensity threshold of 780,000. Apex trigger was set 
to 1–5 s, and allowed charges were 1–3. All fractions were measured twice. In 
a postanalysis process, raw data were converted to peak lists using Proteome 
Discoverer 1.4. For peptide identification, MS/MS spectra were submitted to the 
human IPI database supplemented with INS-DRiP amino acid sequence using 
Mascot Version 2.4 (Matrix Science) with the following settings: 10 ppm and 20 
millimass units deviation for precursor and fragment masses, respectively; no 
enzyme was specified. All reported hits were assessed manually, and peptides 
with Mascot scores <35 were generally discarded.
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Blood Donors and Genotyping.
After informed consent, blood was collected from 46 new-onset T1D patients 
(Supplementary Table 1). PBMCs isolated from donors with celiac disease (CD) 
were used as an age- and HLA-DQ matched control cohort (n=9). The genotype 
of the T1D blood donors was determined by PCR. PCR was performed in a total 
volume of 25 µl, using 50 ng of genomic DNA and 10 pmol of each primer. The 
amplification buffer consisted of 1x Flexi Buffer, 1.5 mM MgCl2, 200 µM dNTPs and 
0.5 unit of Taq DNA polymerase (all reagents were obtained from Promega). PCR 
was carried out in a Peltier Thermal Cycler (PTC-200; MJ Research). After initial 
denaturation at 95 °C for 5 min, 35 cycles were run, consisting of denaturation 
at 94 °C for 30 s, annealing at 60 °C (rs3842752) or 65 °C (rs3842753) for 30 s 
and extension at 72 °C for 30 s. Finally, a 5 min extension step was performed 
at 72 °C. For visualisation, 5 µl of the amplification products were run on a 2% 
agarose MP gel (Boehringer Mannheim) prestained with ethidium bromide. 
Genotyping was assessed by PCR using a common forward primer 
(5’-TGGGGCAGGTGGAGCT-3’) and allele-specific reverse primers. The 
presence of allele A or G in SNP rs3842752 was determined using 5’-(T/G)
GGGGCTGCCTGCA-3’ or 5’-(T/G)GGGGCTGCCTGCG-3’, respectively. The 
presence of allele T or G in SNP rs3842753 has been determined using 
5’-GAGGCGGCGGGTGT-3’ or 5’-GAGGCGGCGGGTGG-3’ reverse primers, 
respectively. 
T cell proliferation assay.
Freshly isolated PBMCs were used to investigate the immunogenicity of 
recombinant INS-DRiP polypeptide in a T cell proliferation assay52. PBMCs were 
seeded (150,000/well) in flat-bottomed 96-well microculture plates (Greiner, 
Nürtingen, Germany) and cultured for 5 days at 37°C in 5% CO2, in a humidified 
atmosphere. Cells were cultured in triplicates in medium alone, with 10 mg/
mL recombinant INS-DRiP polypeptide, or recombinant IL-2 10% (25 units/
mL; Genzyme, Cambridge, MA) as positive control. In the final 16 h of culture, 
50 mL RPMI 1640 (Dutch modification; Gibco) containing 0.5 mCi 3H-thymidine 
(DuPont NEN, Boston, MA) was added per well. After the cells were harvested 
on filters with an automated harvester, proliferation was determined by the 
measurement of 3H-thymidine incorporation in an automatic liquid scintillation 
counter. All results are calculated as mean counts per minute (CPM) in the 
presence of antigen and compared with medium alone.
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Detection of epitope-specific CD8+ T cells in PBMCs of T1D patients. 
Heparinized blood samples were drawn from 24 T1D patients (including new 
onset patients) and 13 sex- and age-matched healthy controls (Supplementary 
table 2).PBMCs were isolated by Ficoll-isopaque density gradient centrifugation 
and frozen in liquid nitrogen until use. For the detection of epitope-specific 
CD8+ T cells, thawed PBMCs were stained with Qdot-labeled multimeric 
complexes. Peptide-HLA-A2 (pHLA-A2) monomers and multimeric pHLA-A2 
complexes were generated as previously described 27. Samples with CD8+ 
T cell counts under 50,000 were excluded from analysis. Experiments were 
performed blinded. The study protocol was approved by the Leiden University 
Medical Center institutional review board. 
Cell culture. 
293T cells were obtained from the institutional cell line collection. Their identity 
was confirmed by the Forensic Laboratory for DNA Research, Department of 
Human Genetics, Leiden University Medical Centre, by short tandem repeat 
analyses and comparison with the STR databases. 293T cells were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 8% heat 
inactivated FCS, 100 U/ml penicillin and 100 µg/ml streptomycin. JY cells were 
maintained in Iscove’s modified Dulbecco’s medium (IMDM) supplemented 
with 8% FCS, 100 U/ml penicillin and 100 µg/ml streptomycin. Validation for 
HLA-A2 surface expression was done by FACS prior to every experiments 
(BB7.2, BD Pharmingen, #551285). All cells have been tested negative for 
mycoplasma by mycoplasma detection kit Lonza (Walkerville, MD). DCs were 
maintained in RPMI-1640 supplemented with 100 U/ml penicillin and 100 µg/
ml streptomycin, glutamax and 10% FCS. For the maturation of DCs during 
pulsing, additional cytokines were added to the medium (see above). For 
maintenance and expansion autoreactive CD8+ T cell clones were specifically 
stimulated every 14 d with irradiated allogeneic PBMCs and irradiated peptide-
pulsed HLA-A2-expressing JY cells in IMDM supplemented with a mixture of 
cytokines similarly as described below. 
Human pancreatic islet isolation. 
Human islets were isolated from brain-dead organ donors. Purified islets 
used in these experiments were unsuitable for clinical islet transplantation 
as described previously38. Human islet isolations were performed in the 
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institutional GMP-facility. Purity of the final islet preparation was assessed by 
1 mmol/l dithizone (Sigma-Aldrich) staining and ranged from 45-95%. Purified 
islets were cultured in CMRL-1066 medium supplemented with 10% human 
serum, 20 µg/ml ciprofloxacin, 50 µg/ml gentamycine, 2 nmol/l L-glutamine, 
250 ng/ml fungizone, 10 mmol/l HEPES and 10 mmol/l nicotinamide. 
Generation and characterization of DRiP1-9-specific CD8
+ T cell clone. 
Freshly isolated PBMCs from a long-term HLA-A2+ individual with T1D (clone#1) 
and from an individual with new-onset T1D (clone#2) were seeded 150,000 
cells/well with 10 ug/ml DRiP1-9 peptide in IMDM supplemented with 10% 
human serum, 0.5% LeucoA, 0.1 ng/ml IL-12, 10 ng/ml IL-7, 25 U/ml IL-2 and 5 
ng/ml IL15. After 14 d of culture, 20,000 cells/well were restimulated specifically 
with 20,000 cells/well irradiated DRiP1-9 peptide-pulsed HLA-A2-expressing JY 
cells (2 µg/ml peptide with 10x106 cells in AIM-V medium (Life Technologies) 
for 2 h at 37˚C and 100,000 cells/well irradiated allogeneic PBMCs in IMDM 
medium supplemented with human serum and cytokines as described above. 
On day 28, CD8+ T cells were double stained with DRiP1-9 tetramers (Tm), single 
cell sorted into round bottom 96-well plates and restimulated as described. 
Expanding CD8+ Tm+ T cell clones were isolated and restimulated every 14 d. 
Every 4-5 d fresh IMDM supplemented with 25 U/ml IL-2 and 10 ng/ml IL-15 
was added to the culture media. 
Lentiviruses production and transduction. 
Third-generation self-inactivating lentiviral vectors were produced as described 
previously 53. HIV p24 concentration was measured with antigen capture ELISA 
(ZeptoMetrix, Buffalo, NY); 1 ng p24 corresponds to 2500 infectious particles. 
Human pancreatic islets were dissociated and dispersed prior transduction. 
The islets were incubated with 0.05% trypsin for 5-10 minutes at 37°C and 
subsequently passed through a 40 μm filter. Immediately after dispersion 
the islets were transduced with HIP-Luc2CP containing lentivirus at MOI=2. 
The medium was refreshed after overnight incubation. Cells were maintained 
in culture for 2 d prior incubation with CTL. Human pancreatic islets were 
maintained in DMEM low glucose supplemented with 8% heat inactivated FBS, 
100 u/ml penicillin and 100 µg/ml streptomycin in ultra-low attachment plates 
as described previously38. 
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293T cells were transfected in suspension using polyethylenimine (PEI). 3 µg of 
PEI (pH 7.4) was used per µg DNA used in the transfection mix supplemented 
with Opti-MEM I reduced serum medium and incubated for 10 minutes at 
room temperature (RT) before adding to the cell suspension. After overnight 
incubation the medium was refreshed and further experiments were performed.
DNA constructs. 
pLV-CMV-PPI-GFP and pLV-CMV-PPI-DRiP-GFP have been generated 
from the intermediate cloning vectors pJET1.2-PPI and pJET1.2-DRiP, 
respectively. pJET1.2-PPI has been generated by cloning PPI (5’UTR to 
PPI termination codon) into pJET2.1/blunt vector using the primers: Fw 
5’-AGCCCTCCAGGACAGGC-3’ and Rv 5’GTTGCAGTAGTTCTCCAGCT-3’ on 
human cDNA. pJET1.2-DRiP was generated by cloning PPI (5’UTR to 3’UTR) 
into pJET2.1/blunt vector using the primers: Fw 5’-AGCCCTCCAGGACAGGC-3’ 
and Rv 5’- TTTTGCTGGTTCAAGGGCTTTATT-3’ on human cDNA. The Insulin and 
INS-DRiP fragment were subcloned into pEGFP-N1 (Clontech) in frame with 
the GFP ORF to generate PPI-GFP and INS-DRiP-GFP expressing vectors and 
subcloned into pLV-CMV vectors. pLV-DRiP-GFP was generated by cloning 
the XhoI/HpaI DRiP-GFP fragment from the pLV-CMV-INS-DRiP-GFP construct 
using DRiP Fw 5’- CGCTCGAGTAAATGCTGTACCAGCATCTGC-3’ and GFP Rv 5’- 
CGGTTAACAACTTACTTGTACAGCTCGTCC-3’ primers into pLV-CMV vector.
Cytotoxicity assays. 
Chromium release assay were performed as previously described38. Briefly, JY 
cells loaded with INS-DRiP1-9 or SP-PPI15-24 peptide were incubated with 100 μl 
Na-chromate (51Cr, 3.7 MBq) and seeded in triplicate for 1 h, at various effector-
to-target (E:T) together with CTLs. After 16 h incubation at 37°C in 5% CO2, 
supernatants were collected, and the release of 51Cr was measured with a 
gamma-counter (Wallac/PerkinElmer, Waltham, MA, USA). Spontaneous and 
maximum releases were obtained by incubation with medium and 1% triton 
in PBS, respectively. The specific lysis was calculated as percentage of specific 
lysis = 100 × (experimental release − spontaneous release) /(maximum release 
− spontaneous release). 
To analyze specific beta cell death, human islet cells were transduced with 
LV- HIP-Luc2CP lentivirus vector as described previously38. Transduced islet 
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cells were incubated with increasing amounts with epitope-specific CD8+ T 
cells in IMDM supplemented with 5% HS, 25 U/ml IL-2 and 10 ng/ml IL-15 for 48 
h. Experiments were performed with different effector-to-islet cells target ratio 
(E:I ratio) and performed in fourfold. Subsequently, cells were lysed in luciferase 
lysis buffer (25 mM Tris/HCl pH 7,8, 2mM CDTA, 2mM DTT, 10% glycerol, 1% 
Triton X-100) and T cell mediated target cell killing was verified by measuring 
light emission using Luciferase Assay Reagent (Promega) and Lumat LB9501 
luminometer (Berthold, Bad Wildbad, Germany). Results are shown as decrease 
luciferase activity. The percentage of beta cell death is calculated using the 
following formula: 100-[(RLUCTLx/ RLUaverage CMV CTL)x100].
Protein analysis. 
Protein lysates were analyzed on SDS-PAGE. Before loading, samples were 
boiled in sample buffer (2% SDS, 25mM Tris-HCl pH 6,8, 1,5 mM Bromophenol 
blue, 0.14 mM β-mercaptoethanol, 10% glycerol) for 5 minutes at 96˚C. Proteins 
were transferred to Immobilon-P (Immobilon-PSQ transfer membrane, pore size 
0.2 μm (polyvinylidene difluoride); Millipore, Etten-Leur, The Netherlands) and 
visualized by standard antibody staining protocols for anti-Green Fluorescent 
Protein (1:2000, Life technology, #A11122), anti-insulin (1:1000 clone H-86, 
SantaCruz sc-9168)and anti-actin (1:5000 clone C4,MP Biomedicals, #691001). 
GFP fusion proteins and insulin were analysed on 10% gels and 15% gels, 
respectively. For INS-DRiP-GFP detection, 100 µg of protein from cells 
transfected with INS-DRiP-GFP was loaded on 10% gel for GFP detection owing 
to low DRiP expression, while 30 µg were loaded on the corresponding 15% 
gels for insulin detection. 
Immunohistochemistry.
Forty-eight hours post transfection, 293T cells were fixed in 4% 
paraformaldehyde supplemented with 0,1% saponin. Blocking was done with 
PBS/BSA 1%, and first and secondary antibodies were diluted in PBS/BSA 1%. 
Anti-proinsulin (Monoclonal Human Pro-Insulin, Beta cell biology consortium) 
was used at 1:500 and secondary antibody coupled to Alexa 568 was used at 
a dilution of 1:500. Nuclei were stained with Hoechst. Cells were analysed by 
confocal microscope (Zeiss).
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Data are presented as mean ± s.d. Statistical calculations were carried out using 
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). The statistical tests 
used for each experiment are indicated in the legend of the corresponding 
figures. P values ˂ 0.05 were considered statistically significant. The number and 
the type of replicates are indicated in the legend of the figures. 
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Supplementary figure 1: Lymphocyte proliferation responses to native beta cell proteins. PBMCs 
isolated from fresh whole blood of T1D patients with the high risk haplotype DQ2/8, DQ2/x or DQ8/x, 
and DQx/x were incubated with a) recombinant GAD65 b) recombinant IA-2 or c) recombinant PPI. The 
x represents any HLA-DQ haplotype except DQ2 or DQ8. P-values have been calculated by a Mann-
Whitney t test.
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Supplementary figure 2: Phenotypical analysis of DRiP Tm+ CD8 T cells using CCR7 and CD45 surface 
markers. The T cell phenotypes are defines as naïve (CCR7+/CD45RA+), central memory (CM) (CCR7+/
CD45RA-), effector memory (EM) (CCR7-/CDRA-), or terminally differentiated effector memory (TEMRA) 
(CCR7-/CD45RA+). The graph represent the percentage of each phenotype within the DRiP Tm+ CD8 T 
cell population of T1D patients (black circles) and matched healthy control subjects (grey circles).
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Supplementary figure 3: T cell receptor analysis of DRiP
1-9
-specific T cell clones. a) TCRα chain and 
TCRβ chain sequences of the two DRiP1-9-specific clones as analysed by IMGT/V-QUEST. b) Chromium 
release assay performed on JY cells loaded with DRiP1-9 peptide (solid lines and black symbols) or CMV 
peptide (dashed lines and open symbols) using the two DRiP1-9-specific clones (circles and squares). 
Data represent mean ± standard deviation (n=3). 
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Supplementary figure 4: mRNA analysis of human islets. A) PCR analysis performed on RNA extracted 
from human islets maintained in ER stress condition (24h-0.1µM Thapsigargin) or inflammatory 
conditions (24h-IFNᵧ/IL1β) using primer set 1 covering the whole insulin mRNA sequence as indicated 
by the arrows on the INS gene schematic representation (upper panel). The upper band shows 
expression of the correctly spliced mRNA (WT), the lower represents an alternative transcript resulting 
from the use of an alternative splicing site (ASS) within exon 3. (b) Insulin and ER stress genes expression 
in human islets following thapsigargin treatment and cytokine mix stimulation assessed by qPCR. 
GAPDH was used as housekeeping gene.
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Supplementary table 2: In silico prediction of HLA-A2 binding peptides within INS-DRIP. a) Prediction 
of HLA-A2 binding peptides using NetMHC 3.4. Scores are predicted IC50 values in nM, binding threshold 
for strong binder (SB) < 50 nM (*) and weak binder (WB) 50 ≥ nM < 500 (**). † Position of peptide within 
the amino acid sequence of INS-DRIP. ‡Binding affinity is predicted using prediction algorithm NetMHC 
3.4. Grey sequences represent peptides that are generated in case translation continues into the poly-A 
tail. b) Overview of the experimentally determined IC50 value, as determined by competition-based 
peptide binding assay of HLA-A2 peptide HBV cAG18-27, INS-DRiP1-9 and non HLA-A2 binding peptide 
MAGE A wt. † Binding affinity thresholds: strong binder < 5μM, intermediate binder 5≥μM<15, weak 
binder 15≥μM<100 and no binder >100μM. The IC50 value is calculated based on the competition 
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Supplementary table 3: Description of donors examined by Qdot analysis. Sex, age, disease duration 
and CD8+ T cell counts and % of INS-DRiP1-9
+ or virus+ CD8 T cells of T1D patients, New onset (NO) T1D 
patients and  healthy control subjects matched for HLA-A2, age and sex.  Disease duration reflects the 
time between the diagnosis of T1D and the moment blood samples were taken for analysis. CD8 T cells 
were identified by flow cytometry. CD8+ T cell counts below 50,000 were excluded from the graphs and 
analyses due to expected inaccuracy of T cell frequencies (frequencies (indicated by italic font and 
marked with *). NA, not applicable. NO, new onset, patients diagnosed within 90 days prior blood 
analysis. NO†, new onset T1D patient tested within a month from diagnosis. 











female 10 5 45,299* 0.0044 0.0111
male 8 12 84,762 0.0012 0.0237
male 17 15 76,037 0.0040 0.0595
female 10 30 207,338 0.0015 0.0053
male 11 6 179,447 0.0045 0.0039
male 23 6 79,898 0.0025 0.0190
female 15 13 151,787 0.0046 0.0040
female 13 18 71,630 0.0042 0.0070
male 10 23 147,814 0.0055 0.0089
male 10 5 215,161 0.0023 0.0136
male 10 13 182,324 0.0022 0.0011
male 14 18 210,107 0.0024 0.0010
male 13 24 150,974 0.0013 0.0013
male 18 19 214,158 0.0038 0.1101
male 19 12 46,175* 0.004 0.004
male 24 6 84,387 0 0.007
male 20 6 83,466 0.004 0.089
New-onset T1D patients
female 14 NO 49,238* 0.01 0.01
female 35 NO 55,632 0 0.02
male 21 NO 40,578* 0.002 0.022
male 13 NO† 115,210 0.002 0.979
male 25 NO 76,212 0.005 0.004
female 13 NO 66,460 0.006 0.19
female 19 NO 42,771* 0.01 0.014
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Supplementary table 3: Description of donors examined by Qdot analysis. continued











female 10 NA 122,400 0.0016 0.0066
male 9 NA 207,458 0.0034 0.0271
male 17 NA 159,001 0.0025 0.0769
female 10 NA 109,319 0.0009 0
male 11 NA 211,298 0.0033 0.2037
male 23 NA 210,190 0.0024 0.0043
female 13 NA 164,197 0.0025 0.0472
female 12 NA 49,202* 0.0062 0.0983
male 11 NA 191,667 0.0005 0.0357
male 10 NA 117,310 0.0026 0.0043
male 10 NA 203,629 0.0005 0.001
male 14 NA 214,768 0.0019 0.0019
male 13 NA 134,032 0.0008 0.0135
SUPPLEMENTARY MATERIALS
Cytokine measurements
Detection of INS-DRiP1-9–specific T cells secreting Granzyme B (GrzB) (U-Cytech, 
#CT229PR5) or interferon gamma (IFNg) (U-Cytech, #CT230PR5) was determined 
by enzyme-linked immunospot (ELISPOT)10, 54. Freshly isolated PBMCs were 
incubated in the presence of 10 mg/mL peptide or diluent alone for 48 hrs. The 
cells were then transferred onto microtiter pre-coated with monoclonal anti–
IFNg or anti–GrzB capture antibody. Detection of cells producing IFNg or GrzB 
was performed using biotinylated anti–IFNg or anti–GrzB detector antibody. 
Data are expressed as the mean number of spots per triplicate divided by the 
mean number of spots in triplicate in the presence of diluent alone. Stimulation 
index values of ≥3 are considered as positive.
HLA-A2 peptide binding affinity
Binding affinity to HLA-A2 was determined by a competition-based cellular 
peptide binding assay. JY cells (HLA-A020) were stripped of their naturally 
bound peptides in ice-cold citric acid elution buffer (1:1 mixture of 0.263M citric 
acid and 0.12M Na2HPO4, PH 3.1). After 90 seconds incubation, the reaction was 
stopped by addition of ice-cold Iscove’s modified Dulbecco’s media (IMDM-2) 
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supplemented with 2% foetal calf serum (FCS). The cell pellet was resuspended 
in IMDM-2 supplemented with 2% FCS and 2µg/ml β2M at a concentration of 
4x105 cells/ml. An 8-fold dilution series of test peptides (final concentration of 
100 µM to 0.8 µM was incubated with fluorescent-labelled reference peptide 
(150 nM) and 4x104 cells for 24 hours at 4°C in the dark. Peptide binding affinity 
was determined by decrease in fluorescence intensity measured by FACS. The 
50% inhibitory concentration (IC50) was calculated by nonlinear regression 
analysis using the following formula: inhibition (%) = ((MF-MFmin)/(MFmax-
MFmin))*100.
Reverse-transcription PCR and real-time PCR. 
Total cellular RNA was extracted from human islets stimulated with cytokine 
mix (IFNγ: 1000U/ml; IL1β: 2ng/ml) or thapsigargin (0.1uM) using Trizol. 200ng 
RNA was reverse transcribed using Superscript RT II kit (Invitrogen, Karlsruhe, 
Germany). Expression pattern of Insulin was addressed by regular PCR using INS 
Fw 5’- AGCCCTCCAGGACAGGC-3’ and INS Rv 5’-TTTT’GCTGGTTCAAGGGCTTTATT-3’. 
Expression of the genes of interest was detected using the following primers: 
Insulin 
Fw 5′-GCAGCCTTTGTGAACCAACA-3′, Insulin Rv 5′-CGGGTCTTGGGTGTGTAGAAG-3′; 
ATF3 
Fw 5’- GTGCCGAAACAAGAAGAAGG-3’, ATF3 Rv 5’- TCTGAGCCTTCAGTTCAGCA-3’; 
ATF4 
Fw 5’- GGTCAGTCCCTCCAACAACA-3’, ATF4 Rv 5’- AGGTCATCTGGCATGGTTTC-3’; 
CHOP 
Fw 5’- GACCTGCAAGAGGTCCTGTC-3’, CHOP Rv 5’- CTCCTCCTCAGTCAGCCAAG-3’; 
XBP 
Fw 5’- GGAGTTAAGACAGCGCTTGG-3’, XBP Rv 5’- CTGCAGAGGTGCACGTAGTC-3’; XBPs 
Fw 5’- CTGAGTCCGCAGCAGGTG-3’, XBPs Rv 5’- GAGATGTTCTGGAGGGGTGA-3’; 
GAPDH 
Fw 5′-ACAGTCAGCCGCATCTTCTT-3′, GAPDH Rv 
5′-AATGAAGGGGTCATTGATGG-3′. 
Real-time PCR was performed in triplicate using the SybrGreen master mix kit 
(Applied Biosystems, Foster City, CA) and an Applied Biosystems Step One Plus 
machine. GAPDH mRNA was used as reference.
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Total RNA was isolated using Nucleospin miRNA (Macherey-Nagel GmbH, 
Düren, Germany) according to manufacturer’s protocol. Oligo(dT)15-primed 
(Promega, Madison, WI) first-strand complementary DNA was synthesized 
from 100ng total RNA template using superscript III Reverse Transcriptase (Life 
Technologies Ltd, Paisley, UK) in 20 µl according to manufacturer’s protocol. 
Polymerase chain reaction was performed to determine the TCR VA and 
VB distribution using forward primers that cover the complete TRAV 
and TRVB repertoire, together with reverse primers specific for the TRAC 
(5’-AGCAGATTAAACCCGGCCA-3’ and TRBC 5’-TTCTCTTGACCATGGCCATC-3’ 
constant region. PCR amplification was performed in a volume of 10 µl, 
containing 0.5 ng cDNA, 1x Green Gotaq Flexi Buffer (Promega, Madison, 
WI),  5 pmol of each primer, 200 µM dNTPs (Promega, Madison, WI), 1.5 mM 
MgCl2 (Promega, Madison, WI) and 0.5 unit of GoTaq G2 Flexi DNA Polymerase 
(Promega, Madison, WI). An initial denaturation step at 95 °C for 2 minutes, was 
followed by 35 cycles of denaturation at 94 °C for 30 seconds, annealing at 65 
°C (TRAV) or 60 °C (TRBV) for 30 seconds and extension at 72 °C for 30 seconds. 
Finally, a 5 minute extension step was performed at 72 °C. The amplification 
products were run on a 1.5% (w/v) agarose MP gel (Roche Diagnostics GmbH, 
Mannheim, Germany) pre-stained with ethidium-bromide. 
TRAV12 and TRBV6 targeting proofreading PCR amplification was performed 
in a volume of 25 µl, containing 5 ng cDNA, 1x Phusion HF Reaction Buffer (New 
England Biolabs), 10 pmol of each primer, 200 µM dNTPs (Promega, Madison, 
WI) and 0.5 unit of Phusion Hot Start Flex DNA Polymerase (New England 
Biolabs). An initial denaturation step at 98 °C for 2 minutes, was followed by 
35 cycles of denaturation at 98 °C for 15 seconds, annealing at 65 °C (TRAV) or 
60 °C (TRBV) for 30 seconds and extension at 72 °C for 30 seconds. Finally, a 5 
minute extension step was performed at 72 °C. Amplicons were purified using 
Nucleospin Gel and PCR Clean-up (Macherey-Nagel GmbH, Düren, Germany) 
according to manufacturer’s protocol.
Purified amplicons were ligated into the pJET1.2/blunt Cloning Vector 
(Thermo Scientific) using T4 ligase (Roche Diagnostics GmbH, Mannheim, 
Germany), and cloned into XL1-Blue Competent Cells. The TRAV12 and TRBV6 
constructs from single colonies were isolated using PureYield Plasmid Miniprep 
System (Promega, Madison, WI) according to manufacturer’s protocol. The 
constructs were sequenced using the T7 promoter target site, TCR sequences 
were analysed using IMGT/V-QUEST version 3.2.16.
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During type 1 diabetes development, cells in the islets of Langerhans engage 
adaptive mechanisms in response to inflammatory signals to cope with stress, 
to restore cellular homeostasis, and to preserve cell function. Disruption of 
these mechanisms may induce the formation of a repertoire of stress-induced 
neoantigens, which are critical in the loss of tolerance to beta cells and the 
development of autoimmunity. While multiple lines of evidence argue for a 
critical role of the endoplasmic reticulum in these processes, the lack of tools to 
specifically monitor beta cell stress hampers the development of therapeutic 
interventions focusing on maintaining endoplasmic reticulum homeostasis. 
Here we designed and evaluated a stress-induced reporter in which induction 
of stress correlates with increased light emission. This Gaussia luciferase-based 
reporter system employs the unconventional cytoplasmic splicing of XBP1 
to report ER stress in cells exposed to known ER stress inducers. Linking this 
reporter to a human beta cell-specific promotor allows tracing ER stress in 
isolated human beta cells as well as in the EndoC-βH1 cell line. This reporter 
system represents a valuable tool to assess ER stress in human beta cells and 
may aid the identification of novel therapeutics that can prevent beta cell stress 
in human pancreatic islets.
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Beta cell destruction in Type 1 diabetes (T1D) results from the combined 
effect of inflammation and autoimmunity. The presence of endoplasmic 
reticulum (ER) stress markers during insulitis points to the involvement of an 
ER stress response in beta cell destruction1. The ER is a central organelle for 
protein synthesis, processing and folding and essential in insulin biosynthesis, 
maturation and secretion2, 3. Perturbations of the ER homeostasis by 
environmental factors triggers the induction of an unfolded protein response 
(UPR) and activation of inositol-requiring protein 1α (IRE1α), protein kinase 
RNA-like endoplasmic reticulum kinase (PERK) and the cleavage of membrane 
bound activating transcription factor 6 (ATF6). Activation of these ER membrane 
bound sensors leads to phosphorylation of eukaryotic translation initiation 
factor 2α by PERK4, activation of transcription factor X-box binding protein 1 
(XBP1) via nonconventional XBP1 RNA splicing by IRE1α5, 6 and translocation of 
ATF6 to the nucleus7, respectively. These different pathways ultimately act in 
concert to restore ER homeostasis by the coordinated regulation of inhibition 
of protein synthesis, degradation of aberrant translation products by the ERAD 
degradation pathway and enhanced protein folding capacity by upregulation 
of chaperone expression. 
The high insulin translation rate makes beta cells extremely sensitive to ER 
stress8 and several lines of evidence suggest that the UPR is a key mechanism 
for the formation of neoantigens and subsequent autoimmune destruction of 
beta cells9-11. We and others have shown that pathophysiological conditions 
characteristic for T1D participate to the increased complexity of the beta cell 
proteome by affecting alternative splicing events12, formation of defective 
ribosomal products (DRiPs)13, activation of post translational modification 
enzymes leading to citrullination and deamidation of autoantigens14-18. These 
processes are likely to increase visibility of beta cells to immune cells and their 
subsequent destruction. Thus, monitoring and understanding the origin of beta 
cell stress is critical to understand autoimmunity, to prevent beta cell failure 
and to design therapeutics to prevent T1D development. While quantitative 
methods for monitoring ER stress in vitro are well established, these methods 
are labour intensive and cannot be translated to selectively address beta cell 
stress in human pancreatic islets because of their multi-endocrine nature. In 
this study, we describe a quantitative bioluminescent method to measure ER 
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stress by exploiting the UPR-induced IRE1α-mediated splicing of XBP1 coupled 
to a Gaussia luciferase reporter gene. We show that this reporter accurately 
reflects the ER stress status in the human beta cell line EndoC-βH1 during 
inflammation when compared to classical ER stress quantification methods. 
Furthermore, it can be used to specifically monitor beta cell stress in primary 
human islets when the reporter expression is driven by the human insulin 
promoter (HIP). This reporter represents a novel tool to identify therapeutics 
targeting beta cell stress in a drug screening platform in human beta cells.
RESULTS
Design of ER stress reporter
Activation of the IRE1 endonuclease by ER stress leads to unconventional XBP1 
splicing in which a 26 nucleotide intronic region is removed (Fig. 1a,b). This 
process causes a shift of the reading frame and gives rise to translation of an 
elongated C-terminal protein as observed by Western blot analysis of lysates 
from 293T cells exposed to ER stress-inducing agent thapsigargin (TG) (Fig. 1c). 
We exploited this stress-induced splicing mechanism to generate a lentivirus 
vector containing a stress-inducible Gaussia luciferase reporter (pLV-CMV-XBP-
GLuc-bc-Puro) (Fig. 1d). In this bi-cistronic construct, where the puromycin 
resistant gene can be used for clone selection, the ER stress-dependent splicing 
positioned the Gaussia luciferase coding sequence in frame with the XBP1 
bona-fide AUG to generate a XBP-Gaussia luciferase fusion protein. Following 
transfection in HEK 293T cells with the XBP-GLuc construct, treatment with TG 
lead to up to increase XBP1 splicing as detected by mRNA analysis (Fig. 1e) 
and to 10-fold induction in light emission after 24h treatment, compared to 
untreated cells, indicating that the reporter is induced by ER stress (Fig. 1f ). 
Validation and characterization of the ER stress reporter in 293T cells
To test the sensitivity of the stress reporter in more detail, 293T cells were 
transfected with pLV-CMV-XBP-GLuc and exposed to various amounts of TG for 
6 hours or to a moderate amount of stress agent and analysed over a 24-hour 
period. ER stress was evaluated by i) the conventional ER stress quantification 
method, qPCR using primers specific for spliced XBP1 (Fig. 2a, b black symbols); 
and ii) light emission after cell lysis to quantify reporter splicing (Fig. 2a, b red 
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Figure 1. Principle of the ER stress reporter. (a) Schematic representation of XBP1 mRNA under normal 
(top) and ER stress conditions (bottom). XBP1 mRNA consists of two open reading frames (ORFs) (white 
and dark grey box). In normal conditions, the retained intron (light grey box) limits translation to the fi rst 
ORF. Upon ER stress, the intronic region is spliced out by p-IRE1α as indicated by the dashed lines, 
allowing a shift of the fi rst ORF, to the second ORF generating a protein with an extended C-terminus. 
The functional ORF is indicated by the black arrow underneath. Position of the primer set for analysis of 
spliced XBP1 are indicated with small arrows with the number 1. (b) Quantifi cation of XBP1s by qPCR in 
293T cells after exposure to TG for 0, 6 or 24 hours. Quantitative PCR analysis was performed in triplicate 
and GAPDH corrected. (c) Western blot analysis of 293T cell lysates treated with 100 nM TG for 0, 6 or 24 
hours analysed with an anti-XBP1-spliced antibody (upper panel) and anti-actin antibody (lower panel). 
(d) Schematic representation of the ER stress reporter construct, pLV-CMV-XBP-GLuc-bc-Puro, encoding 
XBP1 (white box) with retained intron (light grey box) and Gaussia luciferase (red box) driven by a CMV 
promoter. The two ORFs are indicated by black lines. In normal conditions, the intronic region is retained 
and only the fi rst ORF is translated (left arm). The splicing of XBP1 during ER stress results in the 
translation of the fi rst and second ORF resulting in an XBP1-Gaussia fusion protein (right arm). In red the 
in-frame STOP codon of the fi rst ORF is depicted. The diagonal line pattern indicates the translational 
product is not in the functional reading frame. Position of the primer set for analysis of reporter splicing 
are indicated with small arrows with the number 2. (e) Quantifi cation of XBP1s by qPCR in cells 
transfected with the reporter construct after exposure to TG for 0, 6 or 24 hours. Quantitative PCR 
analysis was performed in triplicate and GAPDH corrected. (f ) Luciferase activity measured in pLV-CMV-
XBP-GLuc-bc-Puro transfected 293T cell lysates priorly treated with 100 nM TG for 0, 6 or 24 hours. 
Results are shown as relative light units (RLU) corrected by the protein amount in the sample. 
symbols). In these experiments, a similar spectrum of ER stress quantifi cation 
was obtained with both ER stress quantifi cation methods. Using both 
techniques we show that XBP1 splicing is occurring at minimal amounts of TG, 
shortly after exposure to stress inducer and rapidly reaching a plateau when 
higher doses are used or 8 hours post stimulation. Light emission correlated 
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strongly with the splicing of the reporter construct as determined by PCR using 
primers specific for the reporter (Fig. 2a, b lower panels). To evaluate whether 
the reporter construct may be used as drug screening assay, we tested the effect 
of the MKC394619, an inhibitor of inositol-requiring enzyme 1α in HEK293T 
cells in presence of ER stress inducer TG. As anticipated, the induction of stress 
by TG lead to a substantial increase in XBP1s RNA expression. This effect was 
countered by the presence of the MKC3946, indicating effective inhibition of 
XBP1 splicing (Fig. 2c). Similar results were obtained by measuring Gaussia 
luciferase activity in the cell lysates (Fig. 2d). 
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Figure 2. Characterization of pLV-CMV-XBP-GLuc-bc-Puro in 293T cells. (a) Analysis of the ER stress-
induced reporter in transfected 293T cells exposed to various amounts of TG by classic validation of 
endogenous XBP-1 splicing by qPCR (black dots) and luciferase activity (red dots) (upper panel); 
Validation of reporter splicing by PCR analysis of reporter and GAPDH (lower panel) on agarose gel. (b) 
Similarly, a time course analysis of the ER stress reporter in transfected 293T cells stimulated with 50 
nM TG was performed. Quantitative PCR analysis was performed in triplicate and GAPDH corrected. 
Gaussia activity is expressed in relative light units per μg protein. Each point represents the average 
of 3 experimental replicates. Data are shown as the mean ± SEM. (c) qPCR analysis of the level of 
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expression of XBP1s in 293T cells transfected with the reporter construct after 24 hours treatment 
with 100 nM TG in presence (grey bars) or absence (black bars) of 5 µM MKC3946. Quantitative PCR 
analysis was performed in triplicate and GAPDH corrected. (d) Luciferase activity measured in 
transfected 293T cell lysates after 24 hours treatment with 100 nM TG in presence (grey bars) or 
absence (black bars) of 5 µM MKC3946. Results are shown as relative light units (RLU) corrected by the 
protein amount in the sample. 
Altogether, these data indicate that the reporter accurately reflects stress-
induced splicing of endogenous XBP-1, even shortly after exposure to low 
amount of stress inducing agent and allows screening of ER stress inhibitor drugs.
Evaluation of the ER stress reporter in human beta cells
Beta cell stress is a significant component underlying the pathogenesis of T1D. 
Recently, the human EndoC-βH1 beta cell line has been generated as a promising 
model to study human beta cell biology under T1D pathophysiological 
conditions20. In order to evaluate the potential of the XBP-GLuc construct to 
detect ER stress in a relevant beta cell model, we generated a stable reporter 
cell line by lentiviral transduction followed by puromycin selection; pLV-CMV-
GFP-bc-Puro transduced cells were used as control (Fig. 3a). We confirmed 
that lentiviral transduction and expression of the reporter construct had 
no apparent impact on beta cell viability (Fig. 3b) and function as seen by 
c-peptide secretion after glucose challenge (Fig. 3c). Moreover, the presence of 
the transgene had no effect on the baseline of UPR related gene expression and 
capacity to respond to stress stimulation as seen by the increased expression 
of ATF3 and CHOP upon cytokines stimulation (Fig. 3d). The modified cells 
were then exposed to proinflammatory cytokines mimicking the pathogenic 
inflammatory beta cell microenvironment of pancreatic islet in type 1 diabetes, 
i.e. IFNγ/IL1β or IFNγ/IL1β/TNFα and analysed for endogenous XBP1 splicing 
by qPCR or light emission in cell lysates. Both treatments led to the generation 
of endogenous XBP1s, which correlated with an increase in luminescence (Fig. 
3e). Of note, the induction of stress is enhanced by the presence of TNFα in the 
cytokine mixture. 









































































































































































Figure 3. Evaluation of the ER stress reporter in human beta cells. (a) Transduction of EndoC-βH1 with 
LV-CMV-GFP after puromycin selection (right panels) compared to non-transduced cells (left panels). (b) 
Cell viability as determined by WST assay in non-transduced cells (NTD), GFP transduced (GFP) or 
transduced with the pLV-CMV-XBP-GLuc-bc-Puro construct (reporter). Data are shown as relative 
viability compared to non-transduced cells (set to 1). (c) C-peptide release assay performed on non-
transduced cells (NTD), GFP transduced (GFP) or the reporter cell lines (reporter) after low glucose 
stimulation (grey bars) or high glucose stimulation (black bars). Data are shown as induction c-peptide 
release, low glucose conditions set to 1. (d) qPCR analysis of the level of expression of ATF3 and CHOP in 
non-transduced cells (NTD), GFP transduced (GFP) or the reporter cell lines (reporter) after cytokines 
treatment. Quantitative PCR analysis was performed in triplicate and GAPDH corrected. The data are 
shown as relative expression. The expression in non-transduced cells in absence of stimulation is set to 
1 and used as reference. (e) Analysis of the reporter EndoC-βH1 cells exposed to 1000 U/ml IFNγ and 2 
ng/ml IL-1β (dashed lines) and 1000 U/ml IFNγ, 2ng/ml IL-1β and 50 ng/ml TNFα (solid lines) for 0, 6, 12 
and 24 hours. ER stress was validated using endogenous XBP-1 splicing by qPCR (black lines and dots) 
and luciferase activity (red lines and dots). 
While classical methods allow a precise examination of the ER stress status, 
the presence of various cell types in the islets of Langerhans hampers the use 
of these methods for specific investigation of beta cells. In order to study beta 
cell stress within their islet environment we replaced the CMV promoter by the 
human insulin promoter (HIP) to drive expression of the transgene specifically 
in insulin-producing cells (Fig. 4a)21. We show that while lentivirus vectors can 
moderately modify endocrine cells (~30% transduction efficiency) (Fig. 4b), the 
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use of the human insulin promoter restricts expression of the transgene to beta 
cells (Fig. 4c).
Following transduction with the pLV-HIP-XBP-GLuc-bc-GFP lentiviral 
vector, human endocrine cells were exposed to pro-inflammatory cytokines. 
Using this assay, we demonstrate that primary human beta cells respond to 
inflammatory cytokines by eliciting an ER stress response, as reflected by the 
increased Gaussia activity. Furthermore, our data point to a major contribution 
of IFNγ/IL1β in this process since no increase in light emission was detected 
upon addition of TNFα to the cytokine mixture (Fig. 4d). 
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Figure 4. Evaluation of the ER stress reporter in primary human beta cells (a) Flow diagram of the 
experimental design for the evaluation of beta cell stress in human pancreatic islets. (b) Flow cytometry 
analysis showing the transduction rate of primary human islet cells after cell dispersion and lentivirus 
transduction with LV-CMV-GFP (MOI=3). (c) Flow cytometry analysis of primary human islets cells 
stained with anti-c-peptide and anti-GFP antibodies after cell dispersion and transduction with LV-HIP-
GFP (MOI=3). (d) Schematic representation of the beta cell-specific ER stress reporter construct, 
encoding XBP1 (white box) with retained intron (light grey box) and Gaussia luciferase (yellow box) 
driven by a HIP promoter (black box arrow), and underneath the two reading frames (indicated by black 
lines) (top). Graph depicts the luminescence measured in lysates made of transduced human islets after 
exposure to inflammatory cytokines (1000 U/ml IFNγ, 2ng/ml IL-1β and 50 ng/ml TNFα) (bottom). Each 
point represents the average of 3 experimental replicates. Data are shown as the mean ± SEM.




Islets of Langerhans are responsible for maintaining glucose homeostasis. The 
ER forms the integration interface between the cellular microenvironment and 
adaptation. Dysfunction of this interface may contribute to the development 
of T1D by generation of neoantigens targeted by the immune system and by 
inducing cell death pathways. Therefore, the ability to monitor ER stress is an 
essential step in understanding disease pathogenesis and for the development 
of therapeutic intervention. 
The Gaussia luciferase reporter assay presented here is an easy and rapid 
alternative to traditional methods. In contrast to previous approaches, the 
stress status can be directly measured in cell lysates upon addition of substrate, 
without the need of laborious RNA isolation or protein analysis procedures. The 
IRE1α-XBP1 pathway has a critical role in life and death decision by preserving 
ER homeostasis versus triggering apoptosis by activating the regulated IRE1-
dependent decay (RIDD)22. In beta cells, the IRE1α-XBP1 pathway participates to 
the maintenance of the balance between the beta cell microenvironment and 
beta cell function as it is required for proper insulin biosynthesis and glucose 
responsiveness23-25. By exploiting XBP1 processing in the reporter construct, we 
demonstrate that this reporter accurately reflects endogenous XBP-1 splicing 
after both chemical- and cytokines-induced stress in 293T and EndoC-βH1 cells. 
This approach appeared equally sensitive as currently used ER stress detection 
methods. The generation of stable EndoC-βH1 cells expressing the ER stress 
reporter set the stage for future high throughput compound screening aiming 
at relapsing ER stress20 and can be combined with other assays to monitor beta 
cell functionality, such as the glucose stimulated insulin secretion (GSIS) assay. 
The multi-endocrine nature of human pancreatic islets often complicates 
the analysis of beta cell stress in primary islets, as the classical methods do 
not distinguish which cells are stressed but rather provide a general picture of 
stressed islet cells as whole. This impairs assessing beta cell stress selectively, 
as the other endocrine cell may respond differently to changes in the 
microenvironment counteracting the beta cell stress26, 27. Single cell analyses of 
pancreatic islets are currently the only method offering a real reflection of beta 
cell stress specifically. Yet, these techniques are difficultly translatable for drugs 
screening approach. The method described here, using the human insulin 
promoter to drive transgene expression of an ER stress reporter specifically 
53804 marjolein Kracht.indd   130 08-05-19   18:03
Monitoring ER stress in human beta cells
131
5
in beta cells, represents a rapid and robust alternative allowing the specific 
analyses of beta cell ER stress within the total islet environment. Our results 
using the IRE1α inhibitor, on HEK293T cells show the potential application of 
the reporter as drug screening platform. 
Our results indicate that EndoC-βH1 cells respond differently to cytokines 
when compared to human islets. The relative low induction of ER stress detected 
in primary beta cells compared to the beta cell line after cytokine stimulation, 
might be the result of a high basal level of ER stress in islets resulting from islet 
isolation, in vitro culture conditions and cell dispersion thereby dampening 
in vitro ER stress responses to cytokines. Moreover, EndoC-βH1 cells seem 
particularly sensitive to TNFα in the cytokine stimulation cocktail. Previous 
studies comparing the response of the human beta cell line and primary islets 
to cytokines, have shown that the EndoC-βH1 cells may have an impaired ER 
stress response and do not faithfully reflect the response of human islets to 
cytokines28. While differences in response to cytokines between EndoC-βH1 
and primary human beta cells could reflect intrinsic differences between the 
cell line and primary cells (e.g. EndoC-βH1 cells divide while primary beta cells 
do not), these differences could also point towards a guardian role of other 
endocrine cells27. The glucagon like peptide 1 (GLP1) produced by alpha 
cells for example could represent a possible paracrine mediator of this anti-
inflammatory effect29. Therefore, caution should be taken with the use of 
beta cell lines and, where feasible, results obtained from cell lines should be 
confirmed in primary human beta cells. 
While similar strategies for ER stress evaluation have been successfully used 
in transgenic mice with a XBP1-GFP variant30, the combination of the lentivirus 
vector that can efficiently modify cells without affecting cell function31 and the 
Gaussia luciferase allow a sensitive and quantitative method to measure stress. 
We anticipate that this reporter used in combination with the human insulin 
promoter will represent a powerful tool to address various issues regarding ER 
stress in beta cells in type 1 diabetes as well as type 2 diabetes. 





HEK293T cells were maintained in high glucose Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco-BRL, Breda, The Netherlands) supplemented with 8% 
fetal bovine serum (FBS) (Gibco-BRL), 100 units/ml Penicillin and 100 μg/ml 
streptomycin (Gibco-BRL). 
The human beta cell line, EndoC-βH1 cells32, was obtained from Dr. Raphael 
Scharfmann (Paris Descartes University, France) and maintained in low glucose 
DMEM supplemented with 5.5 μg/ml human transferrin, 10 mM nicotinamide, 
6.7 ng/ml Selenit, 50 μM β-mercaptoethanol, 2% bovine serum albumin fraction 
V, 100 units/ml Penicillin and 100 μg/ml streptomycin. Cells were seeded in 
ECM, fibronectin pre-coated culture plates. Inflammatory stress was induced 
by treating EndoC-βH1 with a mixture of 1000 U/ml IFNγ, 2 ng/ml IL1β and 50 
ng/ml TNFα for the indicated time.
Transfection
HEK293T were transfected in suspension using polyethylenimine (PEI). 
Transfection mixes, consisting of 0.125 μg plasmid DNA, 0.375 μg/μl PEI in a 
total volume of 12.5 μl Opti-MEM (GIBCO) for a 96-well, were incubated for 
10 minutes at room temperature prior adding to the cell suspension. After 24 
hours cells were treated with Thapsigargin (Bio-connect). The concentrations 
and incubation times are indicated in the figures. For treatment with the IRE1α 
inhibitor, transfected cells were pre-treated for 4 h with MKC3946 (5 μM) before 
addition of 0.1 μM Thapsigargin for 24 hours.
Human islet isolation and culture
Pancreatic islets were obtained from human organ donor pancreata. Human 
islets were isolated from organ donors. Islets were only studied if they could 
not be used for clinical purposes and if research consent had been obtained. 
According to the national law ethics approval is not required for research on 
donor tissues that cannot be used for clinical transplantation. The isolations were 
performed in the GMP-facility of LUMC according to the previously described 
protocol33. For experimental use, human islets were maintained in ultra-low 
attachment plates (Corning, NY 14831) in low glucose DMEM supplemented 
with 10% FBS, 100 units/ml Penicillin and 100 μg/ml streptomycin. Dispersed 
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islet cells were treated with 1000 U/ml IFNγ, 2 ng/ml IL1β and 50 ng/ml TNFα for 
24 hours to induce ER stress. All methods were carried out in accordance with 
relevant guidelines and regulations.
Lentivirus production and transduction
Lentiviruses were produced as previously described31. Prior transduction the 
human pancreatic islets were dispersed, then cocultured with virus supernatant 
supplemented with 8 μg/ml polybrene (Sigma). After overnight incubation, the 
medium was refreshed and the cells were allowed to rest for 3 days, before 
continuing with other treatments and analysis. EndoC-βH1 stably expressing 
the reporter construct were established after transduction with the pLV-CMV-
XBP-GLuc-bc-Puro lentivirus (MOI=5) and puromycin selection (1 μg/ml). 
Human islets cells have been transduced at MOI=3 immediately after cell 
dispersion by trypsin as previously described13, 21. After overnight incubation, 
the medium was refreshed and dispersed islet cells were maintained in culture 
in ultra-low attachment plate (Corning, NY 14831) for the duration of the 
experiment.
Construction of a beta cell-specific, stress-induced reporter
The XBP-Gaussia fragment contains the first 558 nucleotides of XBP1 coding 
sequence fused to the last 504 nucleotides from the GLucM43I encoding 
sequence34. The DNA fragment was synthesized by Geneart (thermofisher, 
Regensburg Germany). pLV-CMV-XBP-GLuc-bc-Puro was generated by 
insertion of the XBP-Gaussia fragment into pLV-CMV vector. The XBP Gaussia 
fragment was then subcloned into the pLV-HIP vector 21 to generate a pLV-HIP-
XBP-GLuc-bc-GFP vector.
RNA isolation and quantitative PCR (qPCR)
RNA was extracted using TRIzol reagent (invitrogen) according to 
manufacturer’s procedures. To avoid DNA contamination samples were 
DNase treated prior cDNA synthesis. RNA was reverse transcribed using 
SuperScript III Reverse Transcriptase (Invitrogen). SybrGreen master mix kit 
(Applied Biosystems) was used for detection of endogenous XBP1 splicing, 
ATF3, CHOP and GAPDH by qPCR with the following primers: XBP1s Fw 
5’-CTGAGTCCGCAGCAGGTG-3’, XBP1s Rv 5’-GAGATGTTCTGGAGGGGTGA-3’; 
ATF3 Fw 5’-GTGCCGAAACAAGAAGAAGG-3’, ATF3 Rv 
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5’-TCTGAGCCTTCAGTTCAGCA-3’; CHOP Fw 5’- GACCTGCAAGAGGTCCTGTC-3’, 
CHOP Rv 5’- CTCCTCCTCAGTCAGCCAAG-3’; GAPDH Fw 
5’-ACAGTCAGCCGCATCTTCTT-3’, GAPDH Rv 5’-AATGAAGGGGTCATTGATGG-3’. 
All measurements were performed in triplicate and GAPDH was used for 
normalization. The detection of reporter splicing was assessed by PCR using 
the following primers: Reporter Fw 5’-GAAGCCAAGGGGAATGAAG-3’, Reporter 
Rv 5’-CCGTGGTCGCGAAGTTGCTGG-3’. PCR reactions were analysed on 2% 
agarose gel. 
Western blot analysis
Cells were lysed in Tropix lysis mix (Applied Biosystems). Total protein content of 
the lysates was determined using Bradford reagent assay (Biorad, Veenendaal, 
The Netherlands). Samples were boiled with sample buffer (10% glycerol, 2% 
SDS, 50 mM Tris-HCl pH 6.8, 0.1% Bromophenol blue and 1% β-mercaptoethanol) 
and 50 μg protein was loaded per well of a 10% SDS-polyacrylamide gel. The 
proteins were subsequently transferred to Immobilon-P (Millipore, Etten-Leur, 
the Netherlands) and visualized by standard protocols with rabbit-anti-XBP1, 
specific for the spliced XBP1 form (1:1000; Biolegend POLY6195) and mouse-
anti-actin (1:2000 C4; Millipore) and corresponding HRP-conjugated antibodies 
goat-anti-rabbit IgG (1:5000 sc-2004, Santa Cruz Biotechnology) and goat-anti-
mouse IgG HRP (1:5000 sc-2005, Santa Cruz Biotechnology). 
Gaussia activity measurement
Gaussia activity was determined in cell lysates by luminometry after addition 
of 1 mM coelenterazine (Promega). Experiments were performed in triplicate 
for every condition. Results are corrected for the lysate protein content and 
represented as average Relative light units (RLU) per μg protein. 
Glucose induced C-peptide assay
EndoC-βH1 were seeded 50,000 cells per well in a 96 well plate. Two days post 
plating, cells were preincubated in a modified Krebs-Ringer Bicarbonate buffer 
(KRBH) containing 115 mmol/l NaCl, 5 mmol/l KCl, 24 mmol/l NaHCO3, 2.2 
mmol/l CaCl2, 1 mmol/l MgCl2, 20 mmol/l HEPES, 2 g/l human serum albumin 
(Cealb, Sanquin, The Netherlands), pH 7.4 for 2 hours. After preincubation, 
the buffer was successively changed for 1 hour to KRBH with 2 mmol/l and 
25 mmol/l glucose at 37 °C. C-peptide concentrations were determined in the 
supernatants by ELISA (10-1136-01 Mercodia, Uppsala, Sweden).
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Following dispersion, single cell islet cells were fixed and permeabilized in PBS 
containing 4% paraformaldehyde and 0,1% saponin. Blocking was done with 
1%BSA,0,1% saponin in PBS and in which primary and secondary antibodies 
were also diluted. Primary antibodies against C-peptide (1:1000; Millipore 
CBL94) and GFP (1:1000) and secondary antibodies coupled to Alexa 568 
(1:500) and Alexa 488 (1:500) were used.
Viability assay 
Cell viability was assessed by replacing the culture medium by fresh medium 
containing 10% WST-1 reagent (Roche, Penzburg, Germany). The cells were 
maintained in the incubator at 37 ⁰C, 5% CO2 for 3 h before the absorbance 
was measured in a microplate reader (Bio-Rad model 550, Bio-Rad, Hercules, 
CA, USA) at a wavelength of 450 nm. The results are shown as relative viability 
compared to non-transduced cells. 
Statistical analysis
Data are presented as mean ± SEM. Trend lines were generated by nonlinear 
regression analysis following a one phase exponential association equation. 
Calculations were performed using GraphPad Prism 7. 
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Blood glucose homeostasis is tightly regulated by the endocrine cells within the 
islet of Langerhans. Protein Expression of insulin, glucagon, and somatostatin is 
restricted to beta, alpha, and delta cells, respectively. Yet, recent transcriptome 
analyses have revealed that insulin mRNA is also detected in non-beta 
endocrine cells. We studied alternative splicing of human insulin mRNA in 
pancreatic islets and identified the presence of an insulin mRNA isoform. This 
transcript, encoding the complete preproinsulin signal peptide and B-chain, 
yields an altered C-terminus due to the disruption of the original reading frame. 
The resulting polypeptide is largely identical with the previously identified 
insulin-derived defective ribosomal protein (INS-DRiP). Immunohistochemistry 
on pancreatic sections using antisera raised to detect these alternative insulin 
gene-derived products shows the presence of INS-DRiP in insulin-producing 
beta cells and the product of a splice variant primarily in somatostatin-
producing delta cells. Although the role of this insulin splice variant has not 
yet been defined, its presence in secretory granules of somatostatin-positive 
cells, as revealed by electron microscopy, suggests an endocrine or paracrine 
function. 
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While polyhormonal endocrine cells have been shown to reside in human foetal 
pancreatic islets and in individuals with chronic pancreatitis, fully differentiated 
endocrine cells are classically dedicated to producing a single hormone; i.e. 
glucagon, insulin, somatostatin production by alpha, beta, and delta cells, 
respectively1-3. Under this definition, insulin gene expression is restricted to the 
pancreatic beta cells. However, accumulating data indicate mature human beta 
cells are more plastic than previously assumed4. Whereas the differentiated 
state is maintained by reinforcement of beta cell-specific gene regulatory 
networks and repression of other transcriptional programs5-8, metabolic and 
mechanical stress have been shown to cause spontaneous dedifferentiation 
and transdifferentiation of human beta cells. Conversion of beta cells to alpha 
and delta cell-like states observed in T2D patients has been proposed to 
cause beta cell failure9. In addition, in vitro reaggregation of human islet cells 
induced spontaneous beta cell conversion into glucagon-producing cells10. 
This endocrine plasticity has been proposed to allow dysfunctional beta cells 
to escape apoptosis due to environmental stress as well as replenish the beta 
cell population11, 12. In situ hybridisation and single-cell transcriptome analysis 
of human islet cells have confirmed the presence of insulin mRNA in alpha and 
delta cells13, 14. Approximately 46% of islets cells were found to express more 
than one hormonal transcript type per cell, with a considerable portion of 
endocrine cells containing both insulin and somatostatin transcripts15. 
Alternative splicing increases proteome diversity by generation of multiple 
mRNA transcripts from a single gene that differ in assembly of exons and 
introns. It is estimated that approximately 95% of the human transcriptome 
is alternatively spliced16. Tissue-specific splicing patterns allow expression 
of similar genes in different cell types to produce different proteins which 
differ in biologic composition and activity17. Alternative splicing networks are 
implicated in a broad variety of biological processes, including: maintenance 
of pluripotency, directing cell differentiation, and cell lineage commitment18-21. 
Furthermore, splicing patterns are highly dynamic and therefore provide a 
mechanism to swiftly adapt to changes in the local microenvironment22, 23. The 
beta cell transcriptome was shown to be highly impacted by inflammatory and 
metabolic insults24, 25. Experiments conducted in HEK293T cells overexpressing 
the human insulin gene demonstrated the presence of cryptic splice sites in 
insulin, as multiple insulin isoforms were detected26, 27. 
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In this study, we investigated insulin gene splicing in human pancreatic islets. 
We generated antisera directed against these alternative insulin gene products 
and demonstrate that an insulin isoform protein can be detected in delta cells. 
More specifi cally, high resolution electron microscopy and immune-labelling 
revealed that this variant insulin gene product localized to the secretory granules.
RESULTS
Evidence of  alternative insulin RNA splicing in human islets
Human insulin is encoded by a small gene with only three exons and two 
introns. Yet, PCR analyses performed on RNA isolated from human islets of 
three diff erent donors show the presence of two insulin transcript isoforms 
(Fig. 1A). Nucleotide sequencing of the PCR fragments indicated that the larger, 
most abundant isoform represents wild-type insulin (INS-wt) in which intron 1 
and 2 have been fully spliced out. We recently showed that this mRNA, known 
to encode preproinsulin (PPI), generates a defective ribosomal product (DRiP) 
that is target of islet autoimmunity and associated with type 1 diabetes (T1D) 
pathology28. The shorter isoform results from a cryptic splicing site within 
exon 3 at position 1338, predicted from in silico analysis (supplementary Fig. 
1). The altered open rea ding frame that is formed by alternative splicing may 
lead to the generation of a polypeptide during translation in which the signal 
peptide and B-chain of the canonical PPI are intact but the C-terminal end of 
the molecule is diff erent (referred to as INS-splice). Coincidently this C-terminal 
region would be identical to the INS-DRiP with except of the fi rst 10 N-terminal 
amino acids that contains the diabetogenic T cell epitope (Fig. 1B)28. 
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Figure 1: Insulin gene-derived products. A) Analysis of insulin gene derived transcript 
splicing by PCR on RNA derived from human pancreatic islets of 3 diff erent donors (#1, 2 and 
3) visualized on a DNA gel. The DNA marker is indicated by the M. B) Schematic overview of 
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the human insulin pre-mRNA with the exons annotated by numbers (1-3) and the intronic 
regions represented by a black solid line. Normal insulin splicing and alternative insulin 
splicing are indicated by black and red dashed lines, respectively. The resulting mRNA 
products with translation initiation sites are depicted underneath. For each mRNA molecule 
the potential protein products are displayed, including preproinsulin (PPI) with the signal 
peptide (SP, grey), B-chain (B, green), C-peptide (C, blue), and A-chain (A, yellow) specified. In 
red the INS-DRiP with the E, indicating the previously identified CD8 T-cell epitope and an 
insulin splice variant (also known as INS-splice). Corresponding amino acid sequences are 
indicated with corresponding colours, letters indicate the presence of the complete chain. 
Alternatively spliced insulin is a template for translation in human islets 
In order to investigate these alternative insulin gene-derived proteins, rabbits 
were immunized with a short synthetic polypeptide unique to INS-DRIP 
(DRiP1-13) and a short synthetic polypeptide of the C-terminus common to 
both predicted alternative insulin gene-derived products INS-DRiP and INS-
splice (FS-c). The peptides were selected from analysis of the UniProt human 
protein knowledgebase using the basic local alignment search tool (BLAST) 
to avoid cross reactivity to other known proteins (data not shown). Serum 
specificity was confirmed by ELISA using recombinant PPI, INS-DRiP and INS-
splice. As expected, neither sera cross reacted with PPI (Fig. 2) and while the 
anti-DRiP1-13 serum specifically detected the INS-DRiP polypeptide, the anti-
FS-c antiserum recognized both alternative INS-derived recombinant proteins 
(Supplementary Fig. 2). 
To investigate whether the insulin gene-derived polypeptides are 
generated by islets, human pancreatic sections were stained with either the 
pre-immunization or post-immunization antisera. The localisation of the 
N-terminal INS-DRiP polypeptide within beta cells is in line with our previous 
findings and supports beta cell destruction by CTL directed against the DRiP 
(Fig. 3A). Yet, the antiserum raised to the C-terminus common to INS-DRiP 
and INS-splice did not colocalize with insulin, indicating FS-c positive (FS-
c+) cells are not beta cells (Fig. 3B). To assess the identity of these FS-c+ cells, 
human pancreatic sections were analysed for various endocrine cell markers 
(i.e. insulin, glucagon, and somatostatin). Our results show that the staining of 
the FS-c epitope was restricted to delta cells as indicated by its colocalization 
with somatostatin (Fig. 3C). Of note, staining of other endocrine tissues 
demonstrates that the expression of the INS-splice polypeptide was specific to 
pancreatic islets (Supplementary Fig. 3). 
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Figure 2: Validation of DRiP1-13 and FS-c antisera. Validation of serum responses in an indirect ELISA 
assay to serial dilutions of recombinant PPI (black curves) and recombinant INS-splice (red curve) and 
INS-DRiP (blue) using c-peptide antibody (left panel), FS-c antiserum (middle panel) and DRiP1-13 

















Figure 3: FS-c antiserum exclusively labelled somatostatin-producing delta cells. Immunostaining of 
human pancreatic sections with pre-immunization serum (left panel) and post-immunization serum 
(right panel) (green) in combination with insulin (red). A) Serum derived from DRiP1-13 immunized 
mice. B) Serum derived from FS-c immunized mice. C) Human pancreatic sections stained for glucagon 
(white) and insulin (red) (middle panels) and glucagon (white) and somatostatin (red) (lower panels) in 
combination with FS-c antiserum (green). At the lower right enlarged images of the white enclosure are 
depicted. Nuclei are visualized by DAPI staining (blue). 
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The FS-c antiserum does not cross react with somatostatin
To validate the presence of an insulin gene-derived product and to exclude cross 
reactivity with somatostatin, we generated 293T cells expressing the human 
insulin gene. In these cells, expression of the gene leads to expression of two 
insulin transcript variants, as observed in human islets (Supplementary Fig. 4A). 
Western blot analysis of the cell lysates of surrogate beta cells, indicated that 
PPI is expressed, as well as an alternative insulin-derived product (Fig. 4A). To 
confirm that the spliced isoform is detected with the antiserum, both transcript 
isoforms were isolated and cloned into different expression plasmids. Western 
blot analysis of lysates of 293T cells transfected with the WT insulin cDNA or 
the spliced cDNA demonstrates that the serum specifically detects the spliced 
isoform. The C-peptide is only detected in lysates of cells transfected with the 
INS-wt (Fig. 4B, supplementary Fig. 4B). 
Cross reactivity of the serum to delta cell-specific protein somatostatin 
was excluded by FS-c specificity tested on recombinant somatostatin (Fig. 
4C). Furthermore, antibody blocking assays using recombinant somatostatin 
did not alter detection of recombinant INS-splice, while antibody blocking 
with recombinant INS-splice markedly reduced INS-splice detection (Fig. 4D). 
Similarly, antibody blocking using immunization peptide reduced the mean 
fluorescence of the FS-c+ islet cell population compared to irrelevant peptide 
(Fig. 5A). RNA isolation from the FS-c+ population showed an enrichment of 
somatostatin and INS-splice RNA in these cells when compared to the FS-c- 
cells, confirming our previous finding. (Fig. 5B, Supplementary Fig.4C).




























































Figure 4: INS-splice is insulin gene-derived and serves as template for translation in 293T cells. A) 
Schematic representation of the plasmids CMV-INS/full, encoding all exons (annotated by numbers 1-3) 
and introns (represented by the solid black line) of insulin driven by a CMV promotor. Western blot 
analysis of 293T cell lysates transfected with CMV-insulin/full (T) and non-transfected cells (NT). Lysates 
were made 48 hours post transfection and analysed with anti-c-peptide (left panel), anti-FS-c (right 
panel) and anti-actin (bottom panels). Unspecific background bands (*). B) Schematic representation of 
CMV-INS/wt-bc-GFP, encoding the mRNA of normally spliced insulin, and CMV-INS/splice-bc-GFP, 
encoding the mRNA of alternatively splicing insulin in exon 3. With underneath the western blot analysis 
of 293T cell lysates transfected with CMV-INS/WT-bc-GFP (wt) and CMV-INS/SPLICE-bc-GFP (spl) or non-
transfected (NT). Lysates were made 48 hours post transfection and analysed with anti-c peptide (first 
panel), anti-FS-c (second panel), anti-GFP (third panel) and anti-actin (fourth panel). C) Western blot 
analysis of recombinant PPI (PPI), recombinant INS-splice (SPLICE) and recombinant somatostatin (SST) 
with c-peptide antibody (upper panel), FS-c antiserum (middle panel) and somatostatin antibody 
(lower panel). D) Western blot analysis of recombinant polypeptides with FS-c antiserum that has 
previously been blocked overnight with recombinant PPI, INS-splice or somatostatin. 15% SDS-
polyacrylamide gels were loaded with 50 ng recombinant polypeptide. Antibody blockings were 
performed with 5 µg recombinant polypeptide. All membranes were developed simultaneously on a 
single film to exclude differences in band intensity due to differences in exposure time. The M indicate 
the position of the protein marker were membranes were cut after blotting and put together prior 
development. Loading of recombinant polypeptides was demonstrated by the presence of the HIS-tag 
(right panel). 
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Figure 5: In depth analysis of human pancreatic FS-c+ cells. A) Flow cytometric analysis of human 
pancreatic islets stained with FS-c serum after antibody blocking with an increasing amount of irrelevant 
peptide (PPI15-24) (black histograms) and the peptide used for immunization (red histograms). On the 
top right the mean fl uorescence (MF) of the FS-c+ cell population is depicted. The relative MF of the FS-c+
cell population compared to unblocked antiserum (0 peptide) of antibody blocked with irrelevant 
peptide (black) and relevant peptide (red) (left graph). B) Sorting of FS-c+ human pancreatic islet cells. 
Inset depicts unstained cells. C) Transcriptome analysis of FS-c- and FS-c+ human islet cells for relative 
somatostatin and relative INS-splice expression. 
Expression of INS-splice in delta cell granules
Since the alternatively spliced insulin transcript-encoded isoform has the same 
N-terminus as insulin, we wondered to what extent the presence of the signal 
peptide contributes to the posttranslational processing and localization of the 
isoform protein. Detailed examination of pancreatic coupes by high-resolution 
electron microscopy with immunogold labelled anti-serum demonstrates that 
the polypeptide localizes within secretory granules of delta cells (Fig. 6A,B)29. 
This confi rms that INS-splice is transported to the delta cell granules and 
suggest it to be a secreted protein.








Figure 6: INS-splice is targeted to the delta cell granules. A) Electron microscopic images of human 
pancreatic sections labelling for INS-SPLICE (quantum dots, black * arrow) and insulin (immunogold, 
black arrow) visible as black dots. The granules were identified by the morphology of the secretory 
granules. B) Quantification of the gold+ and QD+ granules in beta and delta cells. Each granule is 
represented as a point. The graphs represent the mean of 30 beta and 30 delta cell granules. 
DISCUSSION
Insulin production and secretion by beta cells is crucial for the maintenance 
of glucose homeostasis. Paradoxically, this hormone is also a major target in 
the CD4+ and CD8+ T cell-mediated destruction of beta cells in type 1 diabetic 
patients 30. While insulin is widely studied for its role in glucose homeostasis 
and islet autoimmunity in T1D, little is known about other insulin gene-derived 
products or splicing isoforms. In this study, we investigate two insulin gene-
derived polypeptides; the INS-DRiP, a defective ribosomal product, and INS-
splice, a protein encoded by an alternatively spliced insulin gene-derived 
transcript that is partly identical to the PPI and INS-DRiP proteins. 
We have previously shown that INS-DRiP may participate to T1D pathology 
as target of CD8+ T cells28. Supporting our previous data, the N-terminus of 
DRiP, containing the CD8+ T cell epitope that is lacking in INS-splice, can be 
detected in pancreatic beta cells by immunohistochemistry. The absence of 
the C-terminus may imply that this protein is rapidly targeted for degradation 
during translation, which is in line with the classic degradation process for 
proteins that lack an in frame stop codon31. 
We also report that alternative splicing of insulin pre-mRNA results in 
a translational product that has an N-terminal region identical to PPI and 
a C-terminal portion that is identical to that of the INS-DRiP protein. Similar 
to wild type insulin mRNA, the alternatively spliced mRNA can be found 
abundantly in both beta and delta cells by single-cell transcriptome analyses 
of human pancreatic islets (available online)32 while hormone production 
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appears to be cell-type exclusive. This could point to the participation of a cell 
type-specific translation machinery in adult endocrine cells. Yet the relevance 
of the insulin gene-derived mRNA and possible translates thereof in endocrine 
cells other than beta cells remains unclear. Several studies suggest that delta 
cells have an important role in beta cell development during organogenesis33, 
34. Also, human pancreatic beta cells have been shown to change cell identity 
via dedifferentiation and transdifferentiation, presumably as a manner to 
evade harsh environmental conditions that could result in their death11. 
Alternative splicing is involved in maintaining lineage differentiation as well as 
maintenance of cell pluripotency and is influenced by the microenvironment 
20, 35. Whether insulin promoter activity in endocrine cells other than beta 
cells is a phenotypic remnant of their common progenitor cell or contributes 
to maintaining their endocrine cell plasticity in adolescence remains to be 
elucidated. 
Both the INS-DRiP and INS-splice open reading frames lacks a STOP 
codon. Nevertheless, the INS-splice product seems to be fully conventionally 
synthesized and processed as it was detectable in delta cell granules 
specifically. The presence of the signal peptide may target the co-translational 
translocation of the polypeptide to the ER lumen and subsequently secretory 
granules 36. Nonstop proteins targeted to the endoplasmic reticulum and 
mitochondria can block translocon channels and should be rapidly cleared to 
allow continued cellular functions. This allows the release of nonstop proteins 
into the organelle and to escape proteasomal degradation37, 38. Although other 
quality control and clearance mechanisms within these organelles are likely, 
we propose that the cotranslational translocation allows the maturation of INS-
splice, explaining the detection of the C-terminal sequence in delta cells.
The observation that this insulin isoform is exclusively detected in delta 
cell is intriguing. Furthermore, this suggests the presence of the preproinsulin 
signal peptide and B-chain in delta cells, which are major targets for islet 
autoimmunity in T1D39-41. The fate of delta cells in context of type 1 diabetes is 
poorly investigated. While, impaired delta cell function has been reported42, we 
are not aware of any reports demonstrating evidence for  delta cell destruction 
by autoreactive CTLs. While the function of the INS-splice polypeptide remains 
enigmatic, its presence in secretory granules implies that this protein is secreted 
and could have paracrine or endocrine functions in humans. 





HEK293T cells were maintained in high glucose Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco-BRL, Breda, The Netherlands) supplemented with 8% 
fetal bovine serum (FBS) (Gibco-BRL), 100 units/ml Penicillin and 100 µg/ml 
Streptomycin (Gibco-BRL). 
DNA constructs
To generate insulin expressing vectors, PCR on human genomic DNA was 
isolated from HEK293T cells. The human insulin gene was cloned by PCR 
using the following primers: INS Fw 5’-AGCCCTCCAGGACAGGC-3’ and INS 
Rv 5’-TTTTGCTGGTTCAAGGGCTTTATT-3’. The PCR fragment was cloned into 
pJet2.1 vector and subcloned into pRRL-CMV vector to generate a pLV-CMV-
INS/full expressing the human INS gene. The same PCR primers were used on 
RNA isolated from purified human islets. The two PCR fragments obtained 
were cloned into pJET2.1 and subsequently cloned into pRRL-CMV-IRES GFP 
to generate a pLV-CMV-INS/wt-bc-GFP and pLV-CMV-INS/splice-bc-GFP. The 
constructs were verified by Sanger sequencing using primer located into the 
CMV promoter.
Polyethlenimine transfection
HEK293T cells were transfected in suspension using polyethylenimine (PEI). A 
transfection mixture for a 6-well consisted of 2 μg plasmid DNA and 6 μg PEI 
(pH 7.4) supplemented with Opti-MEM I reduced serum medium (Gibco) to a 
final volume of 200 μl. Mixtures were thoroughly mixed and pre-incubated for 
10 min at room temperature before adding to the cell suspension, 48 hours 
post transfection cells were harvested for further analysis.
Reverse transcription PCR and real time analysis
RNA was isolated with TRIzol reagent (15596018, Invitrogen). To ensure RNA 
quality all samples were DNase treated (Invitrogen). Reverse transcription was 
performed using 500 ng RNA using Superscript RT III kit (Invitrogen, Karlsruhe, 
Germany). Gene expression was determined using the following primers: Exon 2: 
Fw 5’-GGCTTCTTCTACACACCCAAG -3’, Rv 5’-CGGGTCTTGGGTGTGTAGAAG-3’; 
Splice:  
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Fw 5’-GGCTTCTTCTACACACCCAAG-3’,  
Rv 5’-GCAGTAGTTCTCCAGCCTGCAGGTCC-3’;  
Somatostatin: Fw 5’-CGTCAGTTTCTGCAGAAGTCCCTGGCT-3’,  
Rv 5’-CCATAGCCGGGTTTGAGTTAGCAGATC-3’ and GAPDH;  
Fw 5’-ACAGTCAGCCGCATCTTCTT-3’, Rv 5’-AATGAAGGGGTCATTGATGG-3’. 
Quantitative PCR analysis was performed using the SybrGreen master mix kit 
(Applied Biosystems, Foster City, CA) in triplicate on an Applied Biosystems 
Step One Plus machine.
Generation of custom polyclonal antisera
Custom polyclonal antisera (Eurogentec, secure.eurogentec.com/speedy, 
Belgium) were generated by immunization of rabbits using synthetic peptides, 
MLYQHLLPLPAGEC (DRiP1-13, cysteine serves as anchor residue for the carrier) 
and LLHRERWNKALEPAK (FS-c). During the speedy immunisation programme 
of 28 days the animals were repeatedly injected with synthetic peptide and bled 
prior immunization and post immunization. Immune responses of the bleeds 
were tested for antigen reactivity by ELISA performed by the manufacturer. 
Recombinant polypeptides
Human recombinant polypeptides were synthesized as previously described43. 
Protein encoding cDNA was obtained from human pancreatic islets by 
PCR and cloned in pDest17 for protein production in Escherichia Coli using 
gateway cloning technology (Invitrogen, Carlsbad, CA, USA). Recombinant 
proteins were purified by the His6 affinity purification tag and freeze dried. 
Purified polypeptides were dissolved in 0.05% acetic acid in MQ/PBS to a stock 
concentration of 1 mg/ml.
Enzyme-linked immunosorbent assay 
Nunc maxisorp 96 well plates (Sigma-Aldrich) were coated with 1 µg/well of 
the desired recombinant polypeptide diluted in PBS to reach a final volume 
of 100 µl/well and incubated overnight at 4C. After coating, the wells were 
blocked with 200 µl/well 2% BSA in PBS for 1 h at room temperature (RT), 
followed by 2 h incubation with the primary antibody (i.e. DRiP1-13 (1:1000), 
FS-c (1:1000) or ms-α-C-peptide (1:2500)) of interest and subsequently 2 h with 
HRP-conjugated secondary antibody (i.e. anti-rabbit and anti-mouse (Santa 
Cruz)) for visualization. Antibodies were diluted in 1% BSA in PBS to reach a final 
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volume of 100 μl/well. For detection, 100 μl/well of freshly prepared substrate, 
0.4 mg/ml O-phenylenediamine (P9029, Sigma) in 0.05M phosphate-citrate 
buffer pH 5.0, was used. After 15 minutes incubation the absorbance at 450 
nm was measured. After each step, wells were aspirated and extensive washed 
using 200 μl/well Wash buffer (0.05% Tween-20 in PBS). This was repeated for 
a total of 5 washes with 1 minute soaking to increase the effectiveness of the 
washes. 
Human islet isolation
Pancreatic islets were obtained from non-diabetic human cadaveric donor 
pancreata, given the islets could not be used for transplantation and research 
consent was present. The isolations were performed in the GMP-facility of LUMC 
according to the previously described protocol44. For experimental use, human 
islets were maintained in ultra-low attachment plates (Corning, NY 14831) in 
low glucose DMEM supplemented with 10% FBS, 100 units/ml Penicillin and 
100 μg/ml Streptomycin (Gibco-BRL).
Immunohistochemistry and confocal microscopy
Paraffin embedded tissues were cut into 4 µm sections. Tissues were 
deparaffinized in xylene and rehydrated in a series of ethanol decreasing in 
concentration. Prior antibody incubation antigen retrieval was performed by 
autoclavation in citric buffer (pH 6.0). Sections were blocked for 1 hour with 
2% normal donkey serum in PBS. Primary and secondary antibodies diluted 
in PBS/1%BSA were incubated subsequently for 1 hour at room temperature 
with additional washing steps in between. Primary antibodies against insulin 
(1:100), C-peptide (1:500, CBL94 Millipore), glucagon (1:200 ab10988 Abcam), 
somatostatin (1:500, 13-2366 Emelca Bioscience), DRiP1-13 (1:500) and FS-c 
(1:500). The appropriate Alexa-conjugated antibodies were used (anti-mouse, 
anti-rabbit, and anti-sheep). Nuclei were stained with DAPI vectashield (Vector 
laboratories #H-1500). Immunofluorescence was detected with a Leica SP8 
confocal microscope. 
Flow cytometric analysis of human pancreatic islet cells
Prior flow cytometric analysis of human pancreatic islets, a single cell suspension 
was prepared by dispersion using trypsin and filtration. Thereafter, the islets 
cells were fixed and permeabilized with 4% PFA, 0.1% saponin in PBS for 30 min 
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at 4 degrees. Islet cells were subsequently stained with anti-FS-c as primary 
antibody (1:500) and Alexa-568 conjugated secondary antibodies against 
rabbit (Life technologies 1:500). Antibodies were diluted in 0.1% saponin, 
1% BSA in PBS and incubation time of 1 hour cold. Islet cell populations were 
analysed and sorted using a FACS Aria II (BD biosciences). 
To isolate RNA from sorted cells, fixation, permeabilization and staining 
were performed in presence of RNase inhibitor following the MARIS method 
described by Hrvatin et al45. 
Western blot Sample preparation and immunoblotting
Cell lysates were made using Tropix lysis mix (Applied Biosystems) and the 
protein content was determined by Bradford reagent assay (Biorad, Veenendaal, 
The Netherlands). For analysis 50 μg protein sample was used. Samples were 
boiled with sample buffer (10% glycerol, 2% SDS, 50 mM Tris-HCl pH 6.8, 
0.1% Bromophenol blue and 1% β-mercaptoethanol) for 5 minutes before 
loading the samples onto a 15% SDS-polyacrylamide gel. The proteins were 
subsequently transferred to 0.2 µm pore size Immobilon-P (Merk Millipore) 
and visualized by standard protocols with anti-insulin (1:1000, H-86 sc-9168), 
anti-C-peptide (1:1000, CBL94 Millipore) ,anti-actin (1:5000, C4 MAB1501 
Merck Millipore), anti-GFP (1:2000, A11122 Invitrogen), anti-FS-c (1:1000), anti-
somatostatin (1:1000, 13-2366 Emelca Bioscience).
For antibody blocking assays, the primary antibody was blocked with 5 µg 
recombinant polypeptide overnight at 4°C prior addition to the membranes. 
After this standard western blot protocols were followed. 
Donor samples for electron microscopy (EM)
Electron microscopy datasets were created from nPOD donors. Additional donor 
details can be obtained through the JDRF nPOD online pathology database. 
Tissues were recovered following informed research consent from next of kin in 
the United States and shipped to the nPOD program at the University of Florida 
for processing as previously described46-48. All experiments were conducted 
under the approval of the University of Florida Institutional Review Board and 
the current study fulfills all requirements for tests as approved by the medical 
ethical review board of the University Medical Center Groningen.
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Pancreas sample electron microscopy processing
Pancreas samples were fixed in cold, freshly prepared 2% paraformaldehyde-1% 
glutaraldehyde for 48 hours followed by transfer to phosphate-buffered saline 
for storage at 4°C before shipment to the Netherlands48. Tissue vibratome 
sections (~50 µm; Microm HM 650V) were post-fixed in osmium tetroxide/ 
potassium ferrocyanide, followed by dehydration and flat-embedding as 
previously reported49. Next, regions with islets were selected from toluidine 
stained 1 μm sections using light microscopy. Subsequent ultrathin (80 nm) 
sections were cut (UC7 ultramicrotome, Leica Microsystems, Vienna, Austria) 
and placed on formvar coated copper grids (Electron Microscopy Sciences, 
Hatfield, Pennsylvania). Finally, sections were contrasted with uranyl acetate as 
previously described49, 50.
Immuno-EM
Post-embedding immunolabeling on epon with gold or quantum dots was 
carried out as described before51, using rabbit-α-FSc serum.
EM acquisition and image processing (nanotomy) 
Data were acquired on a Supra 55 scanning EM (SEM; Zeiss, Oberkochen, 
Germany) using a scanning transmission EM (STEM) detector at 28kV with 2.5 
nm pixel size with an external scan generator ATLAS 5 (Fibics, Ottawa, Canada) 
as previously described50, 52. After tile stitching, data were exported as an html 
file and uploaded to www.nanotomy.org.
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Supplementary fi gure 1: Alternative splice site analysis of the human insulin gene. A) Splicing 
analysis of the human insulin exon 3 with Human Splice Finder and ESE fi nder enhancers. The exon is 
schematically indicated by the grey bar, the intronic regions fl anking the exon in a solid black line. 
Splicing enhancer and silence motifs are indicated by diff erent colour bars along the sequence and 
further explained in the legend. The yellow line indicates the ESE/ESS relative strength. B) DNA sequence 
analysis of the retrieved PCR fragment spanning the splicing between 5’ donor site in exon 2 and the 
cryptic 3’ acceptor site in exon 3. 
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Supplementary figure 2: Recombinant polypeptides. A) Amino acid sequence of the recombinant 
polypeptides. Red underlined the location of the immunization peptides used for antiserum 
development are indicated. B) Schematic representation of the recombinant polypeptides. The His tag 
(black box), signal peptide (SP, grey), B-chain (B, green), C-peptide (C, blue), A-chain (A, Yellow) frame 
shift of INS-DRiP and INS-splice (red) are separately indicated. Corresponding amino acid sequences are 
indicated with corresponding colours, letters indicate the presence of the complete chain. The E 
indicates the INS-DRiP-specific CD8 T-cell epitope. C) Validation of serum specificity in an indirect ELISA 
assay to recombinant PPI, INS-DRiP and INS-splice using c-peptide antibody (left panel), FS-c antiserum 
(middle panel) and DRiP1-13 antiserum (right panel).
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Supplementary figure 3: INS-splice is exclusively expressed in pancreatic tissue. 
Immunohistochemistry analysis of a variety of endocrine tissue for ins-splice (red) and glucagon 
(green). A) pancreas, B) Duodenum, C) Testis, D) Thyroid and E) Ovary. Nuclei are visualized by hoechst 
staining (blue).
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Supplementary figure 4: Insulin splicing in transfected 293T cells. A) Analysis of insulin gene-derived 
transcript splicing in 293T cells after transfection with CMV-INS/full (INS) by PCR using the same primer 
set as described in Fig 1. B) Splicing analysis of transfected 293T cells with CMV-INS/wt-bc-GFP (wt) and 
CMV-INS/splice-bc-GFP (spl). Splicing patterns are compared to non-transfected 293T cells (NT). The 
DNA marker is indicated by the M. C) Primer specificity tested on RNA isolated from transfected 293T 
cells with CMV-INS/full (INS), CMV-INS/wt-bc-GFP (wt) and CMV-INS/splice-bc-GFP (spl) for exon 2 (right 
graph) and splice (left graph). All data are expressed as relative expression to non-transfected cells (NT) 
and GAPDH corrected.
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Type 1 diabetes (T1D) results from the immune-mediated destruction of the 
insulin-producing beta cells. Beta cell stress and dysfunction before disease 
manifestation, repositions the beta cell to the center of T1D pathology and 
suggests the immune attack on beta cells is a well-intended response to 
protect the host for dysfunctional cells. The islet microenvironment leading 
to endoplasmic reticulum (ER) stress is a crucial component in regulating 
autoantigen processing (chapter 2) and neoantigen generation (chapters 3 & 
4). Identification of the molecular mechanism underlying beta cell dysfunction 
is critical to design novel therapeutics to restore beta cell ER homeostasis, 
improve function and thereby reduce beta cell visibility to the immune system. 
The specific beta cell stress reporter assay provides a screening platform that 
will aid in the evaluation of compounds relieving ER stress (chapter 5). The 
expression of an insulin-derived isoform in delta cells (chapter 6) could present 
new hope for regenerative medicine and cell replacement therapy while also 
implying the participation of delta cells in the development of autoimmunity.
ISLETS UNDER ATTACK: WHY BETA CELL-SPECIFIC 
DESTRUCTION? 
The unique cytoarchitecture of human islet of Langerhans contributes to 
the harmonized endocrine cell activities which are they key to glycaemic 
homeostasis1. The specific destruction of beta cells in T1D directed research 
to revolve around beta cell autoimmunity, apparently ignoring the other 
endocrine cell types within the Islet of Langerhans. We propose a model in 
which the inflammatory microenvironment combined with the physiological 
stress imposed by the beta cell function drives the immune attack. However, it 
is curious that the other endocrine cells in the islet of Langerhans that reside in 
the same microenvironment and have similar hormone secreting obligations 
seem unaffected by the immune system. Yet, several studies report that 
post T1D onset, glucagon-secreting alpha cells and somatostatin-secreting 
delta cells are impaired in their functions2-5. This is most likely caused by the 
disruption of intracellular connections and paracrine regulation within the 
islet in the absence of beta cell function. Intriguingly, beta cells appeared to be 
more sensitive to metabolically, immunologically and chemically challenging 
conditions than alpha cells, indicating that alpha cells are better equipped to 
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deal with ER stress (figure 1)6, 7. This might explain why the beta cell is singled 
out by the immune system.
Mature endocrine cells, all derived from common progenitor cells, are 
established early in life and barely proliferate throughout life8. Remarkably, 
the mature pancreatic endocrine cells maintain a certain degree of plasticity. 
After metabolic and mechanical stress spontaneous dedifferentiation and 
transdifferentiation of human beta cells was observed9-11. This endocrine 
plasticity is thought to allow dysfunctional beta cells to escape apoptosis 
(beta to alpha/delta cell conversion) due to environmental stress as well as 
compensate for the lost beta cell mass after destruction (alpha/delta cell to 
beta cell conversion)12, 13. The molecular processes that drive differentiation is 
unclear, although it appears that a switch in transcription factors expression14 
and activation of the pluripotency-related microRNA cluster are involved15. 
In addition, several studies indicate that many endocrine cells have multiple 
distinct hormonal transcripts, although hormone-production is largely limited 
to a single hormone type per cell16-18. In this thesis, we demonstrate the 
presence of a protein encoding insulin mRNA isoform in human pancreatic 
islets. This isoform mRNA is detected in beta cells but also in delta cells, while 
protein is detected only in the delta cells. This raises several questions regarding 
the origin, function, and consequence of insulin and insulin variants in alpha 
and delta cells. Is this simply a remnant of endocrine cell development? Could 
this contribute to endocrine cell plasticity? Does the production of an insulin 
splice variant in delta cells make delta cells also target for immunity? Is the 
insulin splice variant secreted and, if so, what receptor does it bind to and what 
is the effect? The answers to these questions could aid in our understanding 
of endocrine cell development, beta cell dysfunction, and potentially direct in 
vitro beta cell regeneration protocols. 
NEOEPITOPES: DRIVERS OF DISEASE PATHOGENESIS?
The interest in neoepitopes and their role in T1D pathology is rapidly 
increasing. The generation of this class of epitopes is highly influenced by the 
environment of peripheral tissues, and this may explain why circulating T-cell 
have not acquired tolerance to these peptides. Therefore, neoepitopes might 
form the missing link between disease susceptibility, beta cell dysfunction, loss 
of peripheral tolerance, and disease progression19-21.




Figure 1: Human beta cells are less resistant to ER stress compared to alpha cells. Representative 
electron microscopy images of human pancreatic islets in normal culture conditions (left panel) 
compared to chemical induced ER stress by 1 µM thapsigargin for 5 hours (right panel). Alpha and beta 
cells are identified based on the phenotype of their granules. In thapsigargin treated samples, the 
swollen ER of beta cells clearly demonstrates ER stress, while this is not present in alpha cells.
Initially, the discovery of neoepitopes focussed on posttranslational 
modification (PTM) of native beta cell proteins, due to altered activity of 
enzymatic posttranslational processes upon ER stress. However, recent 
discovery of neoepitopes derived from alternative translation initiation of insulin 
mRNA22, transpeptidation23, 24, and fusion of two non-contiguous peptides of 
the same protein (cis-splicing) or distinct proteins (trans-splicing), proves that 
the origin of these neoepitope can be far more complex. This raises a strategic 
problem: where do we start looking? A powerful tool in immunopeptidome 
analysis is tandem liquid chromatography-mass spectrometry (LC-MS/MS) 
after immunoaffinity purification of peptide-HLA class I complexes25. It has 
been determined that a large fraction of the HLA class I peptides are the result 
degraded defective ribosomal products (DRiPs)26 and approximately one third 
of transpeptidation27. However, our databases for spectrum identification are 
based on proteome or proteogenomic references thereby ignoring aberrant 
translational products and non-contiguous peptides28. To overcome this 
issue, special databases of predicted splice and fusion products are necessary 
besides the regular proteome database. Of note, these databases are based 
on prediction algorithms and the used techniques and methodologies greatly 
impact the composition of this database29, 30. The first results of this approach 
are promising as peptidome analysis of the immortalized human HLA-A2+ 
beta cells, ECN090, indeed yielded several non-contiguous peptides31. It will 
53804 marjolein Kracht.indd   167 08-05-19   18:03
Chapter 7
168
be difficult to translate this technique to primary human pancreatic islets, not 
to mention patient-derived islets, due to their limited availability for research. 
Caution should be taken in translating cell line-derived observations to clinical 
relevance. Nonetheless, immunopeptidome analysis might provide critical 
knowledge on the dynamics of the peptidome and how this is affected by ER 
stress. Unravelling the immunopeptidome could provide more understanding 
in the fundamental aspects of T1D pathology, biomarkers and therapeutic 
strategies.
IMPLICATION FOR IMMUNOTHERAPY IN T1D
A century after the first trials with exogenous insulin administration as treatment 
for T1D patients, this remains the standard to date. Although our knowledge 
on the disease pathology has vastly evolved over the last decades, strategies 
to prevent or cure diabetes remain beyond our capabilities. A difficult factor 
in the treatment of T1D is the heterogeneity among patients in pathology, 
disease progression, and efficacy of therapeutic intervention32.
 1. T1D biomarkers
Patients vary in genetic susceptibility, immunological background, and beta 
cell fragility. Therefore disease markers are likely person- and time-dependent. 
To utilize this knowledge we should aim for biomarkers assays that incorporate 
these factors to categorize patients enabling personalised therapies. Besides 
the classic genetic and autoantibody biomarker assays, T-cell and beta cell 
markers could provide a valuable contribution33, 34.
T-cells are predominant mediators in T1D pathogenesis. Antigen-specific 
circulating T-cells can be measured in the peripheral blood using recombinant 
islet antigens35, 36. Discovery of novel disease-related epitopes would expand 
the diabetogenic T-cell repertoire that can be implemented for screening and 
provides a better picture of disease stage and development per individual. Of 
note, circulating autoreactive T-cells, especially to neoantigens, are also part 
of the T-cell repertoire in healthy individuals since they are not subject to 
central tolerance31. Inclusion of phenotypical characterization could indicate 
whether they are pathogenic22, 31, 37. In addition, the growing evidence of 
beta cell dysfunction in the pathogenesis of T1D means monitoring beta cell 




functionality could be an important indicator38. Beta cell ER stress has been 
associated with accumulation and secretion of proinsulin39, 40. Measurement of 
the proinsulin/c-peptide (PI/C) ratio could be a useful indicator for beta cell 
dysfunction and might be detectible prior disease onset and progression41-43. 
Another non-invasive marker for beta cell stress are microRNAs44, 45. MicroRNAs 
are short, noncoding RNA molecules that have important roles in regulating 
almost all cellular processes, including insulin synthesis, insulin secretion, 
proliferation, differentiation, and apoptosis. Circulating microRNAs can be 
detected in all types of body fluid and are very stable46. Although beta cell-
specific miRNAs have not yet been identified, microRNA profiles in sera of 
recent onset T1D patients differed from healthy donors, supporting their 
potential use as predictive biomarkers 47, 48. Although the field of T-cell and beta 
cell biomarkers is only in its infancy, we suspect that markers for T cell and beta 
cell (dys)function could be valuable in early diagnosis, definition of disease 
heterogeneity, and stratifying patients for therapeutically strategies.
 2. Re-establishing peripheral tolerance
The critical role of the immune system in beta cell destruction made 
immunomodulatory therapies an attractive approach. Clinical trials with 
immunosuppressive drugs demonstrated transient efficacy with elongated 
beta cell preservation in the treated group. However, long-term treatment 
led to adverse off-target effects and nephrotoxicity49. Antigen-specific 
immunomodulation could be a safer approach, in which unwanted T-cell 
responses are specifically inhibited while maintaining immunocompetence 
to pathogens50. Mapping the diabetogenic immunopeptidome is essential 
to establish well-defined and clinically relevant targets51. Antigen-specific 
immunotherapy includes generation of antigen-specific tolerogenic dendritic 
cells (tolDCs)52, 53 or antigen-specific regulatory T cells (Tregs)
54. Tregs are crucial 
in maintaining self-tolerance and preventing autoimmunity via suppression 
of self-reactive T-cells. Tolerogenic DCs can be generated in vitro from PBMC-
derived precursors55 and antigen-specific Tregs can be established from 
pluripotent stem cells ex vivo, providing a renewable source for treatment56-58. 
In case of patient-derived resources it should be considered that dysfunction 
of these cells might cause reduced immunosuppression59, 60. Furthermore, the 
dynamic phenotype of these immune cells might make it difficult to use this as 
a long-lasting therapy.
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 3. Restore beta cell function and ER homeostasis
The emerging role of beta cell dysfunction prior to clinical signs of type 1 
diabetes urges to make us reconsider our therapeutic strategies. If beta cells 
dysfunction drives the break in peripheral tolerance, this would imply that 
restoring beta cell function prevents diabetes development. Recently, it was 
demonstrated that direct inhibition of inositol-requiring enzyme 1α (IRE 1α), 
an ER stress sensor and activator of the unfolded protein response (UPR), 
reduces ER stress and reverses autoimmune diabetes in mice61. Of course, it 
is unethical to treat individuals at risk without clinical symptoms of disease. 
Nonetheless, several studies indicate that T1D patients have remaining beta 
cell mass with persistent low-level insulin or proinsulin secretion even in long-
standing T1D patients 62-65. These beta cells are most likely in a dormant state 
and thereby evade the immune attack. Reactivating these beta cells might 
restore glucose homeostasis and cure diabetes in these individuals. In this 
case, we should consider to combine immune therapy with beta cell therapy, 
to prevent a relapse. In long standing T1D patients or patients with insufficient 
beta cell mass, a similar approach can be envisaged in combination with beta 
cell replacement, such as islet cell transplantation.
CONCLUSION
The pathophysiology of T1D is extremely complex. Genetic predisposition, 
impaired immune regulation, and beta cell (dys)function all contribute to 
disease initiation and progression. A critical gap in our knowledge is what 
causes the break in peripheral tolerance that eventually leads to beta cell 
destruction. We propose that neoepitopes generated by dysfunctional beta 
cells activate immune surveillance, causing full-blown beta cell autoimmunity. 
ER stress imposed both by intrinsic beta cell physiology and by external 
secondary triggers seems to be a crucial component in this process. 
Understanding the molecular mechanisms underlying beta cell dysfunction 
and neoantigen generation is critical to identify clinically relevant neoepitopes. 
This subsequently provides more insight in the disease dynamics as well as 
contribute to translational research in the development of biomarker assays 
and development of therapeutic strategies targeting autoreactive T-cells and 
beta cell function. Our task will be to restore the balance between immune 




reactivity and beta cell function, in order to prevent, treat, or cure type 1 
diabetes (figure 2).
Figure 2: The viscous cycle of beta cell destruction. Beta cell dysfunction might be the driving force in 
disease onset in predisposed individuals, mainly by the generation of neoepitopes ultimately leading to 
a break in tolerance, amplification of autoimmunity and beta cell destruction. Figure was produced 
using Servier Medical Art www.servier.com. 
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Type 1 Diabetes (T1D) is the consequence of the progressive destruction of the 
pancreatic beta cells by autoreactive CD8+ T cells, resulting in insulin deficiency 
and impaired blood glucose homeostasis. Risk of developing T1D has been 
associated with genetic factors, however genetic susceptibility is not sufficient 
to drive disease pathology. Endoplasmic reticulum (ER) stress in dysfunctional 
beta cells caused by environmental triggers is likely involved in breaking 
peripheral tolerance and drive disease pathogenesis. The ER is essential for 
insulin production and secretion by beta cells. Perturbations of the ER and the 
accumulation of unfolded proteins, lead to activation of the unfolded protein 
response. Signaling cascades induced by the activated ER sensors PERK, 
ATF6, and IRE1α attempt to reduce the ER load and increase the ER capacity 
in order to restore homeostasis. In this thesis, the effect of the inflammatory 
microenvironment on human beta cell function and immunogenicity has been 
investigated. 
Insulin is believed to be a primary autoantigen involved in beta cell 
destruction in T1D patients. The signal peptide of preproinsulin (PPI) is a major 
target of CD8+ T cells. Generation and presentation of this epitope, SP15-24, is 
mediated via signal peptide peptidase and ER aminopeptidase 1 (ERAP1). 
In chapter 2, we demonstrated that ER stress induced by proinflammatory 
cytokines facilitates the processing of SP15-24, via upregulation of ERAP1. 
This upregulation was mediated by a decrease in miR-17 via IRE1α RNase 
activity. MiR-17 overexpression or IRE1α inhibition blunted the effect induced 
by proinflammatory cytokines. These data provide direct evidence of the 
implication of ER stress in autoantigen processing and beta cell immunogenicity. 
T1D was previously assumed to be caused by impaired thymic T cell 
education. However, the implication of beta cell dysfunction prior to disease 
onset rather supports an alternative explanation where the beta cells actively 
contribute to their demise. Besides invading pathogens, the immune system is 
also trained to eliminate dysfunctional cells to prevent them from becoming 
harmful for the entire organism. A well-known example of this is an effective 
antitumor response. In chapter 3.1 we compared the tumor microenvironment 
with the microenvironment of islets during insulitis and argue that diabetes 
might be result of successful clearance of dysfunctional cells by the immune 
system. Neoepitopes are important T cell targets in an effective anti-tumor 
response as they discriminate functional-self from dysfunctional-self. Cancerous 
cells have been shown to generate a wide variety of neoepitopes resulting from 
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mutations, splice variants, defective ribosomal products, and posttranslational 
modification (PTM) of native proteins. In chapter 3.2 the contribution of 
post-transcriptional and post-translational modifications in the generation 
of beta cell neoantigens is evaluated. Compelling evidence supports the role 
of environmental stress-induced neoepitope formation in T1D pathogenesis. 
Altogether, these examples suggest that beta cell destruction resembles an 
effective anti-tumor response. A better understanding of the processes and the 
origin of neoepitopes is essential in our battle against T1D. 
Based on this hypothesis, in chapter 4 we investigated insulin as source of 
neoepitopes generated by unconventional translational processes. The high 
translation rate of insulin combined with the intrinsic physiological production 
pressure during metabolic needs, made this an interesting candidate. This led 
to the identification of an alternative open reading frame within insulin mRNA. 
Production of this defective ribosomal product (DRiP) might be associated with 
ER stress, as was observed in surrogate beta cells. Interestingly the resulting 
polypeptide contains an immunodominant N-terminus that can be presented 
in HLA class I and class II. CD8+ T cells directed to this epitope were found in 
a higher frequency in the circulation of patients. Furthermore, these CD8+ T 
cells killed human pancreatic beta cells in vitro which was enhanced during 
inflammatory conditions, underscoring its relevance to disease pathogenesis.
Chapters 2, 3 and 4 emphasize the importance of ER stress in the processing 
and generation of beta cell (neo-)epitopes and autoimmunity. Therefore, the 
ability to monitor ER stress is essential in understanding disease pathogenesis 
and might contribute to the development of therapeutics. In chapter 5, we 
designed a bioluminescent reporter assay for monitoring ER stress in human 
beta cells. This reporter construct encodes a XBP1-Gaussia luciferase fusion 
protein. Endogenous XBP1 is unconventionally spliced by IRE1α upon ER 
stress, resulting in the shift of the reading frame and therefore translation 
of an elongated C-terminal protein. Similarly, in this fusion construct, the 
C-terminal Gaussia Luciferase is only in the correct reading frame after IRE1α-
mediated splicing, resulting in stress-induced Luciferase expression. ER stress 
quantification was accurate when compared to classical ER stress quantification 
methods and less laborious in execution. In addition, reporter expression driven 
by the human insulin promotor restricts the reporter to beta cells specifically. 
Therefore this assay allows specific monitoring of the ER stress status of beta 
cells in isolated human pancreatic islets. We envisage that this reporter can be 




used in studies on the origin of ER stress, as well as a drug screening platform 
to reduce ER stress. 
Insulin-production by the beta cells is of vital importance, paradoxically, as 
stated earlier, insulin remains also a main autoantigen in T1D. Besides insulin 
and INS-DRiP, we discovered an alternative insulin gene-derived splice variant 
(INS-splice) that contains the PPI signal peptide, the B-chain and the C-terminus 
of INS-DRiP. In chapter 6, we analysed the expression of these insulin variants in 
human pancreatic islets using specific custom-made antibodies. In accordance 
with our previous results, the N-terminus of INS-DRiP containing the CD8+ 
T cell epitope, was detected in pancreatic beta cells. Yet, the C-terminus of 
INS-DRiP was not detected, implying that the polypeptide does not exist as 
mature polypeptide, maybe as consequence of rapid nonSTOP protein decay. 
The mRNA encoding INS-splice is present in beta and delta cells, however, the 
polypeptide appears restricted to delta cells. More specifically, the INS-splice 
polypeptide was localized in the delta cell granules. We suspect this might be 
the consequence of the presence of the PPI signal peptide in INS-splice, which 
drives the co- and posttranslational processing. Although the function of INS-
splice remains elusive, we envision it might take part in beta and delta cell lineage 
development, while it is conceivable that it contributes to maintaining mature 
endocrine cell plasticity as alternative splicing is an important mechanism in 
lineage development and maintaining pluripotency. Its localization in delta 
cell granules also suggest a potential paracrine or endocrine function. 
ER stress in beta cells seems to drive T1D etiology by attracting immune cells, 
increased autoantigen processing, and neoepitope generation. Neoepitope 
formation might have a crucial role in the loss of peripheral tolerance 
and beta cell destruction. Therefore identification of these neoepitopes is 
important for monitoring disease progression, as well as for the development 
of immunotherapies in order to re-establish peripheral beta cell tolerance. 
In addition, our results point to the importance of research to the causes of 
beta cell dysfunction and propose restoration ER homeostasis as potential 
therapeutic target. 
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Type 1 Diabetes (T1D) is het gevolg van de progressieve vernietiging van de 
bètacellen in de alvleesklier door autoreactieve CD8+ T-cellen. Dit leidt tot 
een tekort aan insuline en verstoorde homeostase van bloedglucose. Erfelijke 
factoren kunnen een verhoogd risico geven op het ontwikkelen van T1D, 
maar de genetische aanleg is niet voldoende om de ziekte te veroorzaken. 
Endoplasmatisch reticulum (ER) stress in disfunctionele bètacellen veroorzaakt 
door omgevingsprikkels is waarschijnlijk betrokken bij het doorbreken van 
perifere tolerantie en het initiëren van de pathogenese. Het ER is essentieel 
voor insuline productie en uitscheiding door bètacellen. Verstoringen van het 
ER en de accumulatie van ongevouwen eiwitten leiden tot activering van de 
ongevouwen eiwit respons, door activatie van ER-sensoren PERK, ATF6 en IRE1α. 
Deze sensoren induceren signaleringsketens die trachten de ER-belasting te 
verminderen en de ER-capaciteit te vergroten om de homeostase te herstellen. 
In dit proefschrift is het onderzoek naar de effect van het inflammatoire 
micromilieu op de humane bètacelfunctie en immunogeniteit beschreven.
Insuline wordt beschouwd als een belangrijk autoantigeen dat betrokken 
is bij de vernietiging van bètacellen bij T1D-patiënten. Het signaalpeptide 
van preproinsuline (PPI) is een belangrijk doelwit van CD8+ T-cellen. Vorming 
en presentatie van het epitoop SP15-24 wordt mede tot stand gebracht via 
signaalpeptidepeptidase en ER-aminopeptidase 1 (ERAP1). In hoofdstuk 2 
hebben we aangetoond dat ER stress geïnduceerd door pro-inflammatoire 
cytokinen de verwerking van SP15-24 vergemakkelijkt via opregulatie van ERAP1. 
Deze opregulatie werd gemedieerd door een afname in miR-17 via IRE1α 
RNase-activiteit. MiR-17 overexpressie of remming van IRE1α verminderde de 
insult veroorzaakt door pro-inflammatoire cytokinen. Deze resultaten leveren 
direct bewijs voor de bijdrage van ER-stress bij de auto-antigeen verwerking 
en de immunogeniteit van bètacellen. 
T1D werd geacht te worden veroorzaakt door onvolledige T-cel selectie 
in de thymus.Echter, het aandeel van bètacel disfunctie voorafgaand aan 
ziekte verschijnselen maakt plaats voor een alternatieve verklaring waarin 
de bètacellen actief bijdragen aan hun ondergang. Naast het opruimen van 
binnendringende ziekteverwekkers, is het immuunsysteem ook getraind om 
disfunctionele cellen te elimineren om zo te voorkomen dat ze schadelijk 
worden voor het lichaam. Een bekend voorbeeld hiervan is een effectieve 
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antitumor reactie. In hoofdstuk 3.1 vergeleken we het tumor micromilieu met 
het micromilieu van eilandjes van Langerhans tijdens ontsteking (‘insulitis’) en 
betogen dat diabetes mogelijk het resultaat is van succesvolle verwijdering van 
disfunctionele cellen door het immuunsysteem. Neo-epitopen zijn belangrijke 
doelwitten van T-cellen in een effectieve antitumor respons omdat op deze 
manier ‘functioneel-zelf’ van ‘disfunctioneel-zelf’ kan worden onderscheiden. 
Van kankercellen is aangetoond dat ze een grote variatie aan neo-epitopen 
genereren door middel van onder andere mutaties, alternatieve splicing, 
foutieve ribosomale producten en veranderingen in posttranslationele 
modificatie (PTM) van natieve eiwitten. In hoofdstuk 3.2 wordt de bijdrage 
van post-transcriptionele en post-translationele modificaties in de vorming 
van bètacel neo-antigenen geëvalueerd. Er zijn steeds meer aanwijzingen 
die de rol van omgevingsstress in neo-epitoop vorming in T1D pathogenese 
ondersteunen. Deze voorbeelden tezamen suggereren dat de vernietiging van 
bètacellen op een effectieve antitumor respons lijkt. Een beter begrip van de 
oorsprong van neoepitopen is essentieel in onze strijd tegen T1D.
Op basis van deze hypothese hebben we in hoofdstuk 4 insuline onderzocht 
als bron van neo-epitopen die zijn gegenereerd door onconventionele 
translationele processen. De hoge translatie snelheid van insuline in bètacellen, 
in combinatie met de intrinsieke fysiologische productiedruk tijdens 
metabolische behoeften, maken insuline een interessante kandidaat. Dit leidde 
tot de identificatie van een alternatief open leesraam binnen het insuline-
mRNA. De productie van dit defecte ribosomale product is geassocieerd met 
ER-stress, zoals werd waargenomen in surrogaat bètacellen. Interessant is dat 
het resulterende polypeptide een zeer immunodominante N-terminus bevat 
dat kan worden gepresenteerd in zowel HLA klasse I als klasse II. CD8+ T-cellen 
gericht tegen dit epitoop werden in een hogere frequentie in de circulatie van 
patiënten gevonden. Bovendien waren deze CD8+ T-cellen in staat menselijke 
bètacellen geïsoleerd uit de alvleesklier te vernietigen in vitro. Dit proces 
werd versterkt door ontstekingsfactoren  duidend op de mogelijke relevantie 
hiervan in het ziekteproces.
Hoofdstukken 2, 3 en 4 benadrukken het belang van ER stress bij de 
verwerking en vorming van bètacel (neo)epitopen en auto-immuniteit. 
Daarom is het vermogen om ER stress te monitoren essentieel voor het 
begrijpen van het ziekteproces en kan het bijdragen aan de ontwikkeling van 
behandelingstherapieën. In hoofdstuk 5 hebben we een bioluminescente 




reporter-test ontworpen voor het ER-stress in menselijke bètacellen te 
detecteren. Dit reporterconstruct codeert voor een XBP1-Gaussia luciferase 
fusie-eiwit. In stress situaties wordt endogeen XBP1 geknipt door IRE1α, wat 
een verschuiving van het leesraam veroorzaakt waardoor gedurende translatie 
de C-terminus van het eiwit wordt verlengd. Op een vergelijkbare manier zit 
de C-terminale Gaussia luciferase in dit fusieconstruct alleen in het correcte 
leesraam na IRE1α gemedieerde splicing, wat resulteert in stress geïnduceerde 
expressie van luciferase. De kwantificatie van ER stress bleek gelijkwaardig aan 
klassieke ER stress-kwantificeringsmethoden,  maar was minder bewerkelijk 
in uitvoering. Bovendien kan met behulp van een humane insuline promotor, 
de reporter specifiek tot expressie worden gebracht in bètacellen. Zodoende 
kan specifiek de ER stress status van bètacellen in geïsoleerde menselijke 
pancreaseilandjes worden bepaald. We voorzien dat deze reporter kan worden 
gebruikt om de oorsprong van ER stress te begrijpen en als  screeningplatform 
voor het ontwikkelen van geneesmiddelen om ER stress te verminderen.
Insuline productie door bètacellen is van cruciaal belang, tegenstrijdig 
hieraan is dat insuline ook een van de belangrijkste autoantigenen is in T1D. 
Naast insuline en INS-DRiP, hebben we een splice variant van het insuline 
gen ontdekt dat bestaat uit de PPI signaalpeptide, de insuline B-chain en 
de C-terminus van INS-DRiP. In hoofdstuk 6 analyseerden we deze insuline 
varianten in menselijke eilandjes van Langerhans met behulp van specifieke 
custom-made antisera. In overeenstemming met onze eerdere resultaten 
werd de N-terminus van INS-DRiP, waar het CD8 T-cel epitoop zich bevindt, 
gedetecteerd in bètacellen. De C-terminus van INS-DRiP werd niet gedetecteerd, 
wat erop kan duiden dat het polypeptide niet als volledig polypeptide bestaat, 
mogelijk als gevolg van snelle afbraak van ‘non-STOP’ eiwitten. Het mRNA 
dat codeert voor INS-splice is aanwezig in bèta- en deltacellen, maar het 
polypeptide lijkt beperkt te zijn tot deltacellen. Om specifiek te zijn, was het 
INS-splice eiwit gelokaliseerd in de granules van deltacellen. We vermoeden 
dat dit gerelateerd is aan de aanwezigheid van het signaalpeptide in INS-splice, 
dat de co- en posttranslationele verwerking stuurt. Hoewel de functie van 
INS-splice nog onbekend is, stellen wij voor dat deze splice variant mogelijk 
verband houdt met de ontwikkeling van beta- en deltacellen gedurende 
organogenese, maar het is ook denkbaar dat het bijdraagt  aan het behouden 
van de plasticiteit van volwassen hormoon producerende cellen, aangezien 
alternatieve splicing een belangrijk mechanisme is bij organogenese en het 
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behoud van pluripotentie. De lokalisatie in deltacel granules suggereert ook 
een potentiële paracriene of endocriene functie.
ER stress in bètacellen lijkt T1D etiologie te stimuleren door het aantrekken 
en activeren van afweercellen, een verhoogde verwerking en presentatie van 
auto-antigenen en de productie van neo-epitopen. De formatie van neo-
epitopen speelt mogelijk een cruciale rol in het verlies van perifere tolerantie. 
De identificatie van deze neo-epitopen is dus belangrijk voor bestudering 
en het begrijpen van ziekteprogressie, maar ook voor de ontwikkeling van 
immunotherapieën om de perifere bètacel tolerantie te herstellen. Daarnaast 
toont ons onderzoek het belang van onderzoek naar de oorzaken van bètacel 
disfunctie en stelt herstel van ER homeostase voor als potentieel therapeutisch 
doelwit.
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mij om met beide benen op de grond te blijven staan. Al hoop ik dat onze 
gezamenlijke hobby ons nog vaak naar wonderbaarlijke diepten zal brengen!
Mam, mijn allergrootse supporter, ontzettend bedankt dat je er altijd voor mij 
bent! Ongeacht het tijdstip of de afstand sta jij altijd klaar om mij te helpen en 
moed in te spreken. Ik heb onzettend veel bewondering voor jou: mijn sterke, 
onafhankelijke en zorgzame moeder!
Beste vrienden en familie, bedankt voor jullie interesse in mijn onderzoek, het 
luisterende oor en de altijd bemoedigende woorden. Met trots deel ik jullie 
mede dat het nu eindelijk af is, maar mijn carrière als wetenschapper is pas net 
begonnen! 
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